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ABSTRACT 
 
Huntington’s disease (HD) is a fatal neurodegenerative disease caused by a CAG 
repeat expansion in exon 1 of the huntingtin gene, resulting in an expanded 
polyglutamine (polyQ) repeat in the huntingtin protein. Patients receive symptomatic 
treatment for motor, emotional, and cognitive impairments; however, there is no 
treatment to slow the progression of the disease, with death occurring 15-20 years after 
diagnosis. Mutant huntingtin protein interferes with multiple cellular processes leading to 
cellular dysfunction and neuronal loss. Due to the complexity of mutant huntingtin 
toxicity, many approaches to treating each effect are being investigated. Unfortunately, 
addressing one cause of toxicity might not result in protection from other toxic insults, 
necessitating a combination of treatments for HD patients. Ideally, single therapy 
targeting the mutant mRNA or protein could prevent all downstream toxicities caused by 
mutant huntingtin. In this work, I used animal models to investigate a potential 
therapeutic target for decreasing mutant huntingtin protein, and I apply bioluminescent 
imaging to investigate RNA interference to silence mutant huntingtin target sites. 
The enzyme puromycin sensitive aminopeptidase (PSA) has the unique property 
of degrading polyQ peptides and been implicated in the degradation of huntingtin. In this 
study, we looked for an effect of decreased PSA on the pathology and behavior in a 
mouse model of Huntington’s disease.  To achieve this, we crossed HD mice with mice 
with one functional PSA allele and one inactivated PSA allele. We found that PSA 
heterozygous HD mice develop a greater number of pathological inclusion bodies, 
representing an accumulation of mutant huntingtin in neurons. PSA heterozygous HD 
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mice also exhibit worsened performance on the raised-beam test, a test for balance and 
coordination indicating that the PSA heterozygosity impairs the function of neurons with 
mutant huntingtin. In order to test whether increasing PSA expression ameliorates the HD 
phenotype in mice we created an adeno-associated virus (AAV) expressing the human 
form of PSA (AAV-hPSA). Unexpectedly, testing of AAV-hPSA in non-HD mice 
resulted in widespread toxicity at high doses. These findings suggest that overexpression 
of PSA is toxic to neurons in the conditions tested. 
In the second part of my dissertation work, I designed a model for following the 
silencing of huntingtin sequences in the brain. Firefly luciferase is a bioluminescent 
enzyme that is extensively used as a reporter molecule to follow biological processes in 
vivo using bioluminescent imaging (BLI). I created an AAV expressing the luciferase 
gene containing huntingtin sequences in the 3'-untranslated region (AAV-Luc-Htt). After 
co-injection of AAV-Luc-Htt with RNA-silencing molecules (RNAi) into the brain, we 
followed luciferase activity. Using this method, we tested cholesterol-conjugated siRNA, 
un-conjugated siRNA, and hairpin RNA targeting both luciferase and huntingtin 
sequences. Despite being able to detect silencing on isolated days, we were unable to 
detect sustained silencing, which had been reported in similar studies in tissues other than 
the brain. We observed an interesting finding that co-injection of cholesterol-conjugated 
siRNA with AAV-Luc-Htt increased luminescence, findings that were verified in cell 
culture to be independent of serotype, siRNA sequence, and cell type. That cc-siRNA 
affects the expression of AAV-Luc-Htt reveals an interesting interaction possibly 
resulting in increased delivery of AAV into cells or an increase in luciferase expression 
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within the cell. My work presents a method to follow gene silencing of huntingtin targets 
in the brain, which needs further optimization in order to detect sustained silencing. 
Finally, in this dissertation I continue the study of bioluminescent imaging in the 
brain. We use mice that have been injected in the brain with AAV-Luciferase (AAV-Luc) 
to screen 34 luciferase substrate solutions to identify the greatest light-emitting substrate 
in the brain. We identify two substrates, CycLuc1 and iPr-amide as substrates with 
enhanced light-emitting properties compared with D-luciferin, the standard, 
commercially available substrate. CycLuc1 and iPr-amide were tested in transgenic mice 
expressing luciferase in dopaminergic neurons. These novel substrates produced 
luminescence unlike the standard substrate, D-luciferin which was undetectable. This 
demonstrates that CycLuc1 and iPr-amide improve the sensitivity of BLI in low 
expression models. We then used CycLuc1 to test silencing of luciferase in the brain 
using AAV-shRNA (AAV-shLuc). We were unable to detect silencing in treated mice, 
despite a 50% reduction of luciferase mRNA. The results from this experiment identify 
luciferase substrates that can be used to image transgenic mice expressing luciferase in 
dopaminergic neurons.  
My work contributes new data on the study of PSA as a modifier of Huntington’s 
disease in a knock-in mouse model of Huntington’s disease. My work also makes 
contributions to the field of bioluminescent imaging by identifying and testing luciferase 
substrates in the brain to detect low level of luciferase expression. 
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CHAPTER I 
 
INTRODUCTION 
  
The goal of this dissertation is to investigate methods to modify levels of mutant 
huntingtin protein, the cause of Huntington’s disease. Huntington’s disease is an inherited 
neurodegenerative disease caused by a mutation in the huntingtin gene. The mutation is an 
expanded CAG repeat in exon 1 of the huntingtin gene that encodes a polyglutamine expansion 
in the huntingtin protein, conferring it with many toxic properties resulting in neuron dysfunction 
and cell death. There is currently no cure for Huntington’s disease. The studies in the following 
chapters focus on how to decrease the amount of mutant huntingtin protein. For this dissertation, 
it is helpful to understand the molecular mechanisms of the disease, especially the process by 
which mutant huntingtin is handled by the cell. One essential question in the study of HD 
remains how mutant huntingtin is degraded. Mutant huntingtin accumulates in neurons, forming 
intracellular aggregates and inclusion bodies. Neurons eventually succumb to the toxic effects of 
mutant huntingtin and undergo cell death. Together, neuronal dysfunction and cell death result in 
declining mental and physical functioning and death in Huntington’s disease patients. 
I focus on two strategies that can be applied to treat Huntington’s disease. The first study 
is of puromycin sensitive aminopeptidase (PSA), a potential modifier of the degradation of 
mutant huntingtin. Mutant huntingtin is misfolded and marked for degradation; however it 
accumulates resulting in cellular dysfunction. An increase in the degradation of mutant 
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huntingtin could clear the mutant protein and avoid the disruption of cellular processes. This 
mechanism would ideally prevent the onset and slow the progression of the disease.  
A second approach is to slow or stop the production of mutant huntingtin protein. RNA 
interference (RNAi) is currently being studied as a method to reduce the amount of mutant 
huntingtin mRNA, resulting in lower levels of mutant huntingtin protein. A decrease of mutant 
huntingtin mRNA and protein would prevent downstream toxicity and cell death. A challenge of 
optimizing the design and delivery of RNAi has been the lack of an efficient way to evaluate, in 
vivo, the effectiveness of each sequence, structure, and delivery system. This work examines an 
in vivo system that can be used to screen silencing molecules in the brain. We present a 
luciferase reporter molecule containing human huntingtin sequences that can be used to test and 
compare RNAi approaches in the brain of mice. This method allows screening of silencing 
molecules and delivery systems in live animals. One benefit of this system is that silencing can 
be followed over time in the same mouse, preventing the need to collect mRNA and protein from 
multiple endpoints. RNAi molecules vary in terms of sequence, secondary structure, nucleotide 
and linkage modifications and delivery systems, making it imperative to methodically screen 
candidate molecules. A comparison of different RNAi strategies in the brain will provide an 
optimal design for RNAi therapy to treat Huntington’s disease.  
Chapter I provides an overview of Huntington’s disease, including the molecular 
functions of normal huntingtin, the toxicities of mutant huntingtin, and a discussion of the 
current strategies for treating Huntington’s disease. Chapter I also introduces published research 
which provides the rationale for my research. 
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A. Huntington’s disease 
 
1. What is Huntington’s disease? 
Huntington’s disease (HD) is a neurodegenerative disease caused by an autosomal 
dominant mutation in the huntingtin gene [1]. The mutant allele contains an expansion of a CAG 
trinucleotide repeat in exon 1 encoding a poly glutamine (polyQ) repeat in the mutant huntingtin 
protein [2]. The expanded polyQ region of mutant huntingtin results in protein misfolding, 
aggregation, and confers upon it toxic properties, such as accumulation of mutant huntingtin, 
disruptions in mitochondrial function, and vesicle trafficking and recycling resulting in cellular 
dysfunction and ultimately, neuronal cell death [2]. Huntington’s disease is a complex disease 
because of the multiple functions that huntingtin performs and the many toxicities that are caused 
by the mutant protein. Currently, there is no cure for HD.  
Huntington’s disease is inherited in an autosomal dominant manner. Typically, an 
affected parent carries one mutant allele so there is a 50% chance of passing on the disease. A 
normal huntingtin gene contains 6-36 CAG repeats. Persons with repeat numbers of 37 or above 
are considered to have Huntington’s disease and will develop symptoms and signs as they age 
[2]. An inverse correlation exists between the numbers of repeats with the age of onset of the 
disease, the longer the number of repeats, the earlier the onset of symptoms. The trinucleotide 
repeat is unstable and prone to expansion, especially in spermatogenesis [3]. In homozygous 
patients, the onset of disease is dependent upon the length of the expansion rather than the 
presence of two mutant alleles  The prevalence of HD in populations of Western European 
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descent is 4-10 cases per 100,000 [2].  10% of HD patients are young people under the age of 20 
years old, whose disease results from having 60 or more CAG repeats [2].  
 
2. Clinical presentation and disease progression 
In adult cases of HD, the earliest symptoms are changes in mood, including personality 
changes, depression, anxiety, irritability and obsessive compulsive disorder [4]. Apathy increases 
in severity with disease progression, and psychotic symptoms may develop concurrently with the 
onset of motor symptoms [4]. Sleep disturbances are common in Huntington’s disease, including 
insomnia, daytime somnolence, and reduced total sleep time [5]. Motor symptoms typically 
begin with incoordination and chorea, a quick involuntary movement of the hands and feet. 
Motor symptoms progress to rigidity and dystonia, which refers to sustained muscle contractions 
causing twisting and stiff postures [6].  As the disease progresses, there is cognitive decline, 
difficulty talking, dysphagia, and weight loss. Fatality is often a result of falls, dysphagia, or 
aspiration [6]. Average age of onset is 40 years of age with death occurring within 15-20 years 
[7]. 
Juvenile HD is defined as onset of illness in children younger than 21 years of age and 
represents about 5% of all HD cases [8]. Juvenile cases are characterized by rigidity and 
akinesia, a reduction in movement. The most common presenting symptoms are cognitive 
decline and dysphagia, and as the disease progresses, symptoms include dystonia, seizures, 
chorea, rigidity and akinesia [9]. 
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3. Nigrostriatal system and the function of the basal ganglia. 
 Huntington’s disease is considered a neurodegenerative disease involving the cerebral 
cortex and basal ganglia.The basal ganglia are defined as a collection of  nuclei consisting of the 
caudate nucleus, putamen, globus pallidus, subthalamic nucleus, and substantia nigra. It is best 
known for functioning in the initiation of movement, but recent insights have been made into the 
roles of the basal ganglia in learning-related plasticity, eye movements, as well as cognitive and 
emotional functions [10-13]. Disruptions of all of these functions likely contribute to the clinical 
presentation of HD. In post-mortem evaluation, 80% of HD brains showing atrophy of the frontal 
lobes  and 95% showing atrophy of the caudate nucleus and putamen, collectively known as the 
striatum [14]. Here we focus on the basic organization of the basal ganglia and effect of striatal 
dysfunction as it contributes to the motor symptoms of HD. Information from the cortex projects 
to the striatum (caudate nucleus and putamen) activating medium spiny neurons (MSNs) [15]. 
There are two populations of MSNs: neurons expressing D1 dopamine receptors, substance P, 
and dynorphin, and neurons expressing D2 dopamine receptors and met-enkephalin [16, 17]. D1-
expressing MSNs are part of the direct pathway to initiate movement, whereas D2-expressing 
MSNs are part of the indirect pathway that inhibits movement. To initiate movement, 
glutamatergic cortical input excites D1-expressing MSNs which project to the globus pallidus 
internal segment (GPi). Neurons in the GPi then project to the thalamus. The final connection is 
excitatory from the thalamus back to the cortex, completing the direct pathway [18] (Fig. 1-1 B). 
The indirect pathway begins with input from the cortex to D2-expressing MSNs (Fig. 1-1 A). 
These neurons project to the globus pallidus external segment (GPe) inhibiting neurons that 
project to the subthalamic nucleus (STN) [18]. Neurons from the STN project to the substantia 
nigra pars reticulata (SNr) which projects to the thalamus. The final connection is from the 
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thalamus to the cortex. Normally, the thalamus is inhibited by the GPi/SNr, resulting in no 
involuntary movements. Neurons of the cortex, STN, and thalamus release glutamate and are 
excitatory while neurons of the striatum, GPe, GPi, and SNr release the inhibitory 
neurotransmitter, GABA. Neurons from the substantia nigra pars compacta (SNc) project to 
MSNs in the striatum and release dopamine (DA). D1 and D2 receptors respond differently to 
DA: MSNs with D1 receptors are stimulated by DA and MSNs with D2 receptors are inhibited 
by DA. 
To appreciate the function of the basal ganglia, it is useful to compare and contrast 
Huntington’s disease with Parkinson’s disease. These two diseases affect different cell 
populations within the basal ganglia, resulting in very different clinical pictures. In HD, early 
motor symptoms primarily consist of involuntary movements of the hand and feet, manifesting 
as chorea and incoordination [6]. The neurons most susceptible to the toxic effects of mutant 
huntingtin are the met-enkephalin-expressing D2 medium spiny neurons in the striatum that 
project to the GPe [19, 20]. Loss of these cells results in disinhibition of the thalamus and a 
decrease in activity of the indirect pathway, resulting in involuntary movements such as chorea 
[21]. As HD progresses, D1 MSNs are also lost, decreasing activity of the direct pathway. In late 
stage HD, patients may display hypokinesia or hyperkinesia depending on the balance of direct 
versus indirect pathway activation [21]. 
Parkinson’s disease (PD) is a neurodegenerative disease caused by a loss of dopaminergic 
cells from the substantia nigra pars compacta [22]. Whereas HD patients display increased 
involuntary movements, the clinical characteristics of PD include rigidity, akinesia, postural 
instability, a flexed posture, and a tremor at rest [23]. Two theories exist to describe the 
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pathophysiology of PD: the GPi rate theory and the oscillator theory.  The GPi theory postulates 
that a loss of excitatory SNc input of striatal D1 MSNs result in a decreased activity of the striatal 
input to the GPi. This increases GPi inhibitory effect on the thalamus and therefore also the motor 
cortex to impede the initiation of movement. This reduction in activity of the direct pathway and 
imbalance with the indirect pathway is opposite of the pattern seen in HD.  The second theory of 
basal ganglia dysfunction in PD involves synchronized firing of neurons between the basal 
ganglia nuclei and cortex, so-called oscillations. Studies in PD patients with deep brain 
stimulation implants have revealed different oscillating patterns between the treated and 
untreated states [24, 25]. However, it remains unclear whether oscillations in the basal ganglia 
occur in the non-diseased state. The presence of pathologic changes in oscillations could also 
play a role in other movement disorders of the basal ganglia including HD. In fact, a difference 
in oscillations between normal and R6/1 mice (a mouse model of HD) have been described [26]. 
Regardless of the mechanism behind the basal ganglia dysfunction in movement disorders, it is 
clear that differential activity of D1 and D2 MSNs result in contrasting diseases. Decreased 
activity of D2 MSNs projecting to the GPe results in the increased motor activity seen in HD, 
while decreased activity of D1 MSNs and increased activity of D2 neurons results in impeded 
motor initiation seen in PD. 
 
4. The impact of Huntington’s disease 
HD patients face additional hardships coping with their disease. There is significant 
impact on their families and loved ones. As symptoms increase in severity, HD patients become 
unable to work or participate in activities they enjoy, resulting in a dramatic change in lifestyle. 
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Unable to drive, patients become increasingly dependent on caregivers for transport to frequent 
physician visits. The children of HD patients are faced with the decision of whether to undergo 
genetic testing to determine if they have inherited the incurable disease. Near the end of the 
disease, HD patients require full time care provided by nursing home facilities with an average 
cost for a semi-private room of $75,405 annually according to the 2013 Genworth Cost of Care 
Survey [27]. This value represents a fraction of the financial impact of HD when taking into 
account lost years of employment, the cost of medication, health care visits, and medical 
complications. The prevalence of HD is 4-10 per 100,000 people in the western world [7]. Many 
more are at risk for developing the disease. HD touches millions of people each year. 
 
5. Current treatments 
There is neither a cure for HD nor is there a way to slow its progression. The current 
treatments are based on symptom management. For chorea, there are benzodiazepines and 
dopamine depleting agents. Myoclonus, which is described as sudden involuntary muscle 
contractions, is treated with benzodiazepines and [7]. In Juvenile HD, patients receive levodopa 
for rigidity, muscle relaxants for spasticity, and antipsychotics for psychosis, irritability and 
chorea. To treat depression, anxiety, and obsessive compulsive behavior patients are often 
prescribed selective serotonin reuptake inhibitors (SSRIs), and for manic symptoms patients can 
take mood stabilizers and anticonvulsants [7]. Patients are often given hypnotics to improve 
sleep wake cycles. Clearly, the medication list can become quite long and with that 
organizational and financial challenges.  Patients and their providers must seek balance between 
9 
 
benefit gain from a given medication and the side effect profile. Furthermore, none of these 
medications have the ability to alter the course of the disease.  
A number of dietary supplements have demonstrated neuroprotective properties in cell 
culture or animal models. These include Coenzyme Q10, nicotinamide, and creatine [28-32]. 
These supplements are thought to delay the onset and slow progression of the disease by 
increasing the ability for neurons to withstand toxic insults. Although these have shown benefit 
in the laboratory, their effectiveness in human patients has yet to be determined. Creatine is 
currently in clinical trials for Parkinson’s disease and Huntington’s disease [32]. 
 
B. The functions of huntingtin 
1. Huntingtin is a conserved gene that is essential for development 
Since the discovery of the huntingtin gene in 1993, much has been uncovered about its 
evolution and function [1]. The huntingtin gene is an ancient and highly conserved gene, tracing 
back to the amoeba and sea urchin [33]. The NH2-terminal portion of the protein, containing the 
polyQ region, is the most recently evolved. In humans, huntingtin is expressed in all tissues with 
highest levels in the brain. The function of the polyQ repeat and the relationship between length 
and function is unclear. A wide variety of polyQ lengths are seen across different organisms. 
Drosophila melanogaster and Ciona intestinalis, both invertebrate organisms, do not have a 
glutamine repeat, whereas mice have a short repeat of 7Q [33].  
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One vital role of the huntingtin gene is in brain development.  Mouse embryos null for 
huntingtin are nonviable, terminating at embryonic day 8.5 before the formation of the nervous 
system [34-36]. These embryos exhibit a shortened primitive streak and lack of head folds, 
indicating a failure of head development [37]. Several studies show that a minimum of 50% 
huntingtin protein expression is required for proper development. Mice expressing 
approximately one third the total amount of huntingtin are born with brain structure 
abnormalities and die shortly after birth [38]. Three independent groups created mice with 
“inactivated” huntingtin genes [34-36]. Two of the three groups found that mice with a single 
copy of huntingtin develop normally and were indistinguishable from their wild type (WT) 
littermates [34, 35]. Mice in the third study expressed one full length huntingtin and one 
truncated huntingtin protein and were found to exhibit behavioral and cognitive abnormalities 
[36]. The discrepancy in results could be related to the presence of a 20kDa truncated huntingtin 
protein in the latter study whereas the first two studies did not express truncated proteins. The 
implication from the first two studies is that in mice, having one functioning huntingtin allele is 
sufficient for normal anatomical development meaning that HD is caused not by a loss of 
function, but by the mutant allele’s gain-of-function toxicity. Interestingly, this theory is 
supported by the third study which found that by leaving a 20kDA truncated huntingtin protein, 
the mice were found to possess behavioral abnormalities indicating a functional deficit. 
Findings in human patients support this conclusion as patients with a single mutant 
huntingtin allele are born and develop normally compared with their siblings and peers until the 
onset of the disease as determined by the CAG repeat length. Furthermore, patients homozygous 
for mutant huntingtin (e.g. containing two mutant huntingtin alleles and completely lacking a 
normal huntingtin allele) are initially indistinguishable from patients heterozygous for the mutant 
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allele or those unaffected by the disease[39, 40]. This indicates that either huntingtin in humans 
is completely different from mouse and is not necessary for development or, more likely, that the 
mutant form of huntingtin retains its normal function in development. Caution should be used in 
describing development in HD patients as “normal” as there is preliminary evidence that 
presymptomatic children (ages 7-18) with a single HD gene containing a moderate expansion 
number (<60) may have slight changes in brain structure as measured by functional MRI [41]. In 
general, the accepted theory is that the CAG expansion confers upon huntingtin a deleterious 
gain-of-function mutation, but the effect of moderate or mild loss of function remains an 
important factor in the treatment of the disease. 
 
2. Huntingtin has several protein binding domains 
Huntingtin is a large protein of 348 kDa found predominantly in the cytoplasm [42]. It 
contains conserved domains that are important for interactions with other proteins, known as 
HEAT repeats (named for four of the proteins that it is found in: huntingtin, elongation factor 3 
(EF3), protein phosphatase 2A (PP2A), and mammalian target of rapamycin 1 (mTOR1)) [43]. 
The polyQ region is also important for allowing huntingtin proteins to form homodimers via a 
polar zipper structure [44]. Not only does this enable huntingtin to bind to itself, but also allows 
it to bind other proteins with polyQ regions including transcription factors such as CREB-
binding protein (CBP), TBP-associated factor 4 (TAF4), tumor protein 53 (TP53), and 
specificity protein 1 (Sp1) [43]. The polyQ stretch confers a degree of flexibility to the structure 
of huntingtin which has been shown to adopt multiple conformations by crystal structure [45]. 
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The flexibility and presence of multiple protein binding domains presents the possibility that 
huntingtin is a mediator or scaffold that brings proteins closer together and facilitate interactions.  
Although most huntingtin protein is found in the cytoplasm, there is evidence that 
huntingtin could play a role in the nucleus as well. The COOH-terminal portion of huntingtin 
contains a nuclear localization signal and a nuclear export signal, and the first 17 amino acids in 
the NH2-terminal part of the protein, N17 region, bind to the nuclear pore protein, TPR 
(translocated promoter region) [2, 46]. These properties enable normal huntingtin to enter and 
exit the nucleus, potentially transporting bound molecules across the nuclear membrane. In 
contrast to normal huntingtin, after entering the nucleus, the mutant protein loses its ability to 
exit the nucleus causing an imbalance of import versus export of mutant huntingtin [46]. This 
results in its accumulation in the nuclear compartment [46]. In addition to binding TPR, the N17 
region also binds to mitochondria and is co-localized with the Golgi and endoplasmic reticulum 
[47, 48].  
 
3. Huntingtin is a neuroprotective protein 
Huntingtin has several neuroprotective properties. Overexpression of normal huntingtin 
in cell culture increases survival following toxic insults, and in mouse models, huntingtin 
overexpression prevents apoptosis from excitotoxic chemicals [49, 50]. Inactivation of normal 
huntingtin in adult mice results in apoptotic cell death, an increase in severely abnormal 
behaviors characteristic of HD mice, and decreased lifespan [51]. Overexpression of normal 
huntingtin decreases the toxic effects of mutant huntingtin in cell culture [52]. One way in which 
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it might be neuroprotective is through the regulation and transport of brain derived neurotrophic 
factor (BDNF). BDNF is important for the survival of striatal neurons [53]. In cortical neurons, 
normal huntingtin facilitates the expression of BDNF [54]. In contrast, mutant huntingtin results 
in decreased BDNF transcription. There is reduced BDNF vesicle transport in medium spiny 
neurons (MSNs) (Fig. 1-2 J) [55]. In the striatum, huntingtin acts as a scaffold, binding vesicles 
containing BDNF to HAP1 (huntingtin associated protein 1), which interacts with dynactin to 
transport BDNF vesicles [55]. In neurons, huntingtin overexpression increases BDNF gene 
transcription by inhibiting the neuron restrictive silencing element (NRSE) and improves the 
transport of BDNF [56]. It is possible that a loss of normal huntingtin function could result in 
increased susceptibility to toxic events. Transgenic mice express the human huntingtin mutant 
gene with 128 CAG repeats (YAC128) expressed on a null background (no mouse huntingtin), 
have a more severe behavioral phenotype and shortened lifespan compared with YAC128 mice 
with normal mouse huntingtin [57]. In Drosophila expressing human huntingtin exon1 with 93 
CAG repeats, removing the endogenous huntingtin gene accelerates neurodegeneration [58].  In 
summary, BDNF is critical for neuronal health and huntingtin plays direct roles in regulating its 
expression and transport. 
 In addition to roles in intracellular transport, huntingtin regulates synaptic activity 
through exocytosis and endocytosis at synaptic terminals. Endocytic recycling is important for 
cell health and membrane homeostasis. It is the process by which internalized receptors are 
returned to the cell surface for reuse. Huntingtin co-localized with Rab11, a protein that regulates 
vesicle formation, and decreases Rab11 activation, and mutant huntingtin binding to Rab11 
results in endosomes with abnormal morphology and slowed recycling [59]. 
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What is the role of the polyQ repeat? There is an inverse relationship between length of 
the polyQ in huntingtin and the amount of ATP in the cell, which reflects the energy status of the 
cell [60]. Mice with a deletion of the polyQ stretch develop normally with no gross abnormalities 
[61]. However, there are transient deficits on tests of learning and memory and a very subtle 
effect on motor skill on the accelerating rotarod test. Fibroblasts from these mice indicate an 
increased ATP energy status [61]. In addition, brain tissues from these mice have increased 
levels of microtubule-associated protein 1 light chain 3-II (MAP1 LC3-II also known as LC3-II), 
a marker for increased activation of the autophagy degradation pathway. Mice homozygous for 
the polyQ deletion live longer than WT mice [61]. This last finding suggests that the polyQ 
region in huntingtin plays a role in the regulation of a basal level of autophagy possibly through 
its interaction with autophagic vesicles [62]. 
 
C. Pathways of cell damage caused by mutant huntingtin 
 
1. Mutant huntingtin mediates excitotoxic damage to neurons 
In addition to the loss of neuroprotective BDNF, there is evidence for increased 
excitotoxicity caused by dysfunction at the corticostriatal synapse. Excitotoxicity is defined as 
excessive activation of glutamate and N-methyl-D-aspartate (NMDA) receptors leading to cell 
death. Injection of glutamate agonists into rat striatum results in the same pattern of cell loss as 
in HD [63]. Mouse models with full length human huntingtin have increased glutamate release 
and increased susceptibility to excitotoxicity [64]. There are electrophysiological findings that 
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indicate increased NMDAR sensitivity to NMDA and increased NMDA currents in striatal 
neurons of mutant huntingtin mice with 100Q [65, 66].  
In addition to increased activation of glutamate receptors, in human HD post-mortem 
tissue, there is a reduced uptake of [3H]glutamate compared with controls [67]. Glutamate uptake 
is mediated by the involvement of glial cells in regulating sensitivity to excitotoxicity revealing a 
non-cell autonomous contribution to HD pathogenesis. Expression of mutant huntingtin in 
astrocytes resulted in decreased expression of glutamate transporters and caused neuronal 
dysfunction, demonstrating the importance of glia in protection against excitotoxic damage to 
neurons [68]. 
 
2. Aberrant binding by mutant huntingtin results in transcriptional dysregulation 
Mutant huntingtin disrupts the function of several transcription factors (Fig. 1-2 B, H). 
Specifically, mutant huntingtin binds transcriptional activators Sp1 and TATA binding 
associated factor 130 (TAFII130) and the transcriptional coactivator CBP resulting in general 
transcriptional repression [43]. Affected genes include those for neurotransmitter receptors, 
synaptic transmission, cytoskeletal proteins, intracellular signaling and calcium homeostasis. 
Mutant huntingtin also binds the transcription machinery, which may globally reduce 
transcription [69]. By binding to CBP, mutant huntingtin decreases histone acetyltransferase 
(HAT) activities globally, causing a reduction in histone acetylation, a modification that opens 
chromatin structure allowing genes to be more easily accessed for transcription with the end 
result of decreasing transcription [70]. In addition to changing transcription and chromatin 
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structure, mutant huntingtin interacts with argonaute 2 (Ago2) resulting in fewer P-bodies 
compared with normal huntingtin [71]. Destabilization of P-bodies could increase the level of 
miRNAs in the cells and act to repress gene expression. 
Aggregation of mutant huntingtin could reduce its ability to bind transcriptional 
activators and machinery proteins, and aggregate formation could thus protect cells from 
transcriptional dysregulation [72]. In cell culture, modification of mutant huntingtin exon 1 by 
small ubiquitin-like modifier (SUMO) decreases aggregation of mutant huntingtin and increases 
transcriptional repression, suggesting that sequestration of mutant huntingtin in aggregates can 
reverse its effect on transcription [73].  
 
3. Mutant huntingtin and mitochondrial dysfunction 
Mitochondrial dysfunction plays several roles in the toxicity of HD (Fig. 1-2 I). Mutant 
huntingtin impairs energy metabolism, increases the generation of free radicals, and disrupts 
calcium handling [74-76]. Mutant huntingtin binds to mitochondria, thereby impairing the 
transport of mitochondria in primary neuron cultures and altering the ultrastructure of the 
organelle [77]. Transport of mitochondria to cell processes is important in providing adenosine 
triphosphate (ATP) throughout the cell. Mitochondrial dysfunction can be seen in various 
imaging techniques in the brains of HD patients, specifically in the basal ganglia, cortex and 
thalamus [74]. Mitochondrial activity may be especially important for striatal cells. Mice with 
impaired mitochondrial function exhibit striatal degeneration and hyperkinetic movements [78, 
79]. Mitochondrial impairment is not specific to neurons, although neurons might be more 
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susceptible to it. Altered mitochondrial calcium handling is seen in lymphoblasts from HD 
patients and skeletal muscle in a mouse model of HD [76].  
 
4. Mutant huntingtin forms intracellular aggregates and inclusion bodies 
In HD, huntingtin-containing aggregates are present in the medium spiny neurons of the 
striatum and neurons of all cortical layers [80]. There are two forms of aggregates 
distinguishable by light microscopy. One form is the neuronal intranuclear inclusion body, 
subsequently referred to as an inclusion body, which is spherical, ovoid, or elliptical in shape and 
found in the nucleus (Fig. 1-2 G). The majority of cells contain only one inclusion body per 
nucleus, but occasionally 2 or 3 can be found. The second form is cytoplasmic aggregates, which 
are spherical or oblong in shape, sometimes with extensions and within dystrophic neurites (Fig. 
1-2 E, F) [80]. These two types of aggregates are found in different distribution in juvenile and 
adult HD.  Inclusion bodies are found with greater frequency in juvenile HD than in adult HD 
and are distributed in the cortex [80]. Cytoplasmic aggregates are the prominent feature in adult 
HD, and these are also primarily distributed in the cortex.  
Cleavage of huntingtin is an important process for the development of aggregates (Fig. 1-
2 A). Both inclusion bodies and cytoplasmic aggregates contain NH2-terminal fragments and do 
not stain with an antibody to an internal epitope used to detect larger fragments or full-length 
huntingtin [80]. Both normal and mutant huntingtin are cleaved by caspases and other unknown 
enzymes into multiple fragments [81]. Different fragments have different effects on the 
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formation of aggregates. For example, in cell culture, cleavage at arginine 167, creating a 
fragment known as cp-2, which decreases aggregation and increases toxicity [82]. 
There are opposing views on the role of mutant huntingtin aggregates regarding whether 
they are protective or toxic to neurons. For this discussion, we will consider aggregates and 
inclusion bodies to be equivalent as intracellular structures containing mutant huntingtin protein 
as well as other proteins. The first case holds that aggregates are protective against cellular 
damage by binding and removing toxic huntingtin monomers or oligomers from distribution in 
the cytosol. In HD post-mortem tissue, the neurons that are initially spared are those containing 
inclusion bodies and aggregates, and conversely, MSNs, the cells most susceptible to toxic 
effects of mutant huntingtin, do not show aggregates [83, 84]. One study followed the survival of 
cultured neurons expressing huntingtin exon1 fused with GFP and found a correlation between 
huntingtin inclusion formation and increased survival of neurons [85]. Additionally, it was found 
that sumoylation of huntingtin which decreases aggregation also increases cytotoxicity [86]. 
Alternatively, aggregates may contribute to cellular dysfunction by sequestering important 
cellular proteins out of the cytoplasm including transcription factors, motor proteins, proteasomal 
subunits and chaperone proteins [87-90]. Loss of these proteins and complexes could potentially 
deplete the neurons of their vital functions. Proteasome and transcriptional impairment occurs 
independent of aggregate formation [91-93]. Several studies found that silencing of molecular 
chaperones such as prefoldin or cytosolic chaperonin (CCT/TriC) result in increased aggregate 
formation and cell death [94-96].  
Strict definitions for aggregates and inclusion bodies have yet to be adopted and it is 
possible that all aggregates are not equal [97]. The aggregate population in the striatum of R6/2 
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displayed more cytotoxicity than aggregates from the hippocampus and cerebellum [97]. The 
possibility of multiple conformations and contents of aggregates conferring differing toxicities 
could explain seemingly contradictory findings regarding the properties of huntingtin aggregates. 
As was previously discussed, huntingtin contains nuclear import and export signals and the 
polyQ expansion impairs its ability to export from the nucleus, and a potential distinction exists 
between nuclear and cytoplasmic aggregates/inclusions [46]. Whether aggregates are protective 
or detrimental or whether different aggregate conformations affect disease progression has yet to 
be determined. Once it is clear what role aggregates play, a potential therapy could be to alter 
aggregation and inclusion body formation. 
 
5. Is the damage caused by mutant huntingtin permanent or reversible? 
There is evidence supporting that the cellular damage inflicted by mutant huntingtin is 
reversible. In 2000, a conditional mouse model of HD was created with mutant huntingtin 
expression under tetracycline-regulated control [51]. After 18 weeks of transgene expression, a 
point at which neuropathology and motor dysfunction was evident, the mutant huntingtin 
transgene expression was repressed. After having the mutant transgene repressed for 16 weeks, 
the mice demonstrating less clasping behavior, there was reversal of reactive astrocyte gliosis, 
increased size of the striatum, and decreased nuclear huntingtin staining [51]. The observation 
that the HD phenotype and pathology are reversible in mice demonstrates that cell damage 
incurred from mutant huntingtin toxicity, if reversed prior to neuronal death, is not permanent.  
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D. The processing and degradation of mutant huntingtin 
1. Post-translational modifications and cleavage alter toxicity of mutant huntingtin 
There are many post-translational modifications that alter the toxicity and activity of 
huntingtin including palmitoylation, phosphorylation, ubiquitination, and sumoylation [7]. 
Palmitoylation of cysteine 214 in huntingtin aids its association with membranes for vesicle 
transport, and this modification is impaired by the polyQ expansion leading to decreased 
membrane binding [98]. Phosphorylation occurs at several different positions, mostly in the 
NH2-terminal 17 amino acids and they are generally protective [99-101].  
Rhes (Ras homolog enriched in the striatum) is a small G protein highly expressed in the 
striatum that functions in the sumoylation of huntingtin [102, 103]. Sumoylation of mutant 
huntingtin decreases aggregation and increases the concentration of soluble mutant huntingtin 
[86]. This modification and the down-stream effects result in an increase in toxicity and 
transcriptional dysregulation [73, 86]. 
Acetylation occurs on one site, lysine 444 of mutant huntingtin [104]. In Caenorhabditis 
elegans, increasing acetylation at this site targets mutant huntingtin to the autophagy-lysosomal 
system, while in experiments using mice injected with lentiviral expressed human huntingtin 
fragment with 72Q repeats, blocking acetylation resulted in accumulation of mutant huntingtin 
protein [104]. 
Caspases are proteases well-known for their apoptotic role in programmed cell death, 
however they are also implicated in non-cell death pathways such as synaptic plasticity and 
learning [105]. There are five predicted caspase cleavage sites in huntingtin, 3 sites cleaved by 
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caspases -2, -3, and -6, and two silent sites [81]. NH2-terminal mutant huntingtin fragments have 
been linked to increased toxicity as they are preferentially found in affected neurons and increase 
susceptibility cells to death compared with full-length huntingtin [106, 107]. Preventing the 
cleavage of mutant huntingtin is a potential strategy for modifying disease progression. 
Completely blocking caspase cleavage was found to be protective in cells which could also have 
the effect of blocking cell death pathway [108]. Many studies have investigated the role of 
caspase cleavage using various mouse models and methods for inactivating either the caspase or 
the caspase cleavage site. R6/2 mice expressing dominant negative caspase-1 resulted in delayed 
onset of disease and extended survival [109]. In a YAC72 mice, dominant negative caspases -2, -
6, and -7 were found to be protective while -3, -8, and -9 had no effect [110]. Another study 
inactivated the cleavage sites for caspase -3 and -6 in YAC 128 mice and came to consistent 
conclusion that blocking caspase 6 cleavage is protective, while caspase-3 had no effect [111]. 
However, a third study looked at 150Q huntingtin knock-in mice null for caspase-6 which did 
not exhibit protection from disease phenotype [112]. In summary, there is evidence for a role of 
caspases -1, -2, -6, and -7 in the progression of neuropathology especially caspases -2 and -6 
which have known cleavage sites within the huntingtin gene. 
Similar to caspases, increased levels of calpain are found in HD brains [113]. Calpain 
activation is caused by disturbances in Ca2+ homeostasis resulting from excitotoxicity or 
mitochondrial dysfunction. Calpains preferentially cleave mutant huntingtin over normal 
huntingtin and cleave in the same amino-terminal region as the caspase cleavage sites [81]. 
Aspartic endopeptidases are other enzymes that cleave huntingtin producing two different NH2-
terminal fragments, cp-A (cleaved between amino acids 101-124) and cp-B (cleaved between 
amino acids 146-214) [114].  
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2.  The role of the ubiquitin-proteasome system in the degradation of mutant huntingtin 
 The first line of defense in degrading misfolded proteins is the ubiquitin-proteasome 
system (UPS) (Fig. 1-3 A). The proteasome functions in cells to degrade short lived proteins and 
damaged or misfolded proteins [115]. E3 ubiquitin ligases add ubiquitin molecules to lysine 
residues of the protein to target it for delivery to the proteasome. The proteasome is a multi-unit 
structure in the cytoplasm that unfolds and degrades proteins using a series of proteases and 
peptidases. When the peptides are released, they are further degraded by aminopeptidases into 
single amino acids. Not only is the UPS important for degrading damaged proteins, but it plays 
an important role in cell homeostasis [115]. The UPS may play a role in synapse function and 
plasticity and may also regulate cell signaling by degrading short lived proteins [116]. 
The expanded polyQ present in mutant huntingtin causes it to misfold and interact with 
E3 ubiquitin ligases, including Hrd1, E6-AP, E2-25K, Ube3a, and CHIP (C terminus of Hsp70-
interacting protein) to ubiquitinate lysine residues 6, 9, and 15, thereby targeting it to the 
proteasome [73, 117-120]. Normal and mutant huntingtin can also be targeted to the proteasome 
and lysosome by phosphorylation by the inflammatory kinase, IKK, on serines 13 and 16 [99]. 
The proteasome can only degrade unfolded proteins, rendering it unable to degrade the fibrillar 
or aggregated forms of huntingtin. The proteasome is also inefficient at degrading polyQ tracts 
and in vitro studies show that the proteasome releases them intact [121].  This potentially results 
in expanded polyQ peptides that are free in the cytoplasm, able to contribute to aggregation and 
binding of other polyQ containing proteins. A single aminopeptidase, puromycin sensitive 
aminopeptidase (PSA) is the only identified aminopeptidase able to efficiently degrade polyQ 
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peptides [122]. Through its function of degrading polyQ peptides it could play a role in the 
degradation of both normal and mutant huntingtin and be a potential disease modifier. In fact, 
PSA overexpression reduces inclusion formation in cells transfected with mutant 
huntingtin[123]. Operating on the theory that inclusion bodies represent an accumulation of 
misfolded mutant proteins toxic to the cell, a reduction in inclusion number would represent 
decreased disease burden within the cell. 
Not only does the proteasome fail to effectively degrade mutant huntingtin, but its 
function is impaired by the mutant protein (Fig. 1-2 D) [124]. It has been proposed that 
proteasomal dysfunction is caused by mutant huntingtin before the appearance of inclusion 
bodies. From this perspective, inclusion bodies may offer protection to the cell by removing the 
toxic fibrillar huntingtin products that interfere with proteasomal degradation. 
In addition to impairment of proteasome function, mutant huntingtin aggregates sequester 
the proteasome in vitro [125]. There are two interpretations of this. One is that co-localization of 
proteasomal subunits with aggregates represents aberrant binding of proteasomal subunits which 
could alter their ability to function normally by altering their cell localization and distribution. 
Another interpretation is that the bound proteasomes are attempting to degrade aggregated 
protein. Primary neuronal cell cultures from a conditional mouse model of Huntington’s disease 
have been used to study inclusion body formation and dissolution [126]. These cells develop 
inclusions within two days when the mutant allele is expressed and they disappear five days after 
the allele is suppressed [126]. In primary neuronal cell culture, this dissolution of aggregates is 
abolished with the administration of a proteasomal inhibitor, suggesting that the proteasome is 
functioning in some degree to degrade proteins from the aggregates [126].  
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3. The role of the autophagy-lysosome system in the degradation of mutant huntingtin   
Autophagy is the process by which organelles and the majority of proteins from the 
cytosol are targeted for degradation (Fig. 1-3 B) [127]. A portion of cytosol is enclosed by a 
double membrane called an autophagosome [127]. This structure fuses with a lysosome for the 
degradation of the proteins by acidic hydrolases. Mice that lack Atg7, a gene essential for 
autophagy in neurons, develop ubiquitin-positive aggregates [128]. Thus, autophagy is vitally 
important for the prevention of inclusion bodies. 
In HD patients, aggregates of mutant huntingtin bind and sequester mTOR (mammalian 
target of rapamycin), a negative regulator of autophagy [129]. Removal of mTOR activity in the 
cell increases general autophagy [130]. Mice with one huntingtin allele containing 200 CAG 
repeats have increased markers for autophagy early in the course of the disease [131]. Even 
though there may be increased activation of autophagic vacuoles, this does not necessarily mean 
that autophagosomes are able to complete the process of degradation. Mutant huntingtin has been 
shown to interact with autophagolysosome membrane resulting in a failure to enclose cytosolic 
components for degradation [132]. Regardless of the status of autophagy in Huntington’s 
disease, its importance in degradation of mutant huntingtin is indisputable. In cell culture, 
blocking autophagy increases soluble huntingtin, aggregates, and toxicity [133]. Increasing 
autophagy decreases accumulation of mutant huntingtin in cell culture and decreases aggregates 
and improves behavior in mice [129, 134-136].  
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E. Mammalian models of Huntington’s disease 
1. Chemical models of Huntington’s disease 
 The initial animal models of Huntington’s disease were chemical models that involved 
injections of neurotoxins into the striatum. The result is a model of excitotoxic cell death. Kainic 
and quinolinic acids are glutamate agonists that result in striatal-specific neurodegeneration [2]. 
Injection of 3-nitropropionic acid and malonic acid are mitochondrial toxins, and mice injected 
with these agents have striatal neuron loss and replicate behavioral aspects of HD [137]. These 
models represent Huntington’s disease because they affect the striatum more than other 
structures; however, they are not useful in the study the mechanism of mutant huntingtin toxicity. 
Chemical models of HD can be used to study modulators that may be neuroprotective.  
 
2. Transgenic mouse models with a human huntingtin fragment. 
Table 1-1 is a comparison of commonly used transgenic and knock-in mouse models of 
HD. The first transgenic mouse model of Huntington’s disease was the R6/2 line. R6/2 mice 
contain a fragment of human huntingtin consisting of a single copy of exon 1 with 141-157 CAG 
repeats including the human huntingtin promoter, and it is expressed at 75% of the endogenous 
level of huntingtin mRNA [138]. The onset of HD symptoms is early and the progression rapid. 
In R6/2 mice, by five to six weeks of age there are abnormalities on the raised-beam test and 
rotarod test and decreases in brain size and volume [138]. Inclusions increase in size and number 
with the progression of the disease. There are decreases in D1 and D2 dopamine receptors in the 
striatum at 8 weeks, and by 12 weeks of age there is cell death of medium spiny neurons [138]. 
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R6/2 mice die between 12-15 weeks of age [138]. The R6/2 mouse model exhibits a rapid 
progression of disease and is useful in screening potential therapeutics and modifiers of disease 
because the outcomes can be quickly measured. Development of disease is too rapid for a careful 
analysis of the progression of pathology and avenues of cellular dysfunction. Another drawback 
to this model for studying mechanism of huntingtin toxicity is that it expresses a fragment of 
huntingtin, and it is expressed in addition to the endogenous mouse huntingtin. 
A second type of transgenic mouse expresses the first 171 amino acids of the huntingtin 
protein with 82Q or 18Q  repeats, known as N171-82Q and N171-18Q [139]. It is driven by the 
mouse prion promoter that is only expressed in neurons with expression level that is less than 
endogenous huntingtin [139]. N171-18Q mice were indistinguishable from WT mice, however 
N171-82Q mice develop clasping and rotarod deficits at 15 weeks [139]. N171-82Q mice display 
nuclear inclusions in the cortex, hippocampus, amygdala and striatum, and decrease brain size 
(due to atrophy), and their lifespan is 10-24 weeks of age [139]. With a later onset compared 
with the R6/2 line, the benefit of N171-82Q mice is that the progression of HD can be studied, 
and similar to the R6/2 model demonstrates that the NH2-terminal fragment of mutant huntingtin 
is sufficient to replicate many aspects of the disease. A limitation of this model is that, like R6/2 
mice, the expression of mutant huntingtin fragment results in an increase in total huntingtin 
combined with endogenous mouse huntingtin. 
 
3. Transgenic mouse models with full length human huntingtin 
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 Several transgenic HD mouse lines have been made using yeast artificial chromosome 
(YAC) constructs containing a full length human huntingtin gene. The huntingtin transgene 
includes upstream and downstream sequences and all regulatory elements. Four strains of YAC 
mice were created with different CAG repeat lengths: 18, 46, 72, and 128 repeats [140]. The 
YAC18 construct represents the normal version of human huntingtin and were indistinguishable 
from WT mice. All four lines have increased total amount of huntingtin, with the transgene 
expressing approximately 33% -50% compared with endogenous huntingtin. YAC46 mice 
exhibit eletrophysiological abnormalities compared with YAC18 mice, but lack an increase in 
nuclear staining or other behavioral or pathological findings. YAC72 mice display hyperactivity 
at 7 months, and an increased number of nuclear staining cells [140]. YAC72 mice have 
microaggregates and a few macroaggregates, striatal-specific neuronal degeneration by 12 
months of age, but lack the development of nuclear inclusion bodies [140]. YAC128 are the most 
commonly used YAC HD model. These mice display increased locomotor activity and rotarod 
deficits at 3 months, and then decreased activity at 12 months. In YAC128 mice, there is nuclear 
staining for mutant huntingtin throughout the striatum by 12 months of age, but no inclusions are 
apparent until 18 months of age [64]. YAC128 mice show age-dependent striatal 
neurodegeneration beginning at 9 months, however their lifespan is comparable to WT mice 
[64]. Benefits of this model are that human huntingtin expression is regulated by the human 
promoter, however a limitation of this model is that the total huntingtin level in these mice is 
increased. That YAC72 and YAC128 mice develop neurodegeneration prior to the development 
of inclusion bodies suggests that the inclusion bodies are not the cause of neuronal dysfunction 
and death in this model of HD. The observation that YAC46 mice do not develop the disease, 
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despite the electrophysiological differences from WT, could suggest that mice require a longer 
polyQ length to develop toxicity, or that development of HD is limited by their short lifespan. 
 A second full length human huntingtin transgenic approach uses a bacterial artificial 
chromosome (BAC). BACHD mice contain the whole human huntingtin gene, containing 97 
mixed CAG and CAA repeats, encoding polyQ, and 20 kb flanking sequences at the 5ʹ and 3ʹ 
ends [141]. The BACHD transgene also has two lox P sites to excise exon 1 for conditional 
inactivation. The transgene is integrated five times into the genome, and is overexpressed, 
producing three times the endogenous amount of mRNA and about twice the endogenous 
protein. BACHD mice have progressive deficits on the rotarod and by 12 months a 32% decrease 
in striatal volume is present due to decreased cell volume, rather than from a change in neuron 
number [141]. Huntingtin aggregates can be found starting at 12 months of age, and unlike other 
mouse models of HD where the majority of aggregates and inclusions are found in the striatum, 
BACHD mice form aggregates primarily within the cortex [141]. This pattern of aggregate 
distribution is consistent with adult human HD where the aggregates are primarily cytoplasmic 
and located within cortical neurons. The importance of using transgenic mice expressing full-
length human huntingtin is for studies of RNAi targeting the human gene. 
 
4. Knock-in models of Huntington’s disease 
 Knock-in mice have CAG repeats inserted into the endogenous mouse huntingtin gene 
(Hdh). These animals express endogenous levels of huntingtin unlike transgenic mouse models 
which contain additional copies of mutant huntingtin gene. Another benefit of this model over 
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transgenic models is that it eliminates the possibility of altering other genes by the insertion of 
DNA elsewhere in the mouse genome. Knock-in mice with 48Q repeats did not result in an HD 
phenotype, but repeat lengths of 90Q and 109Q resulted in inclusion and aggregate formation 
after 68 weeks without behavioral abnormalities [142, 143]. Mice with 140Q and 150Q show 
characteristics of HD and behavior and pathology with an earlier onset than the 90Q and 109Q 
mice, and these are commonly used as mouse models to study HD [144, 145]. 
One knock-in model with 150 CAG repeats exhibits a late onset and slowly progressing 
phenotype [146]. Homozygous 150Q mice display aggregates beginning at 9 months of age, and 
at 2 years of age display weight loss, decreased activity, rotarod deficits, and clasping [146]. 
Heterozygous mice were tested alongside the homozygous mice and displayed a more moderate 
phenotype [146]. 
 Another widely used knock-in mouse model contains 140Q repeats and part of the human 
huntingtin first intron to replace the corresponding mouse sequences [145]. 140Q knock-in mice 
demonstrate early and progressive behavioral defects, with an increase in rearing behavior at 1 
month and decrease in rearing behavior from 2 months onward [145]. Locomotor activity is also 
decreased and gait analysis reveals smaller stride length at one year [145]. Intranuclear 
inclusions are first noted in the striatum at four months and progressively grow in size and 
number [145]. 140Q mice display a slow progression of disease with moderate behavioral 
findings, notably an absence of tremor, clasping, or weight loss after one year [145]. One benefit 
of having a slow onset of disease is that 140Q mice can be used to study early disease 
pathogenesis and to test pre-symptomatic interventions [145, 147].  
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In mouse models, as in patients, disease onset is dependent on the length of the CAG 
repeat [148]. Unlike humans, mice tolerate much higher repeat number before manifesting 
behavioral and pathological findings. Knock-in mice with 50 CAG repeats, a length that would 
result in HD in patients, exhibit no detectable behavioral or pathological abnormalities [38]. 
While it is reassuring that in general, greater number of CAG repeats result in earlier disease 
onset in humans and murine models, the threshold for disease onset is dramatically different 
between mice and human. One possible explanation for this discrepancy is that there is 
insufficient time for the mutant gene products to accumulate within neurons of mice due to their 
short lifetime. It is also possible that differences in the sequences surrounding the repeat 
expansion, i.e. the first exon, modify the toxicity of the protein through conformation or stability. 
In knock-in mouse models, the Hdh140Q knock-in mice contain a portion of the human exon 1 
and exhibit an earlier onset of both behavioral abnormalities and neuropathology than the 
Hdh150Q knock-in mice which has a completely murine exon 1 [145, 146]. The value in a 
slower progressing mouse model of HD is that it is believed to more closely represent the 
pathophysiology relevant to understanding the disease process. 
 
5.  Other animal models of HD  
 Rat models have several benefits over mouse models of disease. More behavioral and 
imaging tests are available for rats. One rat model of HD is a lentiviral delivered NH2-terminal 
huntingtin fragment with 18, 44, 66, or 82 CAG repeats [149]. The expression of the huntingtin 
fragment is controlled by either the CMV (cytomegalovirus) or PGK (phosphoglycerate kinase) 
ubiquitous promoters [149]. Mice injected with vectors containing 44-82 repeats develop 
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aggregates and loss of DARPP-32 staining in a repeat length-dependent manner. Huntingtin 
expressed by the CMV promoter (a lower expressing promoter) results in fewer aggregates than 
with the PGK promoter. The second model is a transgenic rat that contains a 1.9kb fragment with 
51Q repeats regulated by the rat huntingtin promoter [150]. At two months of age, these rats 
exhibit anxiety and cognitive decline compared with WT rats, and have motor deficits on the 
rotarod at 10 months, and striatal aggregates and inclusion bodies at 12 months of age [150]. The 
third rat model of HD contains a bacterial artificial chromosome (BAC) insertion of human 
huntingtin with 97 CAA/CAG repeats, the same BAC used to make the BAC97 mouse model 
[141, 151]. BAC97 rats have a single insertion site, with 2.5-4.5 higher expression of the mutant 
human huntingtin compared to endogenous rat huntingtin. By one month of age, BAC97 rats 
show deficits on the rotarod, have decreased anxiety and initial hypoactivity [151]. Beginning at 
3 months aggregates are found in the cortex, amygdala and hippocampus, with few in the 
striatum, and aggregates are seen in the neuropil except for the outer layers of the cortex and 
striatum, where they are located in the nucleus [151]. 
 Larger animals such as pigs, sheep, and non-human primates make good models for HD 
because the size and anatomy of their brains resemble that of humans. Several large animal 
models for HD are being characterized. A pig model was created that expressed NH2-terminal 
huntingtin fragment (208 amino acids) with 105 glutamine repeats [152]. There was a very low 
rate of successful embryo transfer (<1-2%) and of four of five live births resulted in early death 
(1-2 days) with the longest survival greater than 4 months [152]. Unlike murine models, 
transgenic HD pigs contained apoptotic neurons with the greatest number within the striatum, 
which recapitulates one aspect human neuropathology and suggests that the pig model share 
similarities with human disease not found in smaller mammals [152]. A transgenic rhesus 
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monkey model for HD was created using human exon 1 fragment of huntingtin with 84Q repeats. 
These monkeys exhibit nuclear and neuropil aggregates, chorea, and dystonia, however these 
animals survived for less than one month of age [153]. A sheep model expressing full length 
human huntingtin with 73Q repeats show decreased staining for medium spiny neurons at 7 
months of age [154]. While the large size, brain anatomy, and potential lifespan make these 
large-animal models attractive, their usefulness has been limited by unexpectedly poor viability 
of the animals. 
 
F. Therapeutic approaches to treating Huntington’s disease 
1. Strategies to counteract excitotoxicity and increase neuroprotection 
One therapeutic approach to treating HD is to reduce excitotoxicity that contributes to 
cell death. In R6/2 mice, Riluzole, a glutamate antagonist, resulted in an increase in body weight 
and an increase in survival compared with vehicle-treated R6/2 mice [155]. Riluzole did not 
show any beneficial effects in HD clinical trials [156]. Lamotrigine, a glutamate antagonist that 
reversibly inhibits vesicular monoamine transporter type 2 (VMAT2), also showed no positive 
results in clinical trials [157]. Tetrabenazine is a dopamine pathway inhibitor which is approved 
to control chorea and has promise in improving function in other areas as well [158]. In YAC128 
HD mice, tetrabenazine decreased striatal cell death [159].  
Neurons affected by HD have mitochondrial impairment leading to oxidative stress 
making these cells susceptible to excitotoxicity. Creatine is a potential therapeutic found to be 
neuroprotective in R6/2 and N171-82Q mouse models of HD possibly by maintaining energy 
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stability in neurons [30]. In HD patients, creatine prevented some weight loss and increased 
some scores on cognitive tests [160]. Coenzyme Q10 is a cofactor in the electron transport chain 
within the mitochondria and an antioxidant that has been shown to ameliorate the early 
behavioral effects of HD in a 140Q knock-in mouse model of HD although no effect was seen in 
the R6/2 mice [29, 161, 162]. Eicosapentaenoic acid (EPA) is an n-3 fatty acid with antioxidant 
and anti-inflammatory properties [163]. However, the clinical trials thus far have shown no 
benefit with either coenzyme Q10 or EPA [164-166].  
Neuroprotection is another approach to help cells function despite the damaging effects 
of mutant huntingtin, and an approach to improve neuroprotection is to increase BDNF. One 
method of increasing BDNF is to give an infusion of the protein directly into the cerebrospinal 
fluid (CSF), by osmotic mini-pump. This was shown to increase the number of enkephalin-
positive neurons in R6/1 transgenic mice (similar to R6/2 mice) [167]. Drawbacks for humans 
include that this delivery system would require permanent access to the CSF that would be prone 
to infection and inflammation, and the protein has a short half-life, therefore it would have to be 
given on a frequent or constant basis. A second method to increase BDNF is by viral gene 
delivery. Adenoviral delivery of BDNF to the striatum of R6/2 mice expressed by a glial-specific 
promoter, gfa2, delayed the behavioral impairment including clasping [168]. The drawbacks to 
viral delivery of BDNF gene depend on the virus utilized, but could include regulating gene 
expression, potential inflammation and integration into the genome disrupting expression of 
other genes. Other methods of increasing BDNF include implantations of mesenchymal stem 
cells that stably release BDNF and small molecules that can stimulate transcription of BDNF and 
BDNF receptors [28, 169-171]. BDNF mimetics and small molecule drugs, including SSRIs, 
memantine, and ampakines are being tested to increase BDNF [2]. 
34 
 
  
2. Strategies to block proteolysis of huntingtin into toxic fragments 
As described earlier, the NH2-terminal huntingtin fragment has been linked to increased 
toxicity, and blocking caspase cleavage improves cell survival and disease progression in mouse 
models [106-110]. Minocycline, an antibiotic that inhibits caspase 1 and 3, was shown to 
improve disease phenotype in R6/2 mice, however the behavioral benefit could not be replicated 
by another research group [162, 172]. The discrepancies in results from these studies could be 
influenced by different behavioral procedures, mouse husbandry practices or chow formulation, 
however a phase II futility study of 114 HD patients found no benefit with minocycline [173]. 
 
3. Treatment by increasing gene transcription 
 Changes in gene transcription are one of the early events in Huntington’s disease [174]. 
Decreased transcription leading to deficits in protein levels of important genes such as D1 and 
D2 dopamine receptors could contribute to neurodegeneration [175]. Histone deacetylase 
(HDAC) inhibitors block the de-acetylation of histones, leading to more histone acetylation 
opening chromatin for increased transcription. There have been mixed findings with HDAC 
inhibitors in mouse models, and a phase II clinical trial (PHEND-HD) has been completed 
testing sodium phenylbutyrate, a non-selective HDAC inhibitor, for safety and tolerability in HD 
patients [176-179]. While HDAC inhibitors alter transcription indirectly by binding an enzyme, 
another approach is to use compounds that interact with DNA directly. Anthracycline antibiotics 
bind DNA and were found to normalize nucleosome arrangement and correct chromatin changes 
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in HD mice in addition to increasing volume of the striatum, increasing survival in R6/2 mice, 
and increasing distance traveled in open field test (also R6/2 mice), however there are no clinical 
trials for anthracycline at this time [180].  
 
4. Strategies to disrupt aggregates and increase clearance of mutant protein 
Despite the debate over the relative harm or benefit of huntingtin aggregation, several 
aggregate blockers have been investigated. In animal models, Congo red, a chemical dye, 
decreased aggregation by blocking polyQ oligomerization. In one study, Congo red improved 
HD phenotype, but these results could not be replicated [181, 182]. Trehalose blocks inclusion 
formation to improve R6/2 mice disease phenotype, and Riluzole blocks aggregation in HD 
animal models [155, 183]. Increasing clearance of misfolded proteins is important for removing 
the toxic molecules from the cell, and there is evidence that both the ubiquitin-proteasome and 
autophagy-lysosomal pathways are impaired in HD [121, 124, 132]. In animal models of HD, 
increasing autophagy by treatment with the antibiotic rapamycin has shown great promise [127]. 
However this drug is not feasible in humans due to the major side effect of immunosuppression 
[184].  
 
5. Strategies to reduce mutant huntingtin mRNA 
Many possibilities exist to reduce huntingtin mRNA, such as interfering with 
transcription factor binding to the huntingtin promoter and the use of zinc-finger nucleases to 
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knock-out the huntingtin gene [185]. Here we focus on the post-transcriptional modulation of 
huntingtin mRNA levels, specifically gene silencing. There are two main approaches to gene 
silencing, RNA interference and the use of antisense oligonucleotides. The first approach is to 
administer double-stranded, short interfering RNA (siRNA) or short hairpin RNAs (shRNA) 
molecules that utilize the RNAi pathway. These small RNAs specifically target the huntingtin 
mRNA sequences in the cytoplasm as part of the RNA-induced silencing complex (RISC) [186]. 
The second method is to administer short DNA molecules known as antisense oligonucleotides 
(ASOs) to target and cleave mRNA in the nucleus and cytoplasm. The single-stranded ASOs 
bind to complementary sequences in the nucleus and cytoplasm then the complexes are degraded 
by the endogenous RNaseH enzyme to cleave target mRNA [187]. The drawbacks of using gene 
silencing include potential off-target effects and the challenge of delivering to the brain [188, 
189].  
siRNA has been tested in many animal models by intraparenchymal injection into 
affected regions of the brain or by intracerebroventriclular (ICV) infusion. In mice, 
intraparenchymal co-injection of adeno-associated virus (AAV) expressing mutant (100 CAG) 
exon 1 with cholesterol-conjugated siRNA (cc-siRNA) targeting huntingtin resulted in improved 
neuropathology and an improved behavior phenotype compared to mice injected with control cc-
siRNA [190]. ASOs have been tested by intraparenchymal or ICV infusion as well. After ICV 
infusion, ASO spreads throughout many brain structures, but does not penetrate dense regions of 
white matter [191]. There is no immune activation and the effect of one treatment in mice can 
last up to 3 months [191]. However, like siRNAs, ASOs must be delivered repeatedly on a long 
term basis. 
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To avoid the need for repeated administration of silencing agent, several groups are 
working on using viral delivery of shRNAs to target huntingtin in mouse models. AAV is a non-
replicating virus that does not integrate into the cell’s genome. AAV-shRNAs have been tested 
in animal models of HD. shRNA reduced mutant huntingtin mRNA in the striatum of N171-82Q 
mice by 51-55% compared with control, resulting in improved gait and rotarod ability [192]. 
Another group used AAV to express shRNA in the striatum of the R6/2 mice, finding a reduction 
in mutant huntingtin mRNA (75%) and protein (60%), a decrease in size and number of 
intranuclear inclusions and normalization of gene expression in neurons [193]. The treatment had 
no effect on rotarod ability but delayed onset of clasping [193]. This approach would only 
require a single administration of the AAV-shRNA for long term expression of the silencing 
molecule. One challenge of this system is controlling the expression level. 
A significant concern about gene silencing is the potential harm of silencing both alleles, 
as 50% reduction of huntingtin may cause behavioral abnormalities and complete absence of 
huntingtin leads to neuronal cell death [36, 194, 195]. Therefore, it is important to monitor the 
amount of silencing that is achieved. A benefit of these strategies is that they are sequence 
specific and can be targeted to single nucleotide polymorphisms (SNPs) that are different 
between the normal and mutant allele in each individual patient. There is a linkage between at 
least one SNP that makes it a target in approximately 50% of HD patients [196]. Approaches that 
focus on allele-specific silencing will decrease the probability of loss of normal huntingtin 
function as a consequence of treatment, while specifically targeting the disease-causing product. 
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G. Summary 
This introduction provides an overview of the impact of the disease, the role of huntingtin 
in the brain, and the pathological features and mechanisms that are known about huntingtin 
protein. Huntingtin has many functions including an essential role in development. In adulthood, 
huntingtin is implicated in several areas of the cell. It has roles in vesicle recycling, regulation of 
transcription, maintaining the energy state of the cell, and has neuroprotective functions 
involving BDNF. When huntingtin is mutated with an expanded CAG repeat, not only does the 
protein partially lose its ability to function normally, it interacts with other proteins resulting in 
cellular dysfunction and death. A hallmark of the disease is the formation of aggregates and 
nuclear inclusion bodies. Whether these aggregates are protective or harmful has yet to be 
established. However, the formation of aggregates may indicate the accumulation of mutant 
protein and the cell’s inability to rid itself of the toxic protein. This introduction summarizes the 
two pathways by which mutant huntingtin can be degraded: the ubiquitin-proteasome system and 
the autophagy-lysosome system. I introduced a protein called puromycin sensitive 
aminopeptidase, which is the subject of Chapter 2. This enzyme has been implicated in the 
activation of autophagy and the accumulation of inclusion bodies in cells expressing mutant 
huntingtin exon 1 fragment [123].  
Lastly, in this introduction, I discussed the current and potential therapies aimed at 
preventing the onset of HD and/or slowing its progression. The majority of therapeutic strategies 
address only one downstream effect of mutant huntingtin such as change in gene transcription or 
neuroprotection. Decreasing mutant huntingtin is a single method to prevent all downstream 
toxicities. Approaches include targeting the mutant huntingtin protein or mRNA by increasing 
degradation, decreasing transcription or decreasing translation. A promising way to impede 
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translation is to degrade mutant huntingtin mRNA by RNAi. One challenge is in selecting the 
best structure, modifications and delivery systems for the silencing agent. In Chapter 3, I discuss 
the optimization of a system for screening silencing molecules in the brain using in vivo 
bioluminescent imaging. 
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Figure 1-1: Circuitry of the direct and indirect pathways of the basal ganglia. Schematic 
depicting the pathways through the basal ganglia: cortical input enters either the direct or indirect 
pathway by synapsing with medium spiny neurons in the striatum. A.) In the indirect pathway, 
dopamine receptor-containing medium spiny neurons (D2) project to the globus pallidus external 
segment (GPe), connecting to the subthalamic nucleus (STN). The subthalamic nucleus connects 
with the substantia nigra pars reticulate (SNr), which then synapses on the thalamus. B.) In the 
direct pathway, dopamine receptor-expressing medium spiny neurons (D1) project to the globus 
pallidus internal segment (GPi), which projects to the thalamus. Substantia nigra pars compacta 
(SNc) provides dopaminergic input to the striatum. Excitatory glutamate (GLUT) releasing 
connections are red. Inhibitory GABA releasing pathways are blue. The excitatory dopamine 
(DA) pathway is purple with “+”, and the inhibitory dopamine connection is purple with “-“.
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Figure 1-2: Mutant huntingtin negatively affects many cellular processes. A.) Cleavage of 
huntingtin generates NH2-terminal fragments of mutant huntingtin that are more toxic than the 
intact protein. Abnormal protein interactions disrupt intracellular processes. B.) Mutant 
huntingtin binds dynactin and other polyQ containing proteins in addition to binding to itself 
forming oligomers and fibrillar intermediates. C.) NH2-terminal fragments form soluble fibrils 
that interact and more severely impair huntingtin function. D.) Mutant huntingtin is targeted to 
the proteasome by ubiquitin modifications, but it cannot be degraded. E.) Dystrophic neurites are 
a pathological finding in neurons that contain full length and NH2-terminal fragments. F.) 
Cytoplasmic aggregates are a pathological finding located in the cytoplasm of neurons. These 
also contain full length and NH2-terminal fragments and are ubiquitinated. These aggregates are 
known to bind and sequester proteasomal subunits. G.) Neuronal intranuclear inclusion bodies 
are a pathological finding that consists of aggregated mutant huntingtin fragments in the nucleus. 
These inclusion bodies bind transcription factors and contribute to transcriptional dysregulation. 
H.) Transcriptional dysregulation is also caused by soluble mutant huntingtin that binds to 
transcription machinery and transcription activators to result in general transcriptional reduction. 
I.) Mitochondrial dysfunction is caused by mutant huntingtin binding to mitochondria to alter 
movement, structure and calcium handling. J.) Impaired vesicle trafficking and endosomal 
recycling results when mutant huntingtin binds Rab11 thereby altering endosome morphology 
and slowing endosome recycling. 
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Figure 1-3: Diagram of huntingtin degradation pathways. A.) Ubiquitin-proteasome system:  
Proteins labeled with ubiquitin chains are targeted to the proteasome for degradation. Proteins 
are unfolded before they enter the proteasome. Multiple proteasomal endopeptidases cleave the 
proteins, and peptides released into the cytosol are further degraded by aminopeptidases. B.) 
Autophagy-lysosome system: A double membrane forms around proteins or organelles to be 
degraded, forming a structure called an autophagosome. The autophagosome fuses with the 
lysosome to create an autophagolysosome where the proteins are degraded by acidic lysosomal 
hydrolases.
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Table 1-1: Comparison of commonly used mouse models of Huntington’s disease 
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CHAPTER II 
 
 
 
THE EFFECT OF REDUCED LEVELS OF PUROMYCIN SENSITIVE 
AMINOPEPTIDASE ON INCLUSION FORMATION AND BEHAVIOR IN A KNOCK-
IN MOUSE MODEL OF HUNTINGTON’S DISEASE 
 
 
 
 This chapter provides evidence that a decrease in puromycin sensitive aminopeptidase 
(PSA) influences behavior and inclusion formation in Huntington’s disease model mice. We also 
demonstrate the sensitivity of neurons to overexpression of PSA. I designed, carried out, and 
analyzed the majority of the experiments under the supervision of Neil Aronin. Ellen Sapp 
quantified the open field assay. Ken Rock provided the PSA knock-out mice. Miguel Esteves 
provided the AAV-hPSA-HA. A version of this chapter is currently being prepared as a 
manuscript for publication.  
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A.  Abstract 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused 
by an expanded CAG repeat in the huntingtin gene encoding for a polyglutamine (polyQ) region 
in the protein [1, 2]. Mutant huntingtin accumulates in neurons, forming cytoplasmic aggregates 
and nuclear inclusion bodies. Both the ubiquitin-proteasome system and the autophagy-
lysosomal system have contributing roles in degrading mutant huntingtin, but the primary 
mechanism of degrading mutant huntingtin remains unknown. Puromycin sensitive 
aminopeptidase (PSA), an enzyme previously implicated in MHC class I presentation and 
degradation of enkephalin, is highly expressed in the brain and has the unique ability to degrade 
polyQ peptides [197-199]. PSA expression reduces mutant huntingtin aggregates in several cell 
types and has a neuroprotective effect in mouse models of tau-induced neurodegeneration [123, 
200].  
The aim of this study was to investigate the role of PSA in the progression of 
Huntington’s disease using a 140Q knock-in mouse model of HD [145]. Since PSA degrades 
polyQ regions and reduces inclusions in cells, we hypothesized that a decrease in PSA would 
worsen behavioral abnormalities and increase the number of inclusion bodies in neurons of 
knock-in mice. In this study we used Psa+/- Hdh140Q/140Q mice to test the effect of a PSA 
deficiency on HD phenotype. We found that reduced PSA resulted in impaired performance on 
the raised beam test and an increased number of intranuclear inclusion bodies. These findings 
demonstrate that a reduction in PSA expression worsens behavioral progression and alters 
inclusion formation in the HD mouse model. To test over-expression of PSA, we created an 
AAV vector expressing the human homolog of PSA (hPSA). Unexpectedly, over-expression of 
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hPSA in the brain of wild type mice resulted in dosage-dependent astrocyte activation and 
neuron death. The toxicity due to high expression levels of hPSA reveals the potency of the 
enzyme and the sensitivity of neurons to increased amount of PSA.  
B. Introduction 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused 
by an expanded CAG nucleotide repeat within the mutant allele of the huntingtin gene [1]. This 
trinucleotide repeat is part of the coding region of the gene, resulting in a protein with an 
expanded polyglutamine (polyQ) region [2]. Mutant huntingtin accumulates in medium spiny 
neurons of the striatum forming insoluble cytoplasmic aggregates and nuclear inclusions 
resulting in cellular dysfunction and neuron loss [2, 80]. HD affects 4-10 in 100,000 people of 
European descent and is characterized by early motor and psychiatric symptoms followed by 
cognitive decline and death [2].  
HD is one of nine neurological diseases caused by polyglutamine expansions, including 
dentatorubral-pollidoluysian atrophy (DRPLA), spinal and bulbal muscular atrophy (SBMA), 
several types of spinocerebellar ataxias (SCAs), all of which result in misfolding, accumulation, 
and aggregation of the polyQ containing protein [201]. Each disease affects a different subset of 
neurons [201]. In Huntington’s disease, onset is inversely proportional to the length of the polyQ 
expansion [202]. This suggests that the length of the polyQ stretch confers toxicity, perhaps by a 
greater resistance to degradation by the cell. One approach to treating Huntington’s disease is to 
decrease the amount of mutant protein in order to alleviate the cytotoxic burden of mutant 
huntingtin. 
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Huntingtin is degraded by both the ubiquitin-proteasome system (UPS) and the 
autophagy-lysosomal system [127]. Huntingtin is targeted to the proteasome by poly-
ubiquitination on lysine residues [118]. Huntingtin is also phosphorylated on serines 13 and 16 
by the IKK (inhibitor of kappa B kinase) that targets it for degradation by the proteasome and the 
lysosome [99]. Interestingly, the presence of an expanded polyQ region reduces the efficiency of 
phosphorylation, possibly contributing to the accumulation of mutant huntingtin [99]. In human 
HD tissue and HD transgenic mice, huntingtin-containing inclusion bodies and aggregates stain 
positive for ubiquitin [81].  
In post-mortem brain tissue from HD patients, there is decreased proteasome activity 
suggesting that mutant huntingtin impairs its function [203]. The proteasome is only able to 
degrade soluble proteins prior to the formation of aggregates, therefore the role of the UPS 
would be most important early in the disease [124, 204-207]. In HD model neuronal cell culture, 
proteasome activators improve proteasome function and improve viability against toxic insult 
[208]. Treatment with proteasome inhibitors results in accumulation of mutant huntingtin protein 
and inclusion formation cell models and 140Q knock-in mouse model, although few mice were 
examined (n=2) [126, 209].  
Autophagy is also a pathway for the degradation of huntingtin [62, 131, 210-212]. Mutant 
huntingtin aggregates sequester the mammalian target of rapamycin (mTOR), and the loss of 
mTOR activates autophagy [129]. Treatment with activators of autophagy reduces inclusion 
number and cell death in mutant huntingtin-expressing cells, decreases neurodegeneration in a 
fly model of HD, and improves behavior in a mouse model of HD [213, 214]. 
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The mechanism by which the proteasome degrades polyQ repeats in mutant huntingtin is 
not known. In vitro experiments reveal that eukaryotic proteasomes digest polyglutamine 
polypeptides slowly, sometimes expelling polyglutamine stretches intact [121]. Similarly, the 
proteasome is unable to degrade NH2-terminal mutant huntingtin, releasing incompletely 
digested fragments [125]. An insight into the degradation of polyQ repeats has been the 
identification of puromycin sensitive aminopeptidase (PSA), an enzyme with the ability to digest 
polyQ peptides [122]. In cell extracts, PSA has the ability to degrade polyQ stretches up to 30 
amino acids in length [122]. Longer polyQ lengths were unable to be studied due to aggregation 
under the experimental conditions. Nevertheless, the authors concluded that PSA is the only 
enzyme identified with the ability to degrade polyQ peptides, a property that may be critical for 
degradation of the toxic NH2-terminal fragments of mutant huntingtin [122]. 
PSA is a 99 kDa zinc metallopeptidase ubiquitously expressed enzyme with highest 
levels in skeletal muscle, heart, brain, kidney, liver and testes. In the brain, PSA is the most 
highly expressed aminopeptidase [199, 215]. PSA exists as membrane bound and soluble forms, 
implicated in enkephalin degradation, polyQ peptide degradation, and in processing peptides for 
MHC class I presentation [122, 197, 216, 217]. PSA also associates with the spindle apparatus in 
G2/M phase, suggesting that it could be involved in the cell cycle [218]. Reduction of PSA 
results in decreased migration, proliferation, and invasion of PC-3 cells, a prostate cancer cell 
line [219]. PSA knockout mice exhibit increased anxiety, decreased pain response, male 
reproductive abnormalities and female maternal behavior deficits [220-222]. 
Several studies show effects of PSA on the degradation and processing of proteins 
relevant to neurodegenerative diseases. Cu, Zn-superoxide dismutase-1 (SOD1) is a protein that 
is frequently misfolded in both familial and sporadic cases of amyotrophic lateral sclerosis 
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(ALS) [223]. In cell culture experiments, protein levels of SOD1 were inversely related to 
protein levels of PSA, and in a cell-free system SOD1 was shown to be a target of PSA 
proteolysis [223]. Tau is a protein that aggregates in both frontotemporal dementia (FTD) and 
Alzheimer’s disease. Silencing PSA in cell culture results in accumulation of tau, however, the 
effects of PSA on tau are indirect as PSA was not shown to directly cleave tau [224, 225]. 
Another group found that PSA does degrade tau from extracts of brain from FTD and 
Alzheimer’s patients’ brains [226, 227]. PSA is up-regulated in the cerebellum of FTD model 
mice and FTD patients [226]. A Drosophila model of FTD with decreased PSA exhibit increased 
neurodegeneration and increased aggregation of tau [228]. An increase in PSA prevents 
neurodegeneration in FTD mice [226].  
PSA expression has also been shown to affect the accumulation of mutant huntingtin. In 
transfected cell culture and muscle tissue expressing mutant huntingtin, reducing PSA resulted in 
a greater number of aggregates and cell death, while overexpressing PSA resulted in fewer 
aggregates and cell death [123]. The beneficial effects of PSA overexpression on huntingtin-
expressing cells may be the result of an increase in autophagy, as chemically blocking autophagy 
negated the effects of PSA [123]. These findings in cell culture seem to suggest that the 
mechanism of huntingtin degradation by PSA is indirect, through the activation of autophagy 
rather than by increasing the rate of polyQ degradation. However, these experiments were 
performed in cell culture experiments with very high overexpression of PSA, which warrants 
caution in extrapolating this conclusion to the physiologic function of PSA in the brain.  
The aim of this study is to investigate whether PSA level influences the phenotype in a 
knock-in mouse model of Huntington’s disease. Previous studies have been limited to studying 
the interaction of a huntingtin fragment in cell culture and in the muscle tissue of PSA 
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heterozygous animals. Here, we use PSA heterozygous mice crossed with HD 140Q knock-in 
mice to investigate the effect of PSA reduction on disease-related phenotypes in a mouse model 
of Huntington’s disease. The advantage to using a mouse model of HD is that mice can be tested 
for behavioral changes as well as pathological changes. To interpret the effect of PSA on HD, it 
is crucial to examine tissues and cells most affected by the disease.  
Our study showed that at 12 months, the PSA heterozygous HD mice (Psa+/-Hdh140Q/140Q) 
had a worsening of balance and coordination on the raised beam test, and the number of nuclear 
inclusions was significantly increased. The results demonstrated that Psa+/-Hdh140Q/140Q mice 
exhibit a more severe phenotype than Psa+/+Hdh140Q/140Q mice. If a reduction in PSA worsens 
symptoms and increases inclusion number in a mouse model of HD, we wanted to explore 
whether an increase in PSA would delay the onset or reverse behavioral and pathologic 
outcomes. To test this, we created a gene therapy approach to deliver hPSA to the striatum. In 
testing the virus in wild type mice, we found that the virus caused toxicity in a dose dependent 
manner. The observed cell death and glial activation suggest that neurons are sensitive to over-
expression of hPSA at the dose given. 
C. Results 
1. PSA knock-out animals do not breed well and are smaller than littermates. 
 
The study of PSA knock-out animals (PSA-/-) is a challenge for several reasons. In 
agreement with previous studies, we found that PSA knock-out mice do not breed well, 
producing very few litters [197]. For example, one would expect Psa+/- breeding pairs to produce 
Psa+/+: Psa+/-: Psa-/- at a 0.25:0.5:0.25 frequency. In our experience, the average litter size from a 
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representative sample of 15 litters was 4.73± 1.5 pups with a frequency of 0.42: 0.5: 0.083 
(Table 2-2). A second reason discouraging the use of PSA knockout animals is that they are 
smaller compared with age and sex-matched heterozygous or wild type littermates [197]. PSA 
knock-out mice weigh about 65% as much as age-matched heterozygous littermates at one and 
six months of age (Fig. 2-1, unpaired t-test p=0.003 at 1 month, p=0.0247 at 6 months). 
Complete data on weight for each mouse is also shown in Table 2-1. This concurs with findings 
reported for a different line of PSA deficient mice, Psagoku/goku, using the gene-trap method to 
disrupt PSA expression [222]. Psagoku/goku mice display body weight <70% of WT mice [222]. 
The difference in size precluded us from using Psa-/- mice in tests on the raised beam because 
their decreased size and weight could affect their performance in comparison with larger 
animals. The difference in size raises the possibility that developmental differences might exist 
which could affect the comparison between wild type and PSA knock-out HD animals. Since 
heterozygous animals breed normally, are born at expected frequency, and are equal in size to 
wild type littermates, we chose to use heterozygous mice to investigate the impact of a reduction 
in PSA in HD animals. 
 
2. PSA mRNA and protein are expressed in a gene dosage-dependent manner. 
In order to use Psa+/- animals to represent a reduction in PSA, we first assessed whether 
there is a gene dosage effect of the PSA gene. We looked at the relative mRNA and protein 
levels in Psa-/-, Psa+/- and wild type striatum and cortex. Quantitative PCR (qPCR) from striatal 
tissue of PSA mice showed that heterozygous mice express about 50% the amount of PSA 
mRNA as wild type mice (Fig. 2-2 A, Tukey’s pairwise comparison p=0.008). Western Blot 
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analysis of tissues from the cortex shows that heterozygous mice express about 50% as much 
protein as control mice (Fig. 2-2 B, Tukey’s pairwise comparison p=0.0055). In the striatum, 
PSA protein levels in heterozygous mice were 60% of wild type levels, but this did not quite 
reach statistical significance. There was no detectable PSA mRNA or protein in the knock-out 
animals (Fig. 2-2 A, B, C, D). The significant reduction of PSA mRNA from the striatum and 
PSA protein from the cortex (and a non-significant reduction of protein in the striatum) in Psa+/- 
mice suggests that there is gene dosage effect; however there are few animals per group, 
resulting in low experimental power. 
 
3. Psa-/- and Psa+/- mice do not display a locomotor defect on the raised beam test and do 
not form ubiquitin positive nuclear inclusion bodies. 
In a previous study, some Psa-/- mice were observed to have a locomotor defect in their 
hind legs [197]. It was found that Psagoku/goku mice do not have abnormalities on the raised beam 
test, however in this study heterozygous mice were not tested [222]. The raised beam test 
evaluates the balance and coordination of a mouse as it crosses a narrow beam. To confirm the 
raised beam test finding in Psagoku/goku mice and to test Psa heterozygous mice, we tested Psa-/- 
and Psa+/- mice for behavioral defects on the raised beam test. We found no difference in either 
group compared with wild type mice at 6, 8 and 10 months of age (Fig. 2-3 A). Psagoku/goku mice 
have reduced activity in the open field test and reduced rearing compared with wild type mice 
[222]. In our observations regarding general activity, we found the opposite effect in our Psa-/- 
mice. Psa-/- mice exhibited an increase in home cage activity and an abnormal behavior of 
jumping off of the beam.  
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Inclusion bodies and visible aggregates of many mutant aggregating proteins can be 
detected by immunohistochemistry (IHC) with antibodies specific for ubiquitin. In sections from 
Psa-/- mice (9 and 22 months old), there was no staining for ubiquitin positive inclusion bodies or 
aggregates in the striatum (Fig. 2-3 B). There was cytoplasmic staining for ubiquitin but no more 
than in the wild type control. Psa-/- sections (from mice 9, 17, and 22 months old) were also 
stained for huntingtin aggregates to be certain that there is not impairment in degrading normal 
huntingtin. No staining for huntingtin inclusions was seen (Fig. 2-3 C). Psa+/- animals were also 
negative for huntingtin inclusion formation (assessed directly in subsequent experiments).  The 
findings that Psa-/- and Psa+/- mice do not have a locomotor phenotype and Psa-/- mice do not 
have nuclear inclusions or cytoplasmic aggregates, allow us to use these measures as endpoints 
in our study of the effects of reduced PSA on HD mice.  
 
4. PSA reduction does not accelerate the onset of locomotor deficits or reduce activity in 
PSA+/- Hdh7Q/140Q. 
A measure of progression of disease in the knock-in mice is the development of 
behavioral and locomotor abnormalities. Hypoactivity appears in heterozygous (Hdh7Q/140Q) 
knock-in mice at around 4 months of age, and gait abnormalities appear at 1 year of age [145]. 
To test for an early effect of PSA heterozygosity on raised-beam behavior, we analyzed Psa+/- 
Hdh7Q/140Q and compared them with Psa+/- Hdh7Q/7Q and wild type mice (Psa+/+ Hdh7Q/7Q). We 
used the raised beam test to look for early interaction of PSA heterozygosity on heterozygous 
knock-in HD mice beginning at 3 months of age, continuing to 10 months of age (Fig 2-4 A). 
These mice were initially tested every week for the first month (no difference between the 
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groups, data not shown). Over time, mice in all groups became increasingly resistant to crossing 
the beam, therefore time points after 10 months were not tested. Because heterozygous knock-in 
HD mice with Psa+/- versus Psa+/+ showed no difference on the raised beam test by 10 months of 
age, we conclude that there is no effect of the Psa+/- genotype on locomotor abilities of 
Hdh7Q/140Q mice at early time points.  
We also tested these same mice in an open field test at 13 months of age. Psa+/+ 
Hdh7Q/140Q mice showed reduced activity compared with all other groups, including Psa+/- mice, 
the latter of which showed no difference from wild type mice (Fig. 2-4 B). These results show 
that a PSA reduction unexpectedly improves activity in Hdh7Q/140Q mice (Tukey’s multiple 
comparison p=0.00569). The increase in activity of Psa+/- Hdh7Q/140 mice compared with Psa+/+ 
Hdh7Q/140Q mice suggest that PSA heterozygosity might increase general activity in HD animals.  
 
5. PSA deficiency in Hdh7Q/140Q mice does not affect the number of inclusion bodies 
 Inclusion body formation can be used to follow disease progression in knock-in mice. 
Inclusion bodies begin forming at four months of age and continue to increase in size and 
number as the mice age and the disease progresses [145]. At 1.5 years of age, there was no 
difference in the number of inclusion bodies in either the striatum or the cortex of Psa+/- 
Hdh7Q/140Q compared with Psa+/+Hdh7Q140Q mice (Fig. 2-4 C). We did not test Psa+/-Hdh7Q/7Q mice 
because in previous studies they did not exhibit huntingtin inclusion formation (Fig. 2-3).This 
demonstrates that the formation of inclusion bodies in Hdh7Q/140Q mice is not altered by a 
reduction in PSA. 
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6. PSA deficiency worsens locomotor deficits in 12 month old Hdh140Q/140Q mice 
In our experience, Hdh7Q/140Q mice have a less severe phenotype than do Hdh140Q/140Q 
mice, so next we tested the effect of PSA reduction on homozygous knock-in mice (Hdh140Q/140Q) 
to see if there was a change in a more severe disease model. In Psa+/- Hdh140Q/140Q mice, the 
relative decrease in the amount of PSA protein is similar to previous findings, although this 
difference is not statistically significant due to the large variation within each group (Fig. 2-5 A, 
B).  
Previously, in the raised beam test, mice became resistant to crossing the raised beam, 
therefore, in order to preserve accuracy of the test we chose a single time point to test Psa+/-
Hdh140Q/140Q mice for locomotor deficits. We chose to test these mice at one year of age, a time 
point where the animals are more advanced in their disease.  Psa+/-Hdh140Q/140Q mice took longer 
to cross the raised beam than Psa+/+Hdh140Q/140Q mice (n.s.), and were significantly slower in 
beam crossing than wild type mice (Fig. 2-5 C). Psa+/- HD140Q/140Q mice had a significantly 
greater number of foot slips than the Psa+/+ HD140Q/140Q mice and an increase compared with wild 
type mice. Findings that Psa+/- HD140Q/140Q mice performed worse on the raised beam test, in 
terms of footslips, than Psa+/+ HD140Q/140Q mice suggest that PSA heterozygosity increases the 
progression or severity of the HD phenotype in the Hdh140Q/140Q mice at one year of age. This 
contradicts previous findings using Hdh7Q/140Q mice, possible due to an increased polyQ burden 
from twice the amount of mutant Hdh protein. 
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7. PSA reduction increases the number of nuclear inclusions in 12 month old Hdh140Q/140Q 
mice 
 We then looked at the formation of inclusion bodies in 12 month old Psa+/-Hdh140Q/140Q 
mice. Since the number of inclusions correlates with the severity of the disease in knock-in HD 
mice, we predicted that a decrease in PSA will increase the number of inclusion bodies [145]. By 
stereological quantification, there was a significant increase in the number of intranuclear 
inclusion bodies in the Psa+/-Hdh140Q/140Q mice (Fig. 2-6 A-C). No difference in the number of 
neurons was observed between the Psa+/-Hdh140Q/140Q mice and the Psa+/+Hdh140Q/140Q mice (Fig. 
2-6 F). Interestingly, the Psa+/-Hdh140Q/140Q mice had slightly smaller size of inclusions compared 
with Psa+/+Hdh140Q/140Q mice; however this difference was not statistically significant (Fig. 2-6 
D) (Unpaired t-test, p=0.1981).  
Stereological quantification of cytoplasmic aggregates was also performed. These were 
differentiated from nuclear inclusion bodies as they are smaller and irregular in shape and are 
outside of the nucleus. The difference in the number of aggregates was not statistically 
significant, but the average number of cytoplasmic aggregates in the Psa+/-Hdh140Q/140Q was less 
than the Psa+/+Hdh140Q/140Q (Fig. 2-6 E) (Mann-Whitney U test, p=0.1388).  The observations that 
the inclusion bodies are smaller and fewer aggregates are observed could point to a role of PSA 
in the distribution of mutant huntingtin between the nucleus and the cytoplasm.  
 
8. PSA deficiency has no effect on soluble huntingtin and autophagy 
 To test whether the increased number of inclusion bodies represents a reduction in 
soluble huntingtin, we performed western blot analysis on cell extract from the striatum using 
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antibodies generated from amino acids 1-17 of human huntingtin (AB1 antibody [229]). We 
found no change in huntingtin levels among the groups (Fig. 2-7 A).  
  We tested whether a decrease of PSA in HD mice would result in a decrease in autophagy 
[123]. LC3-I is converted to LC3-II representing an increase in autophagy. We could not detect 
LC3-II, a marker of autophagy activation, and we did not find any change in the amount of LC3-
I (Fig. 2-7 B). 
  
9. AAV-hPSA-HA injection in wild type mice leads to hPSA expression in the brain. 
 To investigate the effect of an increase in PSA on behavior and pathology in HD mice, 
we created an AAV vector expressing human PSA (hPSA) tagged with the hemagglutinin (HA) 
epitope, for this study we will refer to it as AAV-hPSA-HA. Human PSA is 98% identical to 
mouse PSA at the amino acid level [199]. To test that the AAV-hPSA-HA virus expresses hPSA 
in the brain, we injected a series of doses, all 3µL in volume, into the striatum of wild type mice 
(Fig. 2-8 A). hPSA can be detected in brain extracts three weeks after intraparenchymal injection 
at concentrations as low as 1e10 GC (genome copies) using HA antibodies. These results 
demonstrate that AAV-hPSA-HA is expressed and can be detected using HA antibodies.  
 
10. Overexpression of hPSA in wild type mice is toxic at high concentrations. 
 In AAV-hPSA-HA-injected wild type mice, we found extensive toxicity demonstrated 
both by the loss of neurons and by glial activation. In order to test whether PSA toxicity in 
mouse neurons is dose dependent, we injected 10-fold dilutions (1e12 GC, 1e11 GC, 1e10 GC, 
and 1e9 GC) of AAV-hPSA-HA, all 3µL in volume, into the striatum and looked for HA, GFAP, 
and DARPP-32 reactivity after three weeks. At 1e11 GC there was spread of hPSA-HA 
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throughout many sections of the striatum, but at ten-fold dilution (1e10 GC) the spread was 
limited to a few sections (Fig. 2-9 A). Doses of 1e10 and 1e9 GC resulted in very few HA 
positive cells (not shown). Staining for glial fibrillary acidic protein (GFAP) revealed a 
widespread activation of astrocytes in the 1e11 GC concentration and limited activation in the 
1e10 GC and control injection sections (Fig. 2-9 B). In the 1e11GC concentration there was a 
complete loss of DARPP-32 staining for medium spiny neurons corresponding with the site of 
injection (Fig. 2-9 C). We confirmed that the cells expressing PSA are neurons by double 
immunofluorescence labeling of HA and DARPP-32 (Fig. 2-9 D). In summary, the extent of 
spread is greatest at the highest dose (1e11 GC) with the adverse effect of eliciting significant 
glial activation. At 1e10 GC concentration, the spread is limited, but there is minimal glial 
activation.  
 To test whether there were contaminants in the viral preparation which could account for 
the observed toxicity, we did a time course experiment to assess whether cell death and astrocyte 
activation corresponds with the expression of hPSA-HA. HA reactivity was detectable at one 
week after injection and preceded the activation of astrocytes and loss of DARPP-32 positive 
cells (Fig. 2-10). That HA reactivity is found before toxicity suggests that there are no 
contaminants in the virus preparation and that expression of hPSA-HA is toxic to cells at the 
measured level. To confirm that the virus was not contaminated, new preparations can be made 
parallel to a control virus to compare toxicities. 
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D. Discussion 
 
We are the first to show that heterozygosity for the PSA gene affects the behavior and 
inclusion formation in a knock-in mouse model of Huntington’s disease. On the raised beam test, 
the Psa+/- Hdh140Q/140Q mice had a greater number of foot slips compared with Psa+/+ Hdh140Q/140Q 
mice (Fig. 2-5 C). Since there was worsened performance on the raised beam test, a test for 
balance and coordination, we conclude that there is functional impairment resulting from PSA 
heterozygosity. 
We measured huntingtin protein from striatal cell lysates and did not detect a difference 
in the amount of full-length mutant huntingtin between the Psa+/- Hdh140/140 and Psa+/+ Hdh140/140 
groups (Fig. 2-7 A). Cell lysates for Western analysis were prepared by performing a low speed 
spin to remove mitochondria, lysosomes, and the nuclei. The fraction of mutant huntingtin 
measured consisted of the soluble, cytoplasmic, full-length mutant huntingtin (Fig. 2-11 A, B). 
This measurement did not include full-length huntingtin associated with aggregates and inclusion 
bodies, NH2-terminal fragments or fibrillar forms of mutant huntingtin. Using stereological 
techniques, we show that decreased PSA results in a greater number of inclusions in neurons of 
the striatum (Fig. 2-6 C). This is consistent with previous findings in the muscle tissue of Psa+/- 
mice transfected with huntingtin exon 1 containing 74Q, in which the number of inclusions was 
increased [123]. The number and size of nuclear inclusions largely represent the insoluble NH2-
terminal fragment of mutant huntingtin. Our interpretation of these results is that PSA 
heterozygosity contributes to an accumulation of insoluble mutant huntingtin. In this 
interpretation there is no increase in full-length mutant huntingtin, but there is an increase of the 
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NH2-terminal fragment of mutant huntingtin as measured by the number and size of cytoplasmic 
aggregates and intranuclear inclusion bodies. In addition to mHtt lost in insoluble fragments, it is 
preferentially membrane bound, and, hypothetically, could bind to any membrane after cell lysis 
[230]. There are several challenges in measuring the content of mutant huntingtin as it is 
distributed throughout multiple compartments, soluble and insoluble conformations, and 
preferentially membrane bound. 
A caveat to our results in Psa+/- Hdh140Q/140Q mice is that we were unable to demonstrate 
that PSA protein was significantly reduced compared with PSA wild type animals in the striatum 
in two experiments, each with groups of 4 or less animals (Figs. 2-2, 2-5). Using groups of three 
mice we show that Psa mRNA is significantly reduced by 45% in striatum of Psa+/- mice. In the 
cortex, also n=3, PSA protein was reduced in Psa+/- mice by 55%. One reason for inconsistencies 
in showing a decrease in PSA protein may be that the sample size, and thus power of the 
experiment was too low to detect the differences. Examination of tissue from additional animals 
is needed to confirm that there is a difference in PSA expression level in Psa+/- mice. 
Since the effect of Psa haploinsufficiency resulted in a greater number of inclusion bodies 
and an earlier deficit on the raised beam test, we sought to overexpress PSA in HD mice to 
determine if there was a therapeutic effect on inclusion formation and behavior. To overexpress 
PSA we created an AAV expressing human PSA tagged with the HA epitope. Upon testing this 
construct in wild type mice, we observed widespread cell loss and astrocyte activation three 
weeks after injection. Potential sources of toxicity include contaminants in the preparation of the 
virus, immunogenicity of the HA tag, expression of a foreign gene, and peptidase activity. The 
expression of hPSA-HA occurs before the astrocyte activation and cell death, suggesting that 
hPSA-HA expression is causing the toxicity rather than contaminants in the viral prep. There 
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were no problems reported in other viral preps performed at the same time in the same facility. 
The HA tag has previously been used to follow AAV-delivered protein expression in the mouse 
brain with no immunogenic result [231]. It is unlikely that hPSA would be identified as a foreign 
protein because it has a sequence consensus with the mouse PSA of 98% [199]. At lower doses 
of AAV-hPSA-HA, there is less glial activation while maintaining detectable HA reactivity three 
weeks after injection, suggestive of a dose response for toxicity. It was reported that high 
overexpression of PSA in Drosophila resulted in toxicity that was not found at lower expression 
levels of PSA [123]. Toxicity was not described in cell culture or in muscle cells overexpressing 
high levels of PSA [123].  Without details on the toxicity in Drosophila that was not published, 
there are several explanations, one being that neurons could be more sensitive to PSA or that all 
cells are sensitive to very high overexpression of PSA. There is a line of transgenic mice 
expressing human PSA at levels two to three fold higher than endogenous PSA without signs of 
developmental abnormality or glial activation [200]. As a transgenic model, these mice have had 
the opportunity to compensate for overexpression of PSA whereas mice injected with AAV-
hPSA-HA are fully developed animals. This does not exclude the possibility that 2-3 fold 
overexpression of PSA is not toxic if suddenly expressed in adult neurons. It would be 
particularly informative to cross the transgenic PSA overexpressing mouse model with knock-in 
huntingtin mice in order to investigate the effect of low PSA overexpression on the progression 
of HD. A reduction in disease severity or a delay in onset in these mice would support our 
hypothesis that PSA is protective in HD. Our view is that suddenly increasing PSA expression in 
neurons to high levels is toxic in the adult mouse brain. We could test the effect of adult onset of 
PSA overexpression by creating a tetracycline-regulated expression system. In this way, the gene 
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can be turned on and off intermittently to avoid toxicity. It would be ideal to identify a small 
molecule enhancer that can increase expression or activity of the endogenous gene. 
 The mechanism of degradation of huntingtin is largely unknown. Understanding the 
degradation of huntingtin is important because it represents possible therapeutic interventions in 
the treatment of Huntington’s disease. PSA is the only identified aminopeptidase able to degrade 
polyQ peptides efficiently making it a likely participant in the degradation of mutant huntingtin 
[121, 122]. PSA is a versatile aminopeptidase, able to cleave bonds between a wide range of 
amino acids at the NH2-terminus of proteins, including huntingtin. This property is especially 
important for huntingtin as the first 17 amino acids of huntingtin, known as N17, is highly 
aggregate-prone; it binds to itself and to the polyQ region of other fragments, full mutant 
huntingtin, and normal huntingtin proteins to promote aggregate formation [232, 233]. It was 
found that deletion of the N17 decreased aggregation of mutant huntingtin [232]. It is possible 
that a reduction in PSA results in reduced degradation of the NH2-terminal residues of huntingtin 
and a greater number of molecules subject to N17-mediated aggregation. This would increase the 
number of inclusions in Psa+/- HD mice. There might be more nuclear inclusions because 
huntingtin aggregates are trapped in the nucleus. This mechanism was proposed in diseases 
where tau protein accumulates and forms aggregates, (so-called tauopathies) including 
frontotemporal dementia (FTD) and Alzheimer’s disease [227]. There are conflicting results of 
whether PSA acts directly on tau protein. One in vitro study using mass-spectroscopy to analyze 
cleavage products found that PSA purified by multiple methods does not result in tau 
degradation products [224]. Another in vitro study using NH2-terminal tau antibodies found that 
purified hPSA cleaved tau in vitro [227]. These conflicting results point to two different 
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mechanisms: a mechanism of direct degradation of tau by PSA or indirect degradation of tau 
possibly by autophagy or the ubiquitin-proteasome system. 
A second mechanism of PSA degradation of huntingtin is through the induction of 
autophagy. In cell culture models expressing an expanded huntingtin fragment, over-expressing 
PSA induces autophagy [123]. In our examination of markers of autophagy in the striatum, we 
could not detect the LC3-II band on western blot from HD mice, so we could not test the 
hypothesis that in PSA+/- mice autophagy would be decreased. In a transgenic mouse expressing 
human PSA resulting in a 2-3 fold increase in PSA activity and total PSA expression, there was 
no increase in autophagy [200]. More evidence for an indirect method of action is that PSA 
expression modifies other diseases that do not contain polyQ regions, such as mutant tau protein 
and mutant SOD1 [123, 200, 223] .  
We assessed expression of PSA in the striatum of Hdh140Q/140Q mice and found no 
difference in expression compared with wild type mice, contradicting the finding in PC-12 cells 
that expression of HD exon 1-74Q induced expression of PSA [234]. The difference between the 
results in cell culture with that in mice and human disease is not unprecedented [234].  In 
neuroblastoma cells, SOD1 overexpression increased expression of PSA whereas in transgenic 
mutant SOD1 mice the expression of PSA in the brain was decreased [223]. The expression of 
PSA in frontotemporal dementia (FTD) patients was not altered except for in the cerebellum 
where it was increased significantly [228]. The cerebellum is a region of the brain unaffected by 
FTD (as in HD) and it is possible that increased PSA is protective in those tissues that are 
unaffected by the mutant protein. 
One limitation is that our study does not uncover any clues to the mechanism by which 
PSA acts on mutant huntingtin. We were able to detect LC3-I, but not LC3-II by Western 
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analysis in all samples tested. LC3-I represents soluble protein, while LC3-II is conjugated with 
the phospholipid phosphatidylethanolamine and correlates with the number of 
autophagolysosomes [235]. LC3-I alone cannot be used to draw any conclusions about the 
upregulation of autophagy, therefore this data is not informative in terms of supporting or 
refuting a change in autophagy status among the mice examined. Supernatant fraction from brain 
lysate is expected to have an abundance of LC3-I, however LC3-II can be detectable at low 
levels even in wild type animals with increased LC3-II detected with polyQ expansion of 
huntingtin [61, 129, 236]. The next step to analyze autophagy in brain lysates would be to test 
the pellet fraction for enriched LC3-II protein. The protein extraction procedure in this study 
employed one high speed spin to isolate the supernatant fraction, and an alternative approach 
would be to use differential centrifugation, two slow speed spins, to first remove nuclei before 
separating cytoplasmic from membrane organelles [236]. It is possible that Western blot 
conditions must be adjusted to detect more subtle bands. In this experiment, the positive control 
would be the Hdh140Q/140Q group of mice, which should induce autophagy, while if Psa operates 
through augmentation of autophagy, we hypothesize that the Psa deficiency would reduce that 
increase [129]. 
Future experiments to extend the results found in this study would use viral delivery 
system to express hPSA at a lower level, by using a weaker promoter. The goal would be to test 
these constructs in an HD mouse model to look for an amelioration of the disease that could 
become gene therapy for HD patients. It is important to analyze the number of cells expressing 
AAV-hPSA and the spread of the virus throughout the brain. Alternatively, the HD knock-in 
mice could be bred with PSA overexpressing mice creating a mouse line that stably expresses 
both human PSA and mutant mouse huntingtin [200]. It is also important to show that PSA 
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degrades the NH2-terminus using purified huntingtin and PSA in an in vitro assay to elucidate 
the mechanism of PSA degradation (direct degradation or indirect through autophagy). Mass 
spectrometry would be particularly useful in determining the fragments created by the 
degradation and to show NH2-terminal degradation. 
 In this study, we find that Psa+/- Hdh140Q/140Q mice have a more severe locomotor 
phenotype and a greater number of intranuclear inclusions compared with HD mice. Assuming 
that there is a significant reduction in PSA protein, the behavioral and neuropathological findings 
support our hypothesis that a reduction in PSA would worsen HD in a knock-in mouse model. 
Our study is significant for using a knock-in model of HD which expresses full length huntingtin 
at endogenous levels rather than an overexpressed fragment of mutant huntingtin in cell culture 
or muscle tissue. HD knock-in mice recapitulate aspects of the human disease and can be used to 
examine changes in the context of the brain as well as changes in behavioral measurements. 
Based on our results with AAV-mediated overexpression of PSA, we conclude that neurons may 
be particularly sensitive to acute PSA overexpression in adulthood. This may limit the utility of 
AAV-based methods for overexpression and gene therapy using PSA. 
 
E. Materials and Methods 
1. Mouse lines and genotyping 
 FVB mice (female, 3-6 months old, FVB/NJ from Jackson Laboratory, Bar Harbor, ME) 
were injected with 3 µL volumes of AAV9-CMV-hPSA-HA with various doses (1e12 GC/mL, 
1e11 GC/mL, 1e10 GC/mL or 1e12 GC/mL AAV9-CMV-Luc-Htt (control virus expressing 
firefly luciferase with huntingtin target sequences in the 3'-UTR). 
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PSA knock-out mice were obtained from Ken Rock (University of Massachusetts 
Medical School, Worcester, MA) [197]. DNA extracted from tail biopsies was used for 
genotyping by PCR. Primers for PSA were PSA.Ex5.L2 5'-
GACAGGAAACCATATCCTGATGA-3', and PSA.Ex5.R2 5'-CTTTCCTTGCTCTGCTTTGC-
3' and primers for the knock-out allele were LacZ.L2 5'-GACGTCTCGTTGCTGCATAA-3', and  
LacZ.L2 5'-CAGCAGCAGACCATTTTCAA-3'. Amplification products are 400bp for the 
knock-out allele and 180bp for the wild type allele. We use HotStarTaq Master Mix Kit 
(Qiagen). The program for PSA is 1) 95C for 15 min, 2) 95C for 30 sec, 3) 55C for 30 sec, 4) 
72C for 90 sec 5) repeat steps 2-4 34 times, 6) 72C for 5 min.  
Huntingtin knock-in mice were obtained from Scott Zeitlin (University of Virginia 
School of Medicine, Charlottesville, VA) [145].The primers for Hdh140Q are CAG140For 5'-
CTGCACCGACCGTGAGTCC-3', CAG140Rev 5'-GAAGGCACTGGAGTCGTGAC-3'. These 
primers span a region of mouse huntingtin that is deleted in the knock-in allele. Knock-in allele 
is represented by a 156bp band and the wild type allele is represented by a 235bp band. The 
program for Hdh140Q/140Q is 1) 95C for 5 min, 2) 94C for 20 sec, 3) 67C for 30 sec, 4) 72C for 15 
sec, 5) repeat steps 2-4 for 40 times, 6) 72C for 5 min. PCR products were separated by agarose 
gel electrophoresis and visualized by ethidium bromide staining and UV-transillumination. 
Mouse housing and procedures were approved by the University of Massachusetts Medical 
School animal protocol A-978-12. 
2. Stereotactic injection  
FVB mice (female, 3-6 months old, FVB/NJ from Jackson Laboratory, Bar Harbor, ME) 
were anesthetized with 250 mg/kg tribromoethanol (2.5 g 2, 2, 2, tribromoethanol dissolved in 
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5mL amylene hydrate into 200mL PBS). Anesthetized mice were placed on a heated pad in a 
stereotactic frame. Superglue (Loctite) was applied to the surface of the fur between the ears, 
avoiding eyes and exposed skin. After 10-20 seconds, the glue is gently pulled off to remove fur. 
The exposed skin is cleaned with betadine and an incision is made posterior to anterior. The skin 
is pulled aside and the needle is placed over the bregma. Unless otherwise stated, measurements 
for drilling the hole and placing the needle are: anterior 1mm, lateral 2mm and ventral 3mm from 
the bregma. Once the needle is lowered, it rests there for 2 minutes before infusion of 3µL at a 
rate of 125nl per minute (NanoFil syringe, World Precision Instruments). After infusion the 
mouse rests for 2 minutes before the needle is withdrawn. The incision is closed with clear, 
undyed suture (monocryl undyed monofilament) and the animals are allowed to recover on a 
heated pad at 37C. 
3. Behavior 
General materials and procedure for the raised beam test: Mice were placed on a 
platform with a bright light shining in the direction of travel. The there was another platform 
connected by a rod with a diameter of 1.5cm, 40cm above the table, and 63cm in length between 
the marks for quantification. At the opposite end of the beam was a dark box. Since mice prefer 
dark conditions, they were motivated to walk across the beam from the light to the dark box. The 
animals were housed 1-2 mice per cage and were identified by number so the experimenter was 
blinded to the genotype. The animals crossed the beam 3 times and were trained on the beam one 
week prior to testing. On the testing date, the time it took to cross the beam and the number of 
foot slips off of the beam were recorded for the third trial for each mouse. The handler was the 
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same for all testing days and blind to genotype. Frequency of testing varied by experiment as 
outlined below. 
 
Raised beam test of Psa-/-, Psa+/-, and Psa+/+ in Figure 2-3 A: Mice in each group were 
tested on different days and their data collected at 6, 8 and 10 months of age are shown.  
 
Raised beam test of Psa+/- Hdh7Q/140Q,Psa+/- Hdh7Q/7Q, and controls in Figure 2-4 A: 
In our testing procedure, animals were tested for three trials at each of the following ages: 3, 4, 5, 
6, 7, 8.5, 10 months of age.  
Raised beam test of PSA+/- Hdh140Q/140Q and controls in Figure 2-5 C and D: mice 
were tested at 12 months of age.  
Open field behavior: Mice were recorded for five minutes in a novel empty cage (16 cm 
x 27 cm). The motion of the mouse was traced on a video screen and scanned into image files. 
Distance traveled was quantified for each minute using imageJ software and converted into 
centimeters traveled. The values for the first minute were used for statistical analysis. 
 
4. RNA extraction and real-time QPCR 
 PSA+/- mice: RNA isolation from striatum and cortex of PSA mice was performed using 
the MAXWELL16 automated nucleotide and protein extraction system (Promega). We followed 
manufacturer’s protocol for tissue homogenization and lysate preparation, and reverse 
transcription was performed according to the protocol for Superscript III Reverse transcriptase 
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(Invitrogen). Sybr green RT-PCR kit (Qiagen) was used with the following program: 1) 95C for 
15 minutes, 2) 95C for 15 sec, 3) 55C for 30 sec, 4) 68C for 30 sec, 5) repeat steps 2-4 40 times. 
Results were normalized to β-actin. Primers amplify a region from exon 23 that is present on 
both wild type and mutant (knock-out) alleles. Primer sequences are: PSA_forward: 5'- 
GCACCATCCAGCAGTGTTGTGAAA-3', PSA_reverse: 5'-
AGCTGTTTGGTAGCTCCACCTCAT-3', Beta_actin_sense, 5'-
CGAGGCCCAGAGCAAGAGAG-3', Beta_actin_antisense, 5'-
CGGTTGGCCTTAGGGTTCAG-3'. 
 
5. Western blot  
The striatum was dissected and homogenized in NP-40 lysis buffer (Boston BioProducts 
Cat BP-119) with complete protease inhibitor. Samples were spun at 4C for 10 min at 16,000 x 
g. Supernatant aliquots were stored at -20C. 30ug of crude lysates were loaded onto gels (3-8% 
acetate for huntingtin and PSA, 12% Bis-Tris for LC-3). Dry transfer was performed using the 
iBlot system (7 minutes for huntingtin and PSA, 5 minutes for LC3). Primary antibodies and 
dilutions are: 1:500 Goat anti-Rat PSA (Chemicon ab3258), 1.0 µg/mL AB1 antibody 
(huntingtin) [229], 1:1000 rabbit anti-ubiquitin,1:10,000 mouse monoclonal anti-α-tubulin 
(Sigma), 1:1000 mouse monoclonal HA antibody (Covance, HA.11 clone 16B12), 2µg/mL LC3 
(Novus Biologicals, NB100-2220). Secondary antibodies are: 1:5000 donkey HRP-conjugated 
anti-goat IgG (Promega V805A) and 1:100,000 rabbit anti-mouse IgG HRP-conjugated (Sigma 
A9044). 
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6. Immunohistochemistry  
Mice were perfused transcardially with 20 mL of PBS followed by 15 mL of 4% 
paraformaldehyde in PBS. Brains were post-fixed at 4C in 4% PFA for 4 hours, then in 2% PFA 
overnight, and then stored in PBS. Coronal sections were cut on a vibratome at thickness of 40 
microns and collected as serial sections. Sections were treated with 30% hydrogen peroxide 
solution diluted 1:10 in PBS. For blocking and antibody binding we followed the Rabbit IgG or 
M.O.M. peroxidase kit protocols (Vector Laboratories). Primary antibodies were incubated 
overnight at 4C. Antibodies were GFAP 1:1000 (rabbit polyclonal, Abcam ab7260), DARPP-32 
1:1000 (rabbit monoclonal, Abcam ab40801), MW8 serum 1:10 (mouse monoclonal, 
Developmental Studies Hybridoma Bank from the University of Iowa), EM48 1:2000 (from 
Steven Hersch, Massachusetts General Hospital), HA monoclonal 1:1000 (Covance, HA.11 
clone 16B12). Sections were developed for 2 minutes with 3, 3’-Diaminobenzidine (DAB) from 
Thermo Scientific, dehydrated and coverslipped. 
7. Stereology 
 Sections were analyzed with a 60x oil immersion objective. Quantification began at the 
center of the mid-dorsal portion of the striatum just below the corpus callosum. The numbers of 
inclusions was counted using an Olympus BX51 microscope with a Nikon DS-Qi1MC camera. 
The nuclear inclusion bodies and cytoplasmic aggregates were counted for each field of view 
using the NIS-Elements RR 3.10 computer program while focusing up and down on the slide. 
Then the objective was moved to the adjacent field of view. Aggregates and inclusions from 35 
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fields of view were quantified and an average was taken for each mouse.  There were no 
differences among sections or dependent on the distance from the corpus callosum, so the 
average number of inclusions per field of view was used for subsequent analysis. 
8. Statistical analysis 
 SAS version 9.2 was used to calculate mixed method ANOVA. Other tests were done 
using IBM SPS statistics version 20 and GraphPad Prism version 6.00 for Windows. 
Figure 2-4 A: Raised beam test of Psa+/- Hdh7Q/140Q, Psa+/- Hdh7Q/7Q, and controls. 
Mixed method ANOVA was used to analyze difference between the groups. This test was 
chosen because there are missing data for some of the time points. 
Figure 2-5 C: Raised beam test of Psa+/- Hdh140Q/140Q and controls- latency to cross 
the beam. Natural log transformation was performed to achieve normal distribution and the 
transformed data passed the Leven’s test for homogeneity of variances. A one-way ANOVA was 
used followed by Tukey’s post-test for multiple comparison.  
Figure 2-5 D: Raised beam test of Psa+/- Hdh140Q/140Q and controls- foot slips off of 
beam. These data are not normally distributed, and no transformation normalized the data. 
Therefore, the non-parametric Kruskall-Wallis test and Dunn’s multiple comparisons test were 
used to analyze the differences between the three groups. Three outliers were included in the 
analysis. 
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Figure 2-4 B: Open field test. The distance traveled in the first minute after introduction 
to a novel cage was used for analysis. Distances were compared using one-way ANOVA with 
Tukey’s multiple comparisons post-test. 
Western blot: Data was tested for outliers using Grubb’s test 
(http://www.graphpad.com/quickcalcs/Grubbs1.cfm) and significant outliers were removed. 
One-way ANOVA was used to test an effect of genotype and unpaired T-test was used for 
pairwise comparisons. 
Measurements of inclusions and aggregates: Data sets were tested for normal 
distribution. Normally distributed data were analyzed by unpaired t-test. Data that were not 
normally distributed were analyzed by Mann-Whitney U test.
77 
 
Figure 2-1: PSA homozygous knock-out mice are smaller in size than heterozygous mice. 
Psa-/- mice are smaller than Psa+/- mice at 1 and 6 months of age (unpaired t-test, 1 month 
p=0.0030 n=3 for Psa+/-, n=2 for Psa-/-; for 6 month p=0.0247 n=4 for Psa+/-, n=2 for Psa-/-). Mice 
are combined male and female as depicted individually in Table 2-1. *p<0.05, ** p<0.01. Data is 
presented as mean ± SD. 
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Figure 2-2: PSA mRNA and protein are expressed in a gene dosage-dependent manner. A.) 
q PCR was done on striatal extracts of Psa-/-, Psa+/-, and Psa+/+ mice. In the striatum, genotype of 
PSA mice affected PSA mRNA levels (One-way ANOVA p=0.0004). By pairwise comparison, 
mRNA levels for heterozygous mice is 49.8% of wild type mice (Tukey’s pairwise comparison, 
mean difference between +/+ and +/- 0.6280 (95% CI 0.1632 to 1.093, p=0.00811), mean 
difference between +/+ and -/- 1.162 (95% CI 0.6253 to 1.699, p<0.001), n=5 for Psa+/+ and 
Psa+/-, n=3 for Psa-/-). B.) Western blot of protein extracts from cortex of PSA-/-, PSA+/-, and 
PSA+/+ mice were labeled with antibodies to mouse PSA and tubulin. Values for PSA protein are 
expressed relative to tubulin. In the cortex, the PSA genotype affected PSA protein levels (One-
way ANOVA p=0.0005).  By pairwise comparison, heterozygous mice have 47.5% PSA of wild 
type mice (Tukey’s pairwise comparison mean difference between +/+ and. +/- 0.5007 (95% CI 
0.1473 to 0.8540, p=0.00552), mean difference between +/- and -/- 0.4467 (95% CI 0.09334 to 
0.8000, p= 0.01315), mean difference between +/+ and -/- 0.9473 (95% CI 0.594 to 1.301, 
p<0.001), n=3 per genotype). C) Western blot of protein extracts from striatum of PSA-/-, PSA+/-, 
and PSA+/+ mice were probed with antibodies to mouse PSA and tubulin. Values for PSA protein 
are expressed relative to tubulin. In the striatum, PSA genotype affects PSA protein levels (One-
way ANOVA p=0.0014). By pairwise comparison, protein extracts from striatum of 
heterozygous mice have 57.8% PSA as wild type (Tukey’s pairwise comparison, mean 
difference between +/- and -/- 0.5840 (95% CI 0.1192 to 1.049, p=0.0137), mean difference 
between +/+ and -/- 1.047 (95% CI 0.5824 to 1.512, p<0.001), n=3 per genotype). D) 
Representative blot of striatal protein extracts for one mouse in each group done in triplicate. For 
all graphs * p<0.05, **p<0.01, ***p<0.001, data is presented as mean ± SD. 
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Figure 2-3: There is no abnormal locomotor behavior or inclusion formation in PSA 
knock-out mice. Psa-/-, Psa+/-, and Psa+/+ mice were tested on the raised beam for locomotor 
abnormality. A.) The left graph in panel A is a comparison of the time in seconds that it took the 
mice to cross the raised beam. The right graph shows the number of foot slips off the beam in the 
same groups of mice. There were no differences between the three groups at 6 months, 10 
months and 14 months of age. For each graph two-way ANOVA was performed and found to be 
not significant (p>0.05). Data is presented as mean ± S.E.M., number of mice in each group is 
shown in the within the bars. B.) Fixed brains from a HD knock-in mouse (Hdh7Q/140Q, 13 month 
old), PSA knock-out mice (Psa-/-, 9 month old (n=1), 22 month old (n=1, not shown)), and wild 
type mice (9 month old (n=3), 22 month old (n=3, not shown) were labeled with an antibody that 
recognizes ubiquitin. Inclusion bodies can be seen in the HD knock-in mouse (arrows). There are 
no ubiquitin positive inclusion bodies in the PSA-/- mice or wild type mice examined. C.) 
Sections from HD knock-in mouse (13 months old), PSA-/- mice (17 months old; 9 and 22 month 
old not shown, n=1 for each age), and wild type mouse were labeled with EM48 for huntingtin 
aggregates (9 month n=3). There are no EM48 positive inclusions in the PSA knock-out mouse 
or the wild type mouse.  
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Figure 2-4: Psa heterozygosity corrects huntingtin-related reduction in open field activity, 
however there are no differences observed on raised beam test or in the number of 
inclusion bodies.  A.) Four groups of mice were tested on the raised beam test. Psa+/+ Hdh7Q/140Q 
(n=7) have an increased latency to cross and in foot slips compared with Psa+/+ Hdh7Q/7Q (n=14) 
(Mixed models ANOVA, p=0.0172 and p=0.0196, respectively. There were no differences 
among the other groups for latency to cross and footslips. Psa+/-Hdh7Q/7Q n=9, for Psa+/-
Hdh7Q/140Q n=4. Tukey’s multiple comparison revealed no significant differences at any age). 
Data is presented as mean ± SEM. B.) At 13 months of age, the same groups of mice were tested 
for activity using the open field test. Each mouse was video recorded once for 5 minutes in the 
open field box and distances traveled in the first minute were used for comparison (see methods 
section). Psa+/+Hdh7Q/140Q mice traveled less distance than the other groups, and Psa+/-Hdh7Q/140Q  
genotype corrected this difference in distance traveled (One-way ANOVA between all groups, 
p=0.0010, Tukey’s multiple comparison test, for Psa+/-Hdh7Q/140Q vs. Psa+/+Hdh7Q/140Q mean diff. 
65.03cm (95% CI 18.98 to 111.1, p=0.0057), for Psa+/-Hdh7Q/7Q vs. Psa+/+Hdh7Q/140Q mean diff. 
45.71cm (95% CI 8.68 to 82.73, p=0.0154), for Psa+/+Hdh7Q/140Q vs. Psa+/+ Hdh7Q/7Q mean diff. -
51.22cm (95% CI -85.67 to -16.78, p=0.00361). Data is presented as mean ± S.D.). C.) We 
performed immunohistochemistry for mutant huntingtin aggregates in brain sections of Psa+/- 
Hdh7Q/140Q and Psa+/+ Hdh7Q/140Q using EM48 antibody. There was no difference in the number of 
inclusion bodies in the striatum or in the cortex at 1.5 years of age (unpaired t-test, cortex 
p=0.1425, striatum p=0.6802, Psa+/- Hdh7Q/140Q n=3, Psa+/+ Hdh7Q/140Q n=5). Data is presented as 
mean ± S.E.M. inclusions per field of view. For all graphs *p<0.05, **p<0.01. 
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Figure 2-5: Psa+/- Hdh140Q/140Q mice exhibit deficits on the raised beam test. A.) Psa+/- 
Hdh140Q/140Q mice appear to express less PSA protein than Psa+/+ Hdh140Q/140Q, however the 
difference is not statistically significant due to large variation within the groups (t-test p=0.0654, 
n=4). B.) Representative blot of one sample from each group in triplicate. C.) Psa+/- and Psa+/+ 
Hdh140Q/140Q mice were tested on the raised beam test at 1 year of age and compared with wild 
type (Psa+/+ Hdh7Q/7Q, n=11) mice. Psa+/- Hdh140Q/140Q mice (n=16) had a greater latency to cross 
the beam compared with wild type mice (Tukey’s multiple comparisons, mean diff. 0.7886 
(95%CI 0.1363 to 1.441, p=0.0177). There was no difference between the Psa+/+ HD140Q/140Q 
mice (n=20) compared with the other groups. Psa+/-Hdh140Q/140Q mice also had significantly 
greater foot slips off of the beam compared with the other two groups. (Tamhane’s Post Hoc test 
Psa+/- Hdh140Q/140Q vs Psa+/+ Hdh 140Q/140Q, mean diff. 7.76 (95% CI 1.3835 to 14.1415, p=0.017) 
Psa+/- Hdh140Q/140Q vs Psa+/+ Hdh 7Q/7Q, mean diff. 9.426 (95% CI 3.2362 to 15.6161, p=0.00289). 
The majority of wild type mice had no foot slips at all. *p<0.05, **p<0.01 Data is presented as 
mean ± SD. 
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Figure 2-6: There is increased inclusion body formation in Psa+/- Hdh140Q/140Q mice. A.) 
Fixed brains from 12 month old Psa+/- Hdh140Q/140Q and Psa+/+ Hdh140Q/140Q mice were labeled 
with MW8, an antibody that labels mutant huntingtin inclusion bodies and aggregates. Nuclear 
inclusion bodies are circular and regular in size within a section. Inclusion bodies are indicated 
with arrows in the enlarged image. Cytoplasmic aggregates are smaller and irregularly shaped. 
Aggregates are indicated with arrowheads in the enlarged image. B.) Sections from Hdh140Q/140Q 
mice were labeled with MW8 (red) and DAPI (blue) stained to show co-localization of inclusion 
bodies with the nucleus. C.) Inclusion bodies were stereologically quantified throughout the 
striatum, and an average per field of view for each mouse was used for comparison. There are a 
greater number of inclusion bodies in the Psa+/-Hdh140Q/140Q (n=9) compared with 
Psa+/+Hdh140Q/140Q (n=8) (unpaired t-test, p=0.0154). D.) Psa+/- HD mice (n=9) have smaller 
inclusion bodies than Psa+/+ HD mice (n=8) on average, although this difference was not 
statistically significant (unpaired t-test, p=0.1981). E.) Psa+/-  Hdh140Q/140Q mice (n=9) have a 
greater number of cytoplasmic aggregates than Psa+/+ Hdh140Q/140Q mice (n=8), although this 
difference is not statistically significant. (Mann-Whitney U-test, p=0.1388). F.) There was no 
difference in the number of neurons as quantified by Nissl staining (unpaired t-test, p=0.4605). 
*p<0.05  Data is presented as mean ± SD. 
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Figure 2-7: Psa+/- Hdh140Q/140Q mice display no change in soluble huntingtin or LC3-I levels. 
A.) Western analysis was performed on protein extract from striatal tissue of 16 month old mice. 
There was no difference in soluble huntingtin levels between the groups (One-way ANOVA, p= 
0.2095, n=5 for each group, each sample was done in triplicate). Representative western blot of 
triplicates of one mouse per genotype. B.)  Antibodies recognizing LC3 were used to detect 
conversion of LC3-I to LC3-II. LC3-II could not be detected in our samples with our conditions. 
There was no difference in LC3-I levels among the groups (One-way ANOVA, p=0.9682, n=5 
for each group, each sample was done in triplicate). Each lane was normalized to tubulin and 
then normalized to a wild type sample on the same blot. Data are represented as average fold-
difference from wild type ± SD. Representative western blot of triplicates of one mouse per 
genotype. 
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Figure 2-8: Dosage-dependent hPSA expression from AAV-hPSA-HA injected striatal 
tissue. Western blot for hPSA-HA using antibodies that recognize HA epitope show a decrease 
in expression of hPSA protein across the dilutions of AAV-hPSA-HA injected striatal extracts. 
There is no detectable expression in 1e9 GC dose or control injection samples (n=3 for all 
groups, control injection is AAV-GFP, NI is no injection, all injections 3µL in volume, samples 
processed 3 weeks after injection. All samples were processed 3 weeks after injection). Data is 
presented as mean ± SD. 
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Figure 2-8: Dosage-dependent hPSA expression from AAV-hPSA-HA injected striatal 
tissue.  
 
 
93 
 
Figure 2-9: Dilution of AAV-hPSA-HA shows dosage-dependent toxicity. A.) Coronal 
sections were taken 3 weeks after injection of AAV-hPSA-HA and labeled with HA antibody. 
There is HA positive staining for the hPSA-HA transgene that can be seen at 1e11 GC and 1e10 
GC doses. HA positive staining areas are delineated by the dashed line. B.) 1e11 GC dose of 
AAV-hPSA-HA shows widespread astrocyte activation (delineated by dashed line) at 4X and 
60X oil immersion magnifications. Dose of 1e10 GC showed astrocyte activation only at the 
injection site. Control injection of 1e12 GC AAV-luciferase (control injection) elicited a small 
amount of GFAP activation around the injection site. The 60X magnification column shows 
representative images within astrocyte activation area. C.) There is decreased staining for 
DARPP-32 positive medium spiny neurons in the 1e11 GC dose of AAV-hPSA-HA. There does 
not appear to be a change in staining for the 1e10 GC dose compared with control injection. D.) 
HA double labeling with DARPP-32 shows co-localization of hPSA-HA with medium spiny 
neurons as well as cells that are negative for DARPP-32 staining. (n=3 for all doses, images are 
from representative samples). 
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Figure 2-10: AAV-hPSA-HA is toxic to cells. A time course experiment was performed 
examining brain sections 1, 2, and 3 weeks after injection of AAV-hPSA-HA (1e12 GC) into the 
striatum (n=3 for each group, representative images shown). The first row shows that HA 
staining is detectable at one week (compared with no injection in the last column), becomes 
darker at two weeks, and then disappears at week three. The second row shows that GFAP 
staining is intense and very concentrated at weeks 2 and 3. In the third row are images staining 
for DARPP-32 positive neurons. These images show a reduction of DARPP-32 staining by the 
second week, and then a loss of reactivity by the third week indicating a complete loss of 
DARPP-32 positive neurons. 
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Figure 2-11: Mutant huntingtin protein is distributed among cytosolic and nuclear 
compartments in soluble and insoluble forms. A.) Full-length mutant huntingtin protein is 
found in its soluble state in the cytoplasm and nucleus and it is also found to be associated with 
cytoplasmic aggregates and intranuclear inclusion bodies. Full-length huntingtin can be cleaved 
into NH2-terminal and COOH-terminal fragments. The NH2-terminal mutant huntingtin 
fragments oligomerize into fibrillar huntingtin that accumulates and results in formation of 
cytoplasmic aggregates and intranuclear inclusion bodies. B.) Estimated distribution of full-
length mutant huntingtin and NH2-terminal mutant huntingtin fragments. The majority of full-
length mutant huntingtin is localized in the cytosolic compartment. The majority of NH2-
terminal mutant huntingtin is estimated to be in an aggregated form, either as cytoplasmic 
aggregates or intranuclear inclusion bodies.
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Table 2-1: Weight of Psa+/+, Psa+/-, and Psa-/- mice at 1 and 6 months of age. 
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Age 
Sex 
  
Mouse 
ID 
Parent 
ID 
DOB 
Psa 
Genotype 
Weight 
(g) 
Average 
bodyweight 
of +/- & +/+ 
(g) 
-/- weight as 
percentage of 
+/- and +/+ 
1 month 
 
Female 
363 339x343 3/8/09 +/- 17.3 
17.30 64.16 364 339x343 3/8/09 +/+ 17.3 
365 339x343 3/8/09 -/- 11.1 
Male 
366 339x343 3/8/09 +/+ 19.9 
20.40 68.63 
367 339x343 3/8/09 +/- 21.4 
368 339x343 3/8/09 +/- 19.9 
369 339x343 3/8/09 -/- 14 
6 months 
Female 
 
326 114x174 9/8/08 +/+ 24.6 
25.35 61.93 
327 114x174 9/8/08 +/- 27.2 
337 224x214 10/31/08 +/- 23.4 
347 294X305 11/15/08 +/+ 26.2 
338 224x214 10/31/08 -/- 15.7 
Male 
339 224x214 10/31/08 +/- 34.7 
30.03 65.59 
361 213X166 9/28/08 +/+ 27.2 
331 265x266 9/12/08 +/- 28.2 
360 213X166 9/28/08 -/- 19.7 
 
Table 2-1: Weight of Psa+/+, Psa+/-, and Psa-/- mice at 1 and 6 months of age. 
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Table 2-2: Genotype frequency of offspring from Psa+/- breeding pairs. Data from three 
mating pairs of Psa+/- mice reveal a less than expected frequency of Psa-/- progeny and a more 
than expected frequency of Psa+/+ progeny. According to Mendelian inheritance pattern, the 
expected frequency for Psa+/- crossed with Psa+/- is 25%, 50%, and 25% for genotypes WT, HET, 
and KO respectively. WT, Psa+/+; HET, Psa+/-; KO, Psa-/-. Average litter size is 4.73 ±1.5 pups. 
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Parent ID DOB WT HET KO 
85, 88 1/20/2008 4     
85, 88 2/15/2008   2   
85, 88 3/14/2008 2 1 3 
85, 88 4/9/2008 2 2   
85, 88 5/1/2008 2 5   
F10a, F10b 4/13/2007   5   
F10a, F10b 5/22/2007   5   
F10a, F10b 8/10/2007 4 2   
F10a, F10b 9/10/2007 2 1   
F10a, F10b 10/17/2007 2   2 
F10a, F10b 11/13/2007   5   
71, 91 1/27/2008 2 2   
71, 91 2/15/2008 2 2   
71, 91 3/15/2008 4 3 1 
71, 91 5/28/2008 4 1   
Sum 30 36 6 
% total 41.67 50.00 8.33 
 
Table 2-2: Genotype frequency of offspring from Psa+/- breeding pairs.
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CHAPTER III 
 
 
 
 
THE OPTIMIZATION OF IN VIVO IMAGING FOR MEASURING GENE SILENCING 
OF HUNTINGTIN TARGET SEQUENCES 
  
 
 
 This chapter describes work I have performed optimizing an in vivo system for following 
RNA interference in the brain. This work was conducted under the guidance of Neil Aronin. Phil 
Zamore provided the initial concept. I planned and executed the majority of the experiments 
presented in this chapter. Edith Pfister designed and cloned the miRNA constructs. AAV 
constructs were packaged by Guangping Gao and Beverly Davidson. 
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A. Abstract 
 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused 
by a CAG trinucleotide repeat expansion in the huntingtin gene. Several types of RNAi 
constructs have been used to silence huntingtin in mice, including siRNA, shRNA, and miRNA. 
Screens to identify the best candidate sequences for silencing are done in cell culture which 
many not bear any resemblance to cells of the target tissue. No method exists to quickly screen 
RNAi molecules in the brain, preventing the identification and comparison of RNAi that could 
be optimal in the brain rather than in cell culture. The lack of techniques for in vivo screening 
impedes identification of the optimal RNAi designs for neurodegenerative diseases. We propose 
using an in vivo reporter system to rapidly compare miRNA and siRNA in the mouse brain. 
For this study, two adeno-associated viruses (AAVs) expressing firefly luciferase with six 
huntingtin target sites in the 3'-untranslated region (UTR) were generated (AAV-Luc-Htt). These 
two vectors represent huntingtin alleles with single nucleotide polymorphisms (SNP) that differ 
between the two vectors. Measurement of in vivo luminescence allows for comparison of the 
silencing efficiencies of RNAi against these two vectors, indicating the degree of allele-specific 
silencing. Allele-specific silencing refers to the knockdown of a mutant allele by targeting a SNP 
that differs from the normal allele. Using allele-specific silencing, expression of the mutant allele 
can be reduced without affecting expression of the normal allele.  
In this study, several methods of in vivo luciferase gene expression in the brain were 
tested. Bilateral co-injection of AAV-Luc-Htt was found to be the most sensitive method for 
detecting silencing of luciferase activity. Using the AAV-Luc-Htt system, silencing of luciferase 
activity in was shown with cholesterol conjugated siRNA, AAV-shRNA and AAV-miRNA. 
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These results are promising, but more work must be done to use the AAV-Luc-Htt co-injection 
method to assess allele-specific huntingtin silencing in the brain. 
 
B. Introduction 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused 
by a CAG trinucleotide repeat expansion in the huntingtin gene [1]. CAG repeats of less than 36 
result in a normal phenotype whereas 37 or greater repeats results in Huntington’s disease. HD 
patients suffer from psychiatric symptoms, motor symptoms, and cognitive decline before 
neurodegeneration of the cortex and basal ganglia results in death. There is no treatment to slow 
the progression of the disease, and current therapies only ameliorate symptoms [7].  
In HD, the mutant huntingtin protein is misfolded, imparting it with toxic functions. 
Mutant huntingtin binds to other proteins resulting in transcriptional dysregulation, it impedes 
vesicle recycling and transport, and causes proteasomal dysfunction [2]. Mutant huntingtin 
mRNA can also be toxic, as it can form foci in the nucleus that co-localize with muscleblind, a 
protein implicated in trinucleotide repeat toxicity, and to induce RNA interference (RNAi) [237].  
RNAi is a candidate strategy for treating Huntington’s disease and other dominant 
neurodegenerative diseases. The benefit of this approach is that degradation of mRNA prevents 
the transcript from being translated, mitigating mRNA toxicity as well as all downstream toxic 
effects of the mutant protein. RNAi was discovered in 1998, as a pathway by which short RNA 
duplexes mediate degradation of complementary mRNA in Caenorhabditis elegans [238]. There 
are two pathways by which RNAi operates in differentiated cells: the short interfering RNA 
109 
 
(siRNA) pathway and the microRNA (miRNA) pathway [186]. In the siRNA pathway, short 19-
21 nucleotide double strand RNAs in the cytoplasm are processed by the enzyme Dicer and 
loaded into the RNA-induced silencing complex (RISC), which binds and cleaves the 
complementary mRNA. In the miRNA pathway, miRNA is transcribed in the nucleus where it 
folds into a secondary structure that is cleaved by the enzyme Drosha into a short hairpin RNA 
(shRNA). The shRNA exits the nucleus and is processed by Dicer and loaded into RISC. 
Endogenous miRNAs generally contains mismatches to the target sequence that result in 
translational repression of the mRNA, however, miRNAs engineered to be fully complementary 
to their target result in RISC cleaving the mRNA target [239].  
RNAi constructs are described as allele-specific when they preferentially degrade one 
allele. Allele-specific RNAi can be designed to target any sequence difference between two 
alleles such as single nucleotide polymorphisms (SNPs) or a microdeletion associated with the 
mutant allele [240-242]. Targeting the CAG repeat with a miRNA also shows allele-specific 
silencing, however the same results were not seen with siRNA [196, 243-245]. Reduced levels of 
huntingtin may have adverse effects, especially if the total knockdown of huntingtin is greater 
than 50% [49, 194, 195, 246]. One way to avoid excessive silencing of huntingtin is to use allele-
specific silencing. In a study examining 109 HD patients and 116 non-HD controls for SNPs in 
the huntingtin gene, it was found that by targeting 5 sequences 75% of HD patients could be 
treated with allele-specific silencing [196]. The use of allele-specific silencing is the most 
specific way to treat HD, yet no one has shown SNP-directed silencing in vivo using RNAi.  
RNAi is particularly well-suited for treating dominantly inherited genetic diseases such 
as Huntington’s disease. Several groups tested siRNA in rodent models of HD. Cholesterol 
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conjugated siRNA (cc-siRNA) has been used to silence huntingtin in rodent models of 
Huntington’s disease resulting in fewer inclusions and ameliorated behavioral abnormalities 
[247, 248]. Unconjugated siRNA against huntingtin was delivered by intraventricular injection 
into newborn R6/2 mice [249]. Viral delivery of shRNA and miRNA is also being extensively 
studied in mice resulting in improved behavior and decrease in size and number of nuclear 
inclusions [250-252]. Work is also being done in rhesus macaques using shRNA targeting 
huntingtin [253]. Of note, there is potential toxicity associated with using a shRNA structure 
thought to be due to high expression level leading to oversaturation of RNAi machinery [254, 
255]. This toxicity is eliminated by using a miRNA-based design [255]. Each of these studies 
utilizes different sequences, structures, and promoters thereby preventing a direct comparison 
between them, and none of these studies used silencing strategies that are allele-specific. 
In vivo bioluminescent imaging (BLI) is a method by which expression of luciferase is 
imaged using a light sensitive camera [256]. This method enables gene expression to be followed 
over time without sacrificing the animal. The BLI technique is fast, convenient, low cost, has the 
potential for medium throughput screening and can be performed longitudinally within each 
animal. BLI has been used for detecting tumor location and growth, gene therapy spread, 
clearance of pathogens, and the migration of adoptively transferred cells [256, 257]. BLI has also 
been used to follow the silencing of genes using siRNA and shRNA in the liver and in tumors 
[257-264]. Studies of RNAi targeting luciferase have been useful for describing the dynamics of 
siRNA silencing in vivo and have shown that luminescence correlates with mRNA and protein 
levels in treated tissues [258, 265]. BLI has also been used to study the brain including 
measuring brain tumor growth, gene transfer in rats, biodistribution of stem cells after strokes, 
and to monitor rhythmic gene expression in the olfactory bulbs of SCN lesioned rats [266-268]. 
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Lentiviral  injection of luciferase gene in mice shows that BLI can be detected in the striatum, 
olfactory bulb, substantia nigra and globus pallidus [265]. One study used luciferase to follow 
silencing in the brain by packaging luciferase plasmid DNA with siRNA in different lipid-
mediated delivery strategies [269]. However, no group has compared the dynamics of silencing 
or systematic comparison of siRNA and miRNA sequences in the brain. Here, we present results 
from an initial investigation into the use of viral-delivered luciferase and bioluminescent imaging 
to follow gene silencing in the brain. 
In this study we created two AAV expressing firefly luciferase reporter genes each with 
six huntingtin target sequences in the 3'-untranslated region (UTR). Using these reporters we can 
test the silencing of huntingtin-targeting RNAi with therapeutic potential. Silencing of luciferase 
activity was detected using cc-siRNA and AAV-shRNA targeting luciferase, and AAV-miRNA 
targeting human huntingtin. Allele-specific silencing was demonstrated by comparing the 
efficiency of an AAV-miRNA to silence a matching SNP target versus a mismatched target. We 
conclude that using AAV-Luc-Htt as a reporter molecule is a promising method for testing 
silencing, especially for studying allele-specific silencing of huntingtin target sites in vivo, 
however it needs further optimization to improve sensitivity to fully function as a way to detect 
gene-silencing dynamics in the brain. 
 
C. Results 
1. Adeno-associated virus delivery of luciferase with human huntingtin SNP sites can be 
detected in the mouse striatum. 
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In order to express luciferase in the brain, we generated two adeno-associated viruses 
(AAV) encoding luciferase mRNA, each with six huntingtin RNAi target sites in the 3'-UTR 
(AAV-Luc-Htt) (Fig. 3-1 B). We used a recombinant AAV2/9 vector, expressing serotype 2 
inverted terminal repeats (ITRs) and serotype 9 capsid proteins with luciferase expression driven 
by the cytomegalovirus (CMV) promoter. Serotype 9 was chosen because it has shown good 
tissue distribution in the brain and specific tropism for neurons in mice [270]. A summary of 
viruses used in this chapter can be found in Table 3-2. Each virus represents an allele of the 
huntingtin gene with six SNP-containing target sequences (Fig. 3-1 B). Since each virus has 
matching target sites that differ only by one single nucleotide, the SNP site, we can potentially 
use these vectors to evaluate allele-specific silencing in vivo. The first four target sequences are 
from human huntingtin and the last two are found in mouse huntingtin.  
Luminescence from AAV-Luc-Htt was detected in vivo following intracranial injections 
into the striatum. A trial of five 10-fold diluted doses identified 1e9GC as the lowest detectable 
dose by BLI, with 1e10GC producing a level significantly above background (Fig. 3-1 C). There 
appeared to be a large degree of variation within each dose, with standard deviation values up to 
50% of the mean. To study the variability at a single dose, a group of 9 mice, injected with 
5e9GC AAV-Luc-Htt, were imaged repeatedly for 28 days (Fig. 3-2 A). Luminescence was 
detected 24 hours after injection and reached stable baseline luminescence by day 10. A 95% 
confidence interval (CI) was calculated for each day and the lower interval was used to 
determine the percent silencing that would be necessary for detection among this group of mice. 
The percent silencing needed to detect silencing on any given day ranged from 26% to 46% with 
an average of 37% silencing minimum needed to detect silencing. To look at variation using 
values from a stably expressing baseline, we looked at three days, 15, 19, and 21, comparing the 
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variability in one week for each mouse (Fig. 3-2 B). From these three days, the 95% CI was 
calculated and individual mice would require silencing of 5-46%with an average of 28% 
silencing to achieve statistically significant decrease in luminescence. One experimental 
approach could be to test silencing for each mouse after establishing a stable baseline. A source 
of variation could be due to differences in luciferin absorption and distribution. Luciferin is the 
substrate that interacts with luciferase to produce luminescence. It is most commonly delivered at 
150mg/kg by intraperitoneal (ip) injection 10 minutes before imaging, in concordance with the 
vast majority of published BLI studies and the manufacturer recommendations for imaging. As a 
large fraction of luciferin is absorbed into the gut after ip injection, variations may arise from the 
animal’s diet prior to injection or by slight positioning differences of the needle within the ip 
space. If differences in luciferin distribution result in intramouse variation, then normalizing 
luminescence within the same animal would reduce variations.    
We propose an experimental design using bilateral intracranial AAV-Luc-Htt injections 
in which one side of the brain acts as a control for the contralateral side (Fig. 3-3 A).  In this 
method, AAV-Luc-Htt is co-injected with RNAi molecules into the striatum on one side of the 
brain and co-injected with control RNAi molecules on the contralateral side. We expect that 
groups without silencing will have a ratio of luminescence close to 1.0 and groups with 
successful targeting of luciferase will have an active RNAi/control RNAi ratio less than 1.0. To 
test this design we injected two groups of mice, either unilaterally or bilaterally, and followed 
luminescence for one week (Fig. 3-3 B). First, we analyzed the unilateral injection group to 
compare luminescence between the injected and un-injected side. Although the luminescence is 
statistically different between the AAV-Luc-Htt injected and un-injected hemispheres, there 
were no significant differences between the sides on any given day (Mixed methods ANOVA 
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p<0.0001, Tukey’s multiple comparisons). These results confirm that although a difference was 
detected overall, the system is not sensitive enough to detect the equivalent of 100% silencing on 
any specific time point due to increased variation seen by analyzing flux. This lack of sensitivity 
could be a result of crossover of luminescence from the injected hemisphere, either from light 
scatter through the tissue or spread of the virus. It could also be due to the sensitivity of the assay 
resulting from a combination of factors including a low concentration of AAV-Luc-Htt and high 
baseline variation in luciferase expression. We then calculated the left- to right-side ratio of both 
groups. The ratio for the bilaterally injected group was approximately 1.0 as expected from 
identical injections without RNAi. The ratio of luminescence from the un-injected side was 
slightly higher than expected at 0.25 illustrating that there is a spread of light or virus to the 
contralateral side. If we consider the unilaterally injected group to represent complete silencing 
and the bilateral group to represent no silencing, there is a difference between the groups, 
significant at each time point (Mixed methods ANOVA p<0.0001, Tukey’s multiple 
comparisons). The 95% CI was calculated from the average ratio for each day (mean ratio 1.164 
95% CI 0.7595-1.569). From this confidence interval, we would need a 35% decrease in 
luminescence on any given day to detect silencing. By analyzing the same data as luminescent 
flux, the minimal detectable silencing would be 40%, which is higher than the variation 
calculated for the mice in Figure 3-2 which only required 37%.We conclude that normalizing 
luminescence within each mouse by calculating a left to right side ratio, results in a more 
sensitive assay, able to detect smaller differences in silencing than comparing left side to right 
side luminescence. 
One caveat to the bilateral injection experimental design is the potential for crossover of 
luminescence from light-scattering or spread of virus through diffusion, or transport. AAV 
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serotype 9 have been shown to undergo retrograde transport after a single 1µL injection to the 
striatum, with viral mRNA detected in retrograde projection targets including the ventral 
tegmental area, thalamus, substantia nigra pars compacta, amygdala, and hippocampus, including 
the contralateral hippocampus [271]. Through diffusion from the injection site there can also be 
extensive spread of the AAV9 gene and gene product into midline structures including 
subventricular zone, septal nuclei [270, 271]. In addition to the spread of virus or viral products 
within the brain, one must also consider the light scattering effect of tissue. The D-Luciferin 
substrate emits short wavelength light, 560nm, resulting in high light scattering properties 
through all tissues, including the brain [272, 273]. The effects of viral diffusion, retrograde 
transport, and light scattering are important factors in the study design, which could limit the 
sensitivity of the assay.    
 
2. RNAi constructs targeting firefly luciferase and human huntingtin SNP sites are 
functional in cell culture. 
 RNAi constructs were tested in cell culture for their ability to silence luciferase and 
huntingtin target sites. Structures and sequences are summarized in Table 3-1. We tested 6 
different siRNA preparations, four experimental siRNA and two control siRNA (Fig. 3-4 A). 
Two of the siRNAs, cc-siLuc and cc-siCon, contain a cholesterol modification that improves 
siRNA transport into cells and enhances resistance to exo- and endonucleases [274]. 
Paradoxically, cholesterol conjugated siRNA (cc-siRNA) were noted to have much higher IC50 
compared with un-conjugated siRNA, approximately 8 nmol compared with 0.13 nmol for firefly 
luciferase siRNA.  
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We also tested AAV-miRNA silencing constructs to verify silencing of the corresponding 
target site in cell culture. AAV-miR2307T and AAV-miR2273G were tested at three different 
concentrations and compared with cells not infected with virus (Fig. 3-4 B). At the highest dose 
tested (100,000 MOI), there was 37% silencing by AAV-miR2273 (Tukey’s multiple 
comparison p<0.0001) and 56% silencing by AAV-miR2307 (Tukey’s multiple comparison 
p<0.0001) compared with the lowest dose tested (10,000 MOI) that showed no silencing. All 
siRNA, cc-siRNA, and AAV-miRNA tested silenced expression of luciferase in cell culture.  
 
3. Cholesterol-conjugated siRNA reduced luminescence 24 hours after injection  
To test silencing of luciferase activity in vivo, we used cc-siRNA targeting luciferase 
mRNA (cc-siLuc). The left side of the brain was co-injected with AAV-Luc-Htt and cc-siLuc 
and the right side was injected with AAV-Luc-Htt and control cc-siRNA (cc-siCon). A second 
set of mice were bilaterally injected with AAV-Luc-Htt in phosphate buffered saline (PBS). The 
resulting luminescence was compared between left and right sides as flux (photons /second), and 
as the ratio between the left and right sides of each mouse (Fig. 3-5 A, B). There was no 
difference between the luminescent flux from cc-siLuc or cc-siCon injections, however when we 
compared the ratio between the left and right sides of each mouse there was a 52.6% decrease in 
luminescent ratio of the cc-siRNA treated mice compared with the PBS control mice 24 hours 
after injection (Repeated measures one-way ANOVA p<0.0010, Sidak’s multiple comparisons 
test mean diff. 0.4847, 95% CI 0.4051 to 0.5644, p<0.0001) (Fig. 3-5 B). This experiment 
demonstrates an instance where by comparing luminescence, there was no detectable silencing, 
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however by normalizing the ratio within each mouse, silencing was detected 24 hours after 
injection.  
 
4. Cholesterol-conjugated siRNA increased luminescence in brain and in cell culture. 
An unexpected result was seen in the cc-siRNA injected group. We observed that co-
injections of cc-siRNA and AAV-Luc-Htt resulted in greater luminescence than injections of 
virus with PBS and this enhancement persisted for at least 12 days after injection (Fig. 3-5 A). 
After 168 days, the difference in luminescence significantly decreased 10-fold in the cc-siRNA 
mice, however luminescence remained stable in the PBS injected mice. There remained a 
statistically significant 1.9fold difference when comparing the cc-siRNA and PBS injected 
groups (cc-siLuc vs PBS, Unpaired t-test p=0.0017; cc-siCon vs PBS, Unpaired t-test p=0.0007, 
Fig. 3-5 C). In order to compare cc-siRNA with PBS within the same mouse, we injected a group 
of mice on the right side with AAV-Luc-Htt and cc-siCon and the left side with AAV-Luc-Htt 
and PBS (Fig. 3-5 D). In a comparison between sides of the same mouse, there was a 2.35 fold 
increase in luminescence on days 5 and 12 after injection (2-way ANOVA, p=0.0015), but we 
found no difference after about six months (Fig. 3-5 D). These results suggest that cholesterol 
conjugation transiently increases luminescence when co-injected with AAV-Luc-Htt by an 
unknown mechanism. 
To explore this effect, we tested the combination of cc-siRNA and AAV-Luc-Htt in cell 
culture. HeLa cells were incubated with AAV-Luc-Htt and either cc-siCon, non-conjugated 
siCon, or no siRNA (Fig. 3-6 A). We also tested cc-siCon and siCon without AAV-Luc-Htt to 
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show that the siRNA were not contaminated with AAV-Luc-Htt. We found that there is a 1.5-
fold increase in luminescence with cc-siCon relative to no siRNA treated cells (Unpaired t-test, 
p=0.0091, p=0.0001 respectively) (Fig. 3-6 A). We did a series of dilutions of AAV-Luc-Htt 
with the same amount of cc-siCon and found 2.6-fold difference in luminescence in the 1e5 MOI 
incubated cells (2-way ANOVA, p<0.0001) (Fig. 3-6 B). There was no difference in cells 
incubated with AAV-Luc-Htt and cholesterol without siRNA (Fig. 3-6 C). To test whether the 
effect of cc-siRNA to increase BLI from AAV-Luc was serotype specific, we tested serotype 2 
(AAV2-Luc) and found a similar 1.8 fold increase (Unpaired t-test p=0.0045) (Fig. 3-6 D). A 
different sequence of cc-siRNA targeting GFP (cc-siGFP) resulted in a 1.2 fold increase, and in a 
different cell type (Neuro2A cells) cc-siCon led to a 1.4 fold increase in luminescence (Unpaired 
t-test, p=0.0062 and p=0.0242 respectively) (Fig. 3-6 E, F). In summary, we found that the 
combination of cc-siRNA and AAV-Luc increased luminescence in cell culture independent of 
siRNA sequence, serotype of virus, or cell type. 
 
5. siRNA targeting luciferase reduces luminescence in vivo. 
To test siRNA that was not conjugated with cholesterol, we co-injected mice with siRNA 
and AAV-Luc-Htt then measured luminescence. We tested siRNA targeting luciferase target 
sequences (siLuc) as well as huntingtin SNP target sequences, 2307 and 2273 (si2307, si2273), 
and a control siRNA (siCon). Due to concerns that luciferase out-expressed siRNA, we used a 
very high dose, 14nmol. Unexpectedly, on day 1, siLuc injected mice showed an increase in 
luminescence on the siLuc injected side, which disappeared on day 2. We detected a significant 
difference in luminescent flux of the siLuc side overall (Fig. 3-7 A, Mixed method ANOVA 
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p=0.0064). The ratio of luminescence from siRNA injected side to PBS injected side was 
compared with the ratio at one year after injection as a reference time point. A significant 
difference was detected in the ratio of luminescence in the siLuc group on the third day after 
injection resulting in a 43% decrease in luminescence. The fact that both methods of analyzing 
data, luminescence and ratio, agree lend support to the conclusion of silencing by siLuc. 
However, a difference was also detected in the siCon injected group suggesting possible 
variation in the injection technique or solution preparation, making it difficult to draw firm 
conclusions from these experiments (Fig. 3-7 D). No differences were observed in groups 
injected with si2307 or si2273 (Fig. 3-7 B, C). The 2307 and 2273 target sites and RNAi 
sequences were chosen for this study because they feature a human SNP site that shows allele-
discriminating properties in cell culture assays and have therapeutic potential [196]. Despite 
having a low IC50 values, neither si2307 nor si2273 demonstrated robust silencing in cell culture 
experiments, achieving a maximum of only 40-50% silencing (Figure 3-4 A). It is possible that 
this assay is not sensitive enough to detect silencing by si2307 and si2273.   
 
6. AAV-Luc-Htt co-injection with AAV-shLuc results in reduction of luciferase activity. 
We next tested the ability of AAV-delivered short hairpin RNA (shRNA) targeting 
luciferase to silence AAV-Luc-Htt. The AAV-shRNA targeting luciferase (AAV-shLuc) differs 
from AAV-Luc-Htt in that it is packaged in AAV serotype 8 and employs the U6 promoter for 
transcription (Table 3-2). U6 is a polymerase III promoter that is specifically used to express 
small RNAs, and AAV-Luc-Htt uses the polymerase II CMV promoter to express luciferase. The 
U6 promoter functions to transcribe small RNAs at a higher level than the CMV promoter (Edith 
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Pfister, unpublished data). The AAV-shLuc virus had been prepared for use in a different study 
(unpublished) and was chosen for this study because it was readily available and because 
serotypes 8and 9 share many characteristics. AAV8 and AA9 both are predominantly found in 
neurons, however AAV8 can also be found in oligodendrocytes and astrocytes whereas AAV9 is 
highly specific for neurons [270, 275]. In a comparison of AAV serotypes after intrastriatal 
injections, AAV8 spread into the striatum while AAV9 distributed along the corpus callosum, 
transducing slightly more neurons  compared with AAV8 [270]. These differences are important 
to consider when interpreting results in experiments using mixture of AAV serotypes. In the 
current study, the left side was co-injected with AAV-Luc-Htt and AAV-shLuc while the right 
side was co-injected with AAV-Luc-Htt and PBS (Fig. 3-8). The side injected with AAV-shLuc 
was significantly decreased 23% compared with PBS control (Mixed model ANOVA, 
p=0.0002). This difference demonstrates that it is possible to detect luciferase silencing by co-
injection of AAV-Luc-Htt and AAV-shRNA. 
 
7. AAV-miRNA targeting SNP site 2273 does not silence luciferase activity in vivo. 
 We next wanted to test vectors targeting huntingtin SNP sites. For this experiment we 
created two viruses, one targeting the SNP site 2273 G and the other targeting SNP site 2273 A 
(AAV-miR2273G or –miR2273A, Table 3-2). These viruses have the same serotype as the 
AAV-Luc-Htt (serotype 9), however there are two differences. The AAV-miR2273 viruses 
contain the chicken β-actin promoter with CMV enhancer (CBA promoter) rather than a CMV 
promoter because it results in a 6.4-fold greater expression [276]. The silencing vectors were also 
designed to have a self-complementary AAV (scAAV) genome rather than the single stranded 
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AAV (ssAAV) genome of the AAV-Luc-Htt. Self-complementary genomes confer increased 
transduction into host cells, resulting in greater saturation within the expected distribution for 
AAV serotype [277]. It is our intention that the scAAV9 vectors would match or exceed the 
distribution of the ssAAV9 and have a greater degree of expression and probability of co-
transducing neurons. On the left side of the brain we co-injected AAV-Luc-Htt with AAV-
miR2273G) matching the target SNP, 2273. On the right side we co-injected AAV-Luc-Htt with 
AAV-miR2273A, which contains a mismatch to the SNP site. We used a 1:1 ratio between 
AAV-miR2273 and AAV-Luc-Htt viruses. We saw no significant difference in the luminescence 
between the sides of the brain (Fig. 3-9 A). In previous experiments, AAV-miR2273G was 
shown to silence the SNP site in cultured cells; however, a high MOI only resulted in modest 
silencing (Fig. 3-4 B). This lack of result in vivo may be due to it not being a very robust 
silencing structure. 
To test an increased dose of AAV-miR2273, we co-injected mice with 9:1 ratio of AAV-
miR2273 to AAV-Luc-Htt. One group received the matching vector, a second group received the 
mismatching vector, and a third group received a control vector (AAV-miRCon). The right side 
of all mice was injected with AAV-Luc-Htt and PBS. The matching vector did not differ in 
luminescence compared with PBS. Unexpectedly, there was an increase in luminescence in the 
injections with mismatching and control vectors (ANOVA p=0.0496, p=0.0076 respectively) 
(Fig. 3-9 B). No difference was found between the left to right ratio of luminescence between the 
groups (Fig. 3-9 C). The lack of silencing luciferase activity upon co-injection with AAV-
miR2273 matching the target site shows that it is inefficient at silencing luciferase to a level that 
is detectable by this in vivo imaging method. As mentioned previously, the siRNA did not show 
robust silencing in cell culture experiments, even at high concentrations (Figure 3-4 A). 
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Similarly, silencing experiments in cell culture using AAV-miR2273 did not reach 50% 
reduction of luminescence even at high MOI (Figure 3-4 B). Silencing in vivo would likely be 
difficult and possibly out of the sensitivity of this study’s design. The increased luminescence in 
the control injection suggests that could be internal error in creating the AAV injection solution 
in this experiment. One possible interpretation is that miR mismatch and miRCon co-injection 
increased luminescence while PBS had no effect and miR match displayed mild silencing. In 
summary, these results are inconclusive, and the system may not be sensitive enough to describe 
subtle silencing without a large number of animals or an improvement in the sensitivity. 
 
8. AAV-miRNA targeting huntingtin SNP site 2307 resulted in silencing of luminescence in 
an allele-specific manner. 
In order to test silencing of a different human huntingtin target site, we used a miRNA 
complementary to the target sequence containing SNP site 2307 (AAV-mir2307, Table 3-2). 
This virus was previously created for a different project and differs from AAV-Luc-Htt in that is 
was packaged using AAV serotype 1 and also uses the polymerase III promoter U6 rather than 
the polymerase II CMV promoter. As stated previously, different serotypes confer different 
properties in terms of tissue distribution and transduction capabilities. Serotype 1 is known to 
have tropism predominantly for neurons, but is also able to transduce microglia and astrocytes at 
a significantly higher rate than serotype 9 [275, 278]. In previous experiments this vector was 
shown to silence luciferase in cell culture (Fig. 3-4 B). We tested a 1:1 ratio of AAV-Luc-Htt 
and AAV-miR2307 compared with PBS. There was no significant difference between the 
luminescence on either side (Fig. 3-10 A). We increased the amount of AAV-miR2307 to five 
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times that of AAV-Luc-Htt and repeated the experiment. In a second group of mice, the same 
AAV-miR2307 was co-injected with the reporter virus that has the alternative, mismatching, 
SNP site. The right side of each mouse was injected with reporter virus and PBS (Fig. 3-10 B). 
Results show that mice with the matching reporter construct had a reduced amount of 
luminescence overall compared with the contralateral side injected with PBS (Mixed model 
ANOVA, p=0.0051). The second group with the mismatching reporter construct had no 
difference in luminescence between each side of the mouse. Surprisingly, although the 
luminescence differed significantly in the matching group, the ratio of left to right side did not 
differ significantly compared to the ratio of the mismatched group (Fig. 3-10 C). This 
discrepancy limits the conclusions that can be drawn from the results. Although we proposed the 
ratio calculation as a method to reduce variation from luciferin absorption, it is possible that it 
may introduce other sources of variation including spread of viruses to midline/contralateral 
structures which is compounded by the use of different serotypes. For this experiment, the 
decrease in luminescence with AAV-miR2307 co-injection suggests that this vector is functional 
against the human huntingtin target sequence containing the 2307 SNP site. Reduction in 
luminescence was not seen with the mismatching vector, suggesting that the matching vector 
may demonstrate allele-specific specificity. This experiment should be repeated using matching 
serotypes as well as comparing luminescence in unilateral injection groups to strengthen 
conclusions. 
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9. A re-injection approach is not sensitive enough for detection of decreases in 
luminescence. 
 In order to compare silencing to a stable baseline of luminescence, we established stable 
expression of AAV-Luc-Htt luminescence before re-injecting the same location with AAV-
miR2307. Mice were injected with AAV-Luc-Htt and imaged after 7-14 days. Using a 5:1 ratio 
of AAV-miR2307 to AAV-Luc-Htt or the same volume of PBS, we injected the AAV-miR2307 
at the same location and followed the luminescence over time. We found no decrease in 
luminescence in either group (Fig. 3-11 A, B). The PBS control injection led to a transient 
increase of luminescence compared to no injection, indicating that re-injection may disturb what 
should be a stable bioluminescence (Fig. 3-11 B). This experiment were repeated in three 
different cohorts (n=4 for each), and each time there was no detectable inhibition of 
luminescence by AAV-miR2307.  
 
C. Discussion 
In this study, we created two AAV-luciferase reporter vectors with huntingtin sequences 
in the 3'-UTR to follow gene silencing in vivo. These vectors present a method for testing gene 
silencing over time as mice can be measured repeatedly by bioluminescent imaging. This is a 
pilot study, meant to guide the optimization of the luciferase silencing system for application in a 
systematic comparison of RNAi in the brain. We co-administered the reporter virus with 
silencing molecules and viruses to study silencing dynamics in the brain. 
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We found that in animals with stable AAV-luciferase expression, luminescence varied 
greatly between animals and between the same animal on consecutive days. We hypothesize that 
this is due to the variable rate of luciferin absorption the intraperitoneal space. We tried several 
methods of delivering luciferin including tail vein injections and implanted pump delivery of 
luciferin. Tail vein injections deliver a reliable dose directly into the circulation, avoiding the 
absorption through gut, subcutaneous fat or intraperitoneal tissue, however the veins become 
damaged upon repeated access, making it impractical for daily injections. We considered using 
an intraperitoneal-implanted pump, such as an Alzet® osmotic pump, however the volume 
constraints require using dramatically less luciferin than the standard dose recommended by 
Xenogen for use with their in vivo imaging system. Less luciferin would result in 
correspondingly lower light output possibly affecting the sensitivity of the assay. However, this 
method has been used successfully in imaging the olfactory bulbs in rats [268]. An alternative is 
to implant a central port for each mouse. This would add another procedure reducing the 
system’s convenience and speed. The bilateral injection method was our solution to correct for 
the daily variation. We present data both as absolute values of luminescence as well as a ratio of 
luminescence from the treated side versus control side. For experiments with siRNA, we 
compared luminescence to a time point representing stable AAV expression that is well past the 
duration of silencing observed for siRNA, approximately 25 days in non-dividing cells [260]. 
While providing an internal control, this method presents additional issues. We found that 
luminescence from one side of the brain crosses over to the other side as illustrated in Figure 3-2 
C. This is likely a combination of light scattering through the tissue and spread of the virus to 
midline or contralateral structures of the brain. While correcting for one source of variation, the 
spread of luminescence across the midline presents its own limitation, reducing the sensitivity of 
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the assay. We also found discrepancies between results seen by analyzing luminescence but were 
not significant when comparing ratios, such as in experiments with AAV-miR2307 (Fig. 3-10 B, 
C). We found that in a single group of animals, if we calculate the ratio of the left to right side 
injection, the minimum silencing that can be detected is improved from 40% to 35%. This 
highlights the limitations of this method to robustly identify silencing of luciferase. Throughout 
this study presented both the luminescent data and results presented as a ratio in order to evaluate 
the system for such inconsistencies. 
Injections with 0.9nmol cc-siRNA targeting firefly luciferase resulted in an initial 52% 
decrease in luminescence on day one that was not sustained over time. This difference was seen 
by the ratio method and not by the comparison of flux. The duration of silencing may be limited 
by the increasing level of expression from the AAV-Luc-Htt vector, which begins low and 
increases over several weeks until reaching a stable plateau. The amount of cc-siRNA remains 
fixed or begins to diminish as molecules not incorporated into RISC are degraded by the cell,  
leading to a fundamental imbalance between the amount of siRNA and luciferase transcript 
within the cell. While silencing was observed with cc-siRNA, it may need a higher dose to 
demonstrate a sustained decrease in luminescence. Several studies have used cc-siRNA to 
silence huntingtin in mice and rat models, one of which uses intravenous injection and another 
uses neonatal intraventricular injections [247-249]. In one study, 0.5nmol of huntingtin-targeting 
cc-siRNA was co-injected with AAV-Htt100Q. Treated mice developed smaller intranuclear 
inclusions, fewer neuropil aggregates, with greater survival of neurons, and improved behavioral 
phenotype. Huntingtin protein was reduced by 56-66% after 3 days [248]. In this study, we used 
a higher dose of cc-siRNA, nearly twice as much, and showed 52% silencing of luciferase 
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activity one day after injection, however we did not see a difference on the second or third days 
after injection.  
For testing siRNA without cholesterol conjugation, we increased the dose to 14nmol to 
favor silencing of luciferase. At this dose, we detected a 43% decrease in luminescence three 
days after injection with siLuc. The difference in silencing dynamics compared with cc-siRNA 
may be due to the absence of a cholesterol moiety which may facilitate transmembrane transport 
of cc-siRNA. Several groups who have measured silencing of luciferase in the liver by siRNA 
observe silencing to peak 2-3 days after injection which would correspond with the timing 
observed in this experiment [258-260]. The single day of silencing likely represents the peak 
knockdown further highlighting the limited sensitivity of this assay. Testing of huntingtin 
specific siRNA did not result in silencing of luminescence. One factor may be that the 
huntingtin-specific siRNA was not as robust at silencing as the siLuc siRNA, as depicted in the 
dual luciferase assays shown in Figure 3-4. The maximal silencing achieved in cell culture, under 
highly efficient transfection conditions is a modest 40-50% reduction in luciferase activity. Even 
if we were able to achieve this maximal silencing efficiency in vivo, the BLI assay may currently 
have adequate sensitivity for detection. Another limitation is the single injection. There are many 
studies following single intravenous injections of naked siRNA to silence genes in the liver, 
which readily takes up siRNA into hepatocytes. Studies of unconjugated siRNA in the brain 
predominantly use convection delivery, repeated injection, or infusion into the lateral ventricles 
[279-282]. A continuous, high-dose, delivery methods may be necessary to achieve detectable 
silencing in the brain. 
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We proceeded to test the silencing properties of two AAV-miRNAs targeting huntingtin 
sequences as well as one AAV-shRNA targeting luciferase. AAV-shLuc and AAV-miR2307 
decreased luminescence, globally, by 23% and 42% respectively. Interestingly, there was no 
difference in silencing when AAV-miR2307 was used with the mismatching construct, 
suggesting preferential silencing of the match target sequence. AAV-miR2273G did not result in 
any silencing.  Differences in luminescence were not significant at any individual day for any of 
these vectors reflecting limitation in sensitivity of this assay. These vectors differed from each 
other in many different ways including promoter, serotype, and genome structure as summarized 
in Table 3-2. Due to these inconsistencies, the trends identified in these experiments cannot be 
used to directly compare silencing vectors. Nevertheless, there are several notable observations. 
The two viruses effective in silencing luciferase used the U6 promoter to express the silencing 
hairpin RNA. The U6 promoter is an RNA polymerase III promoter that expresses short RNA at 
a high level compared with polymerase II promoters such as CMV and CBA promoters (E. L. 
Pfister, unpublished data). Also, AAV-miR2307 was effective when used at a higher, 5:1 ratio, 
compared with an equal ratio of silencing virus to reporter virus. Based on these observations, 
future experiments should employ the U6 promoter and 2:1 (or greater) ratio of silencing virus to 
luciferase virus. An additional discrepancy between the silencing constructs includes the design 
of the hairpins, each of which differed in their stem and loop length, sequence, and 
complementarity. The nomenclature to identify the hairpin as short hairpin RNA (shRNA) or 
microRNA (miRNA) reflects the predicted method of RNA processing. These differences could 
impact the validity of processing, which could alter the silencing efficacy (E. L. Pfister, 
unpublished data). Future experiments should compare viral hairpin RNA constructs with 
identical promoters, serotype, and hairpin structure.  
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Several groups have used viral delivery of shRNAs to target huntingtin in mouse models. 
AAV-delivery of shRNA expressed under the U6 promoter in a different transgenic mouse 
model, N171-82Q HD mice, reduced levels of the human huntingtin transgene mRNA in the 
striatum by 51-55% two weeks after injection [192]. This resulted in improved gait and rotarod 
performance [192]. Another group used AAV and the U6 promoter to express shRNA in the 
striatum of a transgenic mouse model, finding a reduction in mutant huntingtin mRNA (75%) 
and protein (60%) 10 weeks after injection [193]. There was a decrease in size and number of 
intranuclear inclusions and normalization of gene expression in neurons. The treatment had no 
effect on rotarod ability but delayed onset of clasping [251]. A study was done to test RNAi as a 
post-symptomatic therapy for HD by injecting AAV-expressing shRNA under control of the U6 
promoter into the striatum of mice with a mutant huntingtin transgene after the onset of 
symptoms. shRNA therapy decreased aggregates and restored dopamine releasing protein 
(DARP) expression, a gene that is down-regulated in affected striatum [252].  In another study, 
normal rhesus macaques were injected with AAV-U6-miRNA targeting huntingtin. They found a 
45% reduction in huntingtin mRNA 6 weeks after injection [253]. Huntingtin silencing from 
AAV-shRNA was also shown using a rat model of HD. First, rats were injected with AAV-U6-
shHtt, and after 2 weeks they were injected with AAV-NH2-terminal Htt70Q. They found no 
toxicity from the shRNA expression and observed silencing of huntingtin two weeks after 
injection of AAV-Htt70Q [283]. These previous studies employ the U6 promoter, which is the 
same promoter used in the two vectors in this study that successfully decreased luminescence.  
Bioluminescent imaging is a valuable tool for following reporter gene expression in vivo, 
primarily as it is noninvasive and allows for repeated measurements. BLI has been used in 
several studies of gene silencing. One group used liposomal siRNA directed at luciferase in mice 
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expressing ROSA26-SLS-luciferase in tissues expressing Cre-recominase from the ubiquitous 
probasin promoter [259]. Since the animals expressed luciferase ubiquitously, they measured 
luminescence in ex vivo tissues and saw knockdown only in the liver 4, 8 and 16 days after IV 
injection, with the greatest silencing on day 4 at 75% [259]. They did not find silencing in 
spleen, heart, lung, kidney, or adrenals and did not examine the brain [259]. Another group used 
siRNA targeting luciferase in lipid nanoparticles delivered by IV injection resulting in a 
maximum inhibition of bioluminescence in the liver 3 days after injection [258]. At the highest 
dose they saw nearly complete silencing for 2 weeks. Using high pressure tail vein injection 
(HPTV) of luciferase plasmid and siRNA polyplexes, silencing was observed for 3 weeks with 
silencing greatest on day 3 [260]. Using naked siRNA and luciferase plasmid in a HPTV 
injection there was 81% silencing of luciferase in liver after 3 days [284]. In this study we 
detected silencing on day 3 with siRNA and day 1 with cc-siRNA. These studies found silencing 
to be the greatest 3-4 days after treatment, which confirms what we saw with unconjugated siLuc 
where silencing was the greatest 3 days after injection.  In this study, we chose to focus primarily 
on “naked” unconjugated siRNA which has limited ability to cross cell membranes, but with the 
advantage of a lower risk of toxicity in the brain. The drawback to using unconjugated siRNA is 
that due to a low efficiency of uptake into cells it requires high concentrations to be effective.  
The use of different AAV serotypes limits the conclusions that can be made as each 
serotype have slightly different properties of spread and transduction into cells. All viruses used 
in this dissertation are recombinant adeno-associated viruses (rAAVs), meaning that they share 
the inverted terminal repeats (ITRs) of serotype 2, but express a different gene for the capsid 
protein. The capsid protein binds the virus to the cell surface receptors, thus defining the tropism 
for that virus. Recombinant AAV expressing capsid proteins from serotype 1, 8, or 9, are notated 
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as rAAV2/1, rAAV2/8, and rAAV2/9 or simply as AAV1, AAV8, and AAV9. Each serotype 
binds to one or more specific cell surface molecules: sialic acid for AAV1, heparin sulfate 
proteoglycan for AAV2, laminin receptor for AAV8, and galactose for AAV9 [285-288]. There 
are many published comparisons of tissue spread among serotypes, however no single study to 
date compares serotypes 1, 8 and 9 that were used in mouse injection experiments. Several 
studies report equal spread of AAV1, 5, 7 and 8 throughout the mouse and rat striatum [289-
291]. One study found serotypes spread differently depending on their concentration, and that all 
serotypes spread equally well at high doses, however a low dose, AAV5 and 7 were superior to 
AAV8 [289]. AAV9 and rh10 have been shown to have a far greater spread than AAV7, 8, 9, 
and rh10 [270]. Although the total spread was impressive in the AAV9-injected animals, the 
variation among the three animals was very large, with the number of transduced cells ranging 
from 12 to 1,282 within the striatum [270]. In a second study, the same group showed single 
injection into the striatum of AAV9 filling the medial aspect of the striatum and diffusing to 
nearby structures, including septal nuclei [271]. To summarize the published findings, no groups 
has compared the spread from single injections of AAV1, 8, and 9, however serotypes 1 and 8 
spread through the striatum equally well and there is a possibility that AAV9 shows superior 
spread to AAV8. The concentration of the virus may play a role, with lower concentrations 
limiting spread. The co-injection experiments in this chapter employ lower concentrations of the 
AAV9 reporter virus compared with the AAV1, 8, or 9 silencing virus. Taken together, although 
the reporter virus is packaged in the high potency and high spread serotype, the low 
concentration may limit its spread relative to the silencing constructs. 
AAV can also spread by diffusion and anterograde/retrograde transport to distant 
anatomical locations in the brain. This has been shown in serotypes 1, 5, 8 and 9, possibly by a 
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serotype –independent mechanism [271, 291, 292].  Viral mRNA from injections of AAV9 into 
the striatum have been detected in the substantia nigra pars compacta, hippocampus, amygdala 
and thalamus [271]. There is the possibility that virus can cross to the contralateral side of the 
brain, in one study, a small degree of positive cells were found on the contralateral side, up to 
15% in some sections [271].  
A valuable addition to this study would be a comparison of viral spread and the degree of 
overlap of the reporter virus and silencing virus. A mismatch in distribution of the co-injected 
viruses could underrepresent the effectiveness of the silencing vectors. This can be evaluated by 
fluorescently labeling cells transduced by each virus and assessing the degree of co-labeling. A 
gene for a fluorescent protein marker, such as green fluorescent protein (GFP), can be included 
in the silencing virus, and thus cells expressing the silencing hairpin RNA would also express a 
fluorescent protein. Fluorescent proteins cannot be used in the luciferase reporter construct, as 
including two genes would exceed the DNA packaging limits of the AAV. However, 
immunofluorescent staining can be performed with fluorescently labeled antibodies against the 
luciferase protein, or by tagging the luciferase with an easily labeled tag, such as hemagglutinin. 
One could also use fluorescent in situ hybridization (FISH) to evaluate spread and co-
localization of the luciferase mRNA with a fluorescent protein in the silencing virus. siRNA can 
also be labeled with fluorescent tags such as Cy5 or Cy3 and co-localized with fluorescently 
labeled luciferase mRNA or protein. In this way, one could assess the degree of co-transduction 
and determine whether the lack of silencing is due to inefficiency of RNAi or due to inefficient 
co-transduction of cells.  
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Other limitations of this study are that in many experiments there were fewer animals 
than were required to achieve reasonable experimental power. This was due to the unexpectedly 
high variation. For most experiments, there was only one independent experiment for each 
reported result, and aspects of each experiment differed in various ways, including viral 
components, doses, and injection sites.  
In our experiments with cc-siRNA, we observed an unexpected result that co-injection of 
cc-siRNA with AAV-Luc-Htt initially increased luminescence ten-fold compared with PBS. 
After six months the increase was attenuated to a two-fold difference in luminescence in one 
experiment and the effect was eliminated in a second experiment (Fig. 3-5 A, C). A similar 
increase in luminescence was observed in cell culture co-transfections of cc-siRNA and AAV 
where the effect was independent of siRNA sequence, AAV serotype, or cell type. There are 
several possible explanations: cc-siRNA could alter AAV transduction efficiency, it could 
increase viral gene expression, or cc-siRNA could increase the delivery of AAV from the pipet 
tip, resulting in increased delivery of AAV.  
An experiment to test whether the cc-siRNA improves the viral transduction into cells 
can be done by labeling the viral capsid with Cy5 fluorescent dye. By exposing cultured cells to 
Cy5-labeled virions with and without cc-siRNA, the degree of transfected viral particles can be 
quantified [293]. This experiment would reflect cellular transport of the capsid rather than the 
expression of a fluorescent or luminescent protein. Cy5 labeled virus can also be used in vivo to 
study the effect on cell tropism and anatomical spread. Comparing Cy5 labeled AAV with and 
without cc-siRNA could reveal differences in the number of cells, area of transduction, and cell-
type specificity, through co-labeling with cell-type specific antibodies. In order to study if the 
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effect is related to enhanced transcription or translation, cells (or mice) stably expressing AAV-
Luciferase could be transfected (or re-injected) with cc-siRNA. Increased luminescence would 
be observed with an increase in transcription or translation, and Western analysis and 
quantitative PCR could be used to detect relative increases in protein and mRNA, respectively. 
This is one way to discern whether the interaction is independent of AAV transduction into cells 
and whether there is enhancement of transcription or translation. Improvement in AAV 
transduction efficiency would present an advance to gene therapeutics and the effect of cc-
siRNA warrants further study. While this thesis was being edited, these experiments were 
repeated by a different member of the lab using different reagents. Unfortunately, they were 
unable to replicate these results.  
The present study demonstrates the possibilities and limitations in using AAV-Luc-Htt 
and BLI to follow gene silencing in the brain. There is a large variation within experimental 
groups which contributed to our inability to detect modest decrease in luminescence. If this 
model requires large numbers of mice in order to achieve statistical significance, then would not 
be a reasonable tool for screening applications. There is the potential that with stronger RNAi 
potency, new luciferase substrate with left-shifted spectrum that AAV-Luc-Htt can be used to 
compare sequences, hairpin structures, promoters, and delivery of RNAi and potentially validate 
allele-specific silencing of huntingtin sequences in the mouse brain.  
 
E. Materials and Methods 
1. Stereotactic injection  
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FVB mice (female, 3-6 months old, FVB/NJ from Jackson Laboratory, Bar Harbor, ME) 
were anesthetized with 250 mg/kg tribromoethanol (2.5 g 2, 2, 2, tribromoethanol dissolved in 
5mL amylene hydrate into 200mL PBS). Anesthetized mice were placed on a heated pad in a 
stereotactic frame. Superglue (Loctite) was applied to the surface of the fur between the ears, 
avoiding eyes and exposed skin. After 10-20 seconds, the glue is gently pulled off to remove fur. 
The exposed skin is cleaned with betadine and an incision is made posterior to anterior. The skin 
is pulled aside and the needle is placed over the bregma. Unless otherwise stated, measurements 
for injection location are: anterior 1mm, lateral 3mm and ventral 2mm from the bregma. Once 
the needle is lowered, it rests there for 2 minutes before infusion begins by micropump syringe 
(NanoFil syringe, World Precision Instruments). Injections were performed at a rate of 125nl per 
minute, for values see below. After infusion the mouse rests for 2 minutes before the needle is 
withdrawn. The incision is closed with clear, undyed suture (monocryl undyed monofilament) 
and the animals are allowed to recover on a heated pad at 37C. 
AAV dilution series (Figure 3-1 C): Mice were injected unilaterally with 1µl of AAV9-CMV-
Luc-Htt (AAV-Luc-Htt) at each concentration: 1e13 GC/mL, 1e12 GC/mL, 1e11 GC/mL, 1e10 
GC/mL, 1e9 GC/mL; n=3-5 mice per concentration. 
Unilateral control injection (Figure 3-2 A, B): Mice were injected with 5e9GC AAV-Luc-Htt 
on the right side cortex (coordinates: at the bregma (anterior 0.0) lateral 2mm, ventral 2mm), 
volume of injection is 0.67µL, n=9 mice. 
Injection of cholesterol conjugated siRNA (Figure 3-5): Mice were co-injected on the left side 
with 2e10GC AAV-Luc-Htt and 0.9nmol cc-siRNA targeting luciferase from Photinus pyralis 
(firefly luciferase, siLuc, Table 3-1). The same mice were co-injected on the right side with 
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2e10GC AAV-Luc-Htt and 0.9nmol control cc-siRNA targeting luciferase from Renilla 
reniformis (renilla luciferase, siCon, Table 3-1). A second group of mice were injected bilaterally 
with 2e10 GC AAV-Luc-Htt and PBS.  A third group of mice were injected with 2e10 GC AAV-
Luc-Htt and 0.9nmol cc-siCon on the right side and with 2e10GC AAV-Luc-Htt and PBS on the 
left side. The total volume of each injection was 4µL, n=5 per group. 
Injection of siRNA (Figure 3-7): For each siRNA, groups of mice were co-injected on the left 
side of the brain with 5e9GC AAV-Luc-Htt and 14nmol siRNA. The right side was injected with 
5e9GC AAV-Luc-Htt and of PBS. Total injection volume is 3.75µL, n=4-8 per group 
Injection of AAV-shRNA targeting firefly luciferase (Figure 3-8): Mice were injected with 
5e9GC AAV-Luc-Htt and 1.15x10GC AAV-shLuc (Table 3-1), at a 1:2 GC ratio of AAV-Luc-
Htt and AAV-shLuc. On the right side, each mouse was injected with 5e9GC AAV-Luc-Htt and 
1.65µL PBS. Total volume of injection was 1.9µL, n=9 mice per group. 
Injection of AAV-shRNA targeting SNP site 2273 (Figure 3-9): For results shown in Figure 3-
9 A, mice were injected into the cortex at measurements from the bregma: anterior: 0mm, lateral 
3mm, ventral 1mm. The left side was injected with 5e9GC AAV-Luc-Htt and 5e9GC AAV-
miR2273G (Table 3-1). The right side was injected with the same amount of AAV-Luc-Htt and 
5e9GC AAV-miR2273A (Table 3-1). Total volume of injection was 0.6 µL at a ratio of 1:1 GC 
between the AAV-Luc-Htt and AAV-miRNA, n=8 mice per group. For results shown in Figure 
3-9 B, C, groups of mice were injected on the left side with 5e9GC AAV-Luc-Htt and 4.5e10GC 
of either AAV-miR2273G, AAV-miR2273A, or AAV-miRCon (Table 3-1). Each mouse was 
injected on the right side with 5e9GC AAV-Luc-Htt and PBS. Total volume of each injection 
was 3.71µL at a ratio of 9:1 GC between AAV-Luc-Htt and AAV-miRNA, n=5 mice per group. 
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Injection of AAV-miRNA targeting SNP site 2307 (Figure 3-10): For results shown in Figure 
3-10 A (n=5) the left side was injected with 5e9GC AAV-Luc-Htt, 5e9GC AAV-miR2307 
(Table 3-1), and PBS. The right side was injected with the same amount of AAV-Luc-Htt and of 
PBS. Total volume of injection was1.5µL at a ratio of 1:1 between the AAV-Luc-Htt and AAV-
miRNA. For results shown in Figure 3-10 B, C, one group of mice (n=11) was injected on the 
left side with 5e9GC AAV-Luc-Htt and 2.5e10GC AAV-miR2307 (Table 3-1). The right side 
was injected with the same amount of AAVLuc-Htt and PBS. A second group of mice (n=8) 
were injected on the left side with 5e9GC AAV-Luc-Htt with the 2307C SNP site and 2.5e10GC 
AAV-miR2307 and on the right with PBS. All injections were 1.9µL in volume at a ratio of 1:5 
between the AAV-Luc-Htt and AAV-shRNA. 
AAV-miR2307 re-injection (Figure 3-11 A, B): Mice were injected with 5e9GC AAV-Luc-
Htt. After 7-12 days, mice were re-injected 2.5e10 GC AAV-miR2307. All injections were 
1.9µL in volume, n= 4 mice per group. 
2. Imaging mice 
Mice were anesthetized with 5% isofluorane and placed into the Xenogen (now Caliper) 
in vivo imaging system (IVIS 100). 10 minutes prior to imaging, mice are injected with 
150mg/kg D-luciferin into the intraperitoneal (ip) space (from a 30mg/mL stock solution 
dissolved in sterile water). Luminescent measurements were taken by 1 minute exposure. A 
region of interest is drawn over each injection site to quantify luminescence from the injected 
area. Data was collected as flux (photons / second).  
3. Cell culture experiments 
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Testing of AAV-Luc-Htt and cc-siRNA: HeLa cells were grown to confluence in 24 well 
plates. Cells were incubated with dilutions of AAV-Luc-Htt with 0.9nmol of control cc-siRNA 
(targeting Renilla luciferase or GFP) per well. Doses of virus were 1000 MOI, 10,000 MOI, 
100,000 MOI. AAV-Luc-Htt at 100,000 MOI was also incubated with 0.9nmol of cholesterol. 
Cells were lysed after 24 hours by adding 100uL passive lysis buffer (Promega Dual-Luciferase 
Reporter Assay System) and placed on a shaker for 20 minutes at room temperature. Cell lysates 
were measured for luminescence in a Glomax luminometer.  
Dual luciferase assay: HeLa cells were grown to confluence in 24-well plates. Different 
concentrations of siRNA were made in serum-free media with either 0.025 µg/well pSiCheck 
with the target sequences or a combination of 0.025µg/well pAAV-Luc-Htt and 0.05µg/well 
pRLTK.  The siRNA and vector mixture was combined with lipofectamineLTX (Invitrogen) and 
400µL was placed into each well. Concentrations of siRNA were: 20 nmol, 10 nmol, 2 nmol, 1 
nmol, 0.5 nmol, 0.2 nmol, 0.05 nmol, 0.02 nmol, 0.005 nmol, 0.002 nmol, and 0.0005 nmol. 
Doses for cc-siRNA were: 80 nmol, 60 nmol, 40 nmol, 20 nmol, 10 nmol, 6 nmol, 2 nmol, 1 
nmol, 0.6 nmol, and 0.2 nmol. Each concentration was performed in triplicate. After 24 hours the 
cells were lysed with 100uL of passive lysis buffer and measured for luminescence using the 
Promega Dual Luciferase Reporter Assay System and Glomax luminometer. Data were graphed 
and the IC50 was calculated using Igor Pro software (WaveMetrics, Portland, OR). 
Testing of AAV-miRNA silencing: HeLa cells were grown to confluence in 24 well plates. 
Each dilution of AAV-miRNA was made in serum-free media (OptiMEM) and 200uL containing 
the designated MOI of virus was added to each well of cells. The cells were incubated with virus 
overnight and checked for GFP activity. Then they were transfected with 0.025ug/well pSiCheck 
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vector (Promega) containing the target sequence using Lipofectamine LTX (Invitrogen). 
pSiCheck vectors express both Firefly and Renilla luciferases. The target sequence is inserted 
into the 3'-UTR of Firefly luciferase and silencing of firefly luciferase is normalized to the 
constant expression of Renilla luciferase. Cells were lysed after 24 hours and measured for 
Firefly and Renilla luciferase activity. All concentrations were performed in triplicate. 
4. Cloning 
Target sites were synthesized as ultramer oligos with 15nt of sequence flanking each SNP 
site. We created two ultramers with each SNP site. Ultramer C1 has one variation of each SNP 
nucleotide, and ultramer C2 has an alternate SNP nucleotide. The sequences are C1: 3'-
CTAGAGCCTTTGGAAGTCTGCGCCCTTGTGCCCTGCCGAGAAGCTGCTGCTGCAGA
TCAACCCCGAGGAGATGGGGACAGTAATTCAACGCTAGAAGAGCCTGCTCCCTCAT
CCACTGTGTGCACTTCAGTCTCAGTGCCGAGCTCAGCGCCTTGGCTCTGCTGTCTGA
GCAGCTATCTCGGCTAGACACAT-5' and C2: 3'-
CTAGAGCCTTTGGAAGTCTGTGCCCTTGTGCCCTGCCGAGAAGCTGCTGCTACAGAT
CAACCCCGAGGAGATGGGGACAGTACTTCAACGCTAGAAGAGCCTGCTCCCTCATC
TACTGTGTGCACTTCAGTCTCAGTGCCGAGCACAGCGCCTTGGCTCTGCTGTCTGAG
CAGCTCTCTCGGCTAGACACAT-5'. SNP sites are underlined. Xba1 sites were added before 
and after each ultramer for insertion into the 3'-UTR of pGL3-control vector and we sequenced 
the resulting clones to check for correct insertion. The luciferase genes with ultramers were 
amplified with a SalI site, the PCR product was digested with EcoRI and SalI, and inserted into 
pAAV-CMV backbone. 
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Figure 3-1: Allele-specific gene silencing, AAV-Luc-Htt design and in vivo testing. (A) 
Allele-specific RNAi is designed to discriminate between single nucleotide polymorphisms 
(SNPs), preferentially cleaving the matching SNP site over the mismatching SNP site. In 
Huntington’s disease, allele-specific RNAi is designed to target the SNP variation present on the 
CAG expanded allele. (B) We have created two luciferase reporter constructs containing 
huntingtin target sequences in the 3'-UTR. Each colored bar is a 30bp fragment of sequence 
surrounding the indicated SNP site. Each SNP is identified by a four digit code and the letter 
representing the SNP nucleotide. The first four sites are human huntingtin SNP sites and the last 
two sites are found in mouse huntingtin. C.) Mice were unilaterally injected with 10-fold 
dilutions of AAV-Luc-Htt and imaged after two weeks. The 1e10GC injected mice emit more 
light than all other groups (One-way ANOVA p<0.0001, Tukey’s multiple comparison test, all 
groups n=5). BG, background. Data is presented as mean ± SEM, **p<0.01, ***p<0.001. 
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Figure 3-2: Variation in luminescence of AAV-Luc-Htt injected mice.  A.) Mice (n=9) were 
injected with 5e9GC AAV-Luc-Htt on the right side and imaged over 28 days. Stable baseline is 
achieved starting at day 10. B.) Three days within the stable baseline are selected for comparison 
(15, 19, and 21), and data points are plotted as luminescence (flux, photon/second) for each 
mouse. Each mouse displays different degree of variability, with standard deviations ranging 
from 5-40% of its total flux. All data is presented as mean ± SD. 
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Figure 3-2: Variation in luminescence of AAV-Luc-Htt injected mice. 
144 
 
Figure 3-3: Experimental design for in vivo measurement of RNAi gene silencing. A.) 
Luciferase reporter constructs with the huntingtin target SNP sites are packaged in AAV capsid 
(AAV-Luc-Htt). AAV-Luc-Htt virus is co-injected into the left side of the brain with 
experimental RNAi molecules. The right side is co-injected with the reporter construct and either 
control RNAi molecules or PBS. Beginning 24 hours after injection, the mice are anesthetized, 
injected into the ip space with the luciferase substrate and imaged to measure luminescence. A 
region of interest, ROI, is drawn over each side of the brain, then quantified and analyzed both as 
luminescence (flux, photons/second) and as a ratio of experimental / control injected side. B.) 
Mice were injected with 5e9GC AAV-Luc-Htt in the right striatum (unilateral injection, n=5) or 
into each hemisphere (bilateral injection, n=7) and imaged for seven days. The ratio is calculated 
as the flux from the left hemisphere divided by the flux from the right hemisphere. The ratios 
from each day were compared at each time point (Mixed method ANOVA for ratio group, 
p<0.0001; for unilateral injection group, p< 0.0001, Tukey’s multiple comparisons). Both groups 
showed a difference between the left and right sides, however only the ratio group showed 
differences between sides on each day. All data is presented as mean ± SD. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.   
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Figure 3-4: RNAi constructs silence luciferase and huntingtin targets in cell culture. (A) 
siRNA and cc-siRNA molecules were tested against their target sequences in dual luciferase 
assays. siRNA are tested at 11 doses and cc-siRNA are tested at 10 doses, each dose is done in 
triplicate. Data is presented as luminescence of target normalized to control luciferase for each 
dose. IC50 values were calculated from the curve using Igor Pro wave-fitting software 
(WaveMetrics, Portland, OR). (B) Cells were infected with the AAV-miRNA and then 
transfected with the matching reporter construct to measure silencing of huntingtin target sites. 
Luminescence was normalized to cells transfected with reporter construct and no AAV. At 
100,000 MOI of AAV-miR2273, there was a 32% silencing compared with 10,000 MOI/well 
(mean diff. 0.5854 (95% CI 0.5030 to 0.6679, p<0.0001)) for 30,000 MOI there was 10% 
silencing (mean diff. 0.2798 (95% CI 0.1400 to 0.4197, p=0.0001)). For AAV-miR2307 there 
was a 55% silencing compared with 10,000 MOI (mean diff. 0.3910 (95% CI 0.2511 to 0.5309, 
p<0.0001)) and for 30,000 MOI 12% silencing (mean diff. 0.4560 (95% CI 0.3736 to 0.5385, 
p<0.0001)). Data is presented as mean ± SD. *** p<0.001, ****p<0.0001 
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Figure 3-4: RNAi constructs silence luciferase and huntingtin targets in cell culture.
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Figure 3-5: Cholesterol-conjugated siRNA silences luciferase activity in the brain 24 hours 
after injection. (A) To test silencing by cholesterol-conjugated siRNA, mice were co-injected 
with AAV-Luc-Htt and cc-siRNA. In one set of mice, the left side of the brain was co-injected 
with AAV-Luc-Htt and cc-siLuc, and the right side was co-injected with AAV-Luc-Htt and cc-
siCon. There was no difference in the luminescence from either injection over time. In a second 
set of mice, both sides were injected with AAV-Luc-Htt and PBS alone. There was no difference 
in either of the injections over time. (B) For the same experiment, results were calculated using 
each mouse as its own control. The luminescence from the left was divided by luminescence on 
the right side. One day after injection, there was a difference between the ratio in the cc-siRNA 
treated group compared with the PBS treated group. There was a decrease of 52.6% (Sidak’s 
multiple comparisons test, mean diff. 0.4847 (95% CI 0.4051 to 0.5644, p<0.0001, n=5 for both 
groups). There were no differences at the other time points. (C)  To investigate the effect of cc-
siRNA on long-term luciferase activity in the same mice, we compared luminescent flux at 168 
days. Comparison of left side injections and right side injections show a 1.9- and 1.7-fold 
differences respectively (Unpaired t-test p=0.0017 and p=0.0007, respectively) (D) To compare 
the effect of cholesterol-conjugated siRNA on AAV-Luc-Htt, mice were co-injected on the left 
side with PBS and on the right side with cc-siCon. We found a significant increase in 
luminescence on the cc-siCon side at 5 and 12 days after injection (2-Way ANOVA p=0.0015, 
Tukey’s multiple comparison test, n=5). After 6 months, there was no difference in luminescence 
between the sides of the brain. Data is presented as mean ± SEM. ***p<0.001, ****p<0.0001 
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Figure 3-6: Cholesterol-conjugated siRNA increases luminescence in AAV-Luc-Htt treated 
cells. (A) HeLa cells were incubated with 10,000 MOI AAV-Luc-Htt and either control cc-
siRNA (cc-siCon), unconjugated control siRNA (siCon), no siRNA. Cells were also incubated 
with only cc-siCon or siCon to ensure no contamination with AAV-Luc-Htt. There was a 
significant increase in the luminescence with a mixture of AAV-Luc-Htt and cc-siCon compared 
with both no siRNA and siCon treated groups (T-test, p=0.0091 and p=0.0001 respectively). (B) 
Different concentrations of AAV-Luc-Htt were combined with cc-siCon or no siRNA. Overall, 
there was an increase in luminescence in the cells treated with cc-siRNA (2-way ANOVA 
p<0.001). At 100,000 MOI there was a 2.62-fold increase in luminescence in cc-siRNA treated 
cells (Bonferroni posttest, mean diff. 11570 (95% CI 9531 to 13600, p<0.0001)). (C) 100,000 
MOI AAV-Luc-Htt was tested with cholesterol and there was no difference from the untreated 
group. (D) AAV2-Luciferase was incubated with either cc-siCon or no siRNA. There was a 
1.81-fold increase in luminescence in the cc-siRNA treated cells (T-test p=0.0045). (E) Cells 
were incubated with 1000 MOI AAV-Luc-Htt and cc-siRNA targeting GFP (cc-siGFP). There 
was a 1.22-fold increase in luciferase in the cc-siGFP group (T-test, p=0.0062). (F) Neuro2A 
cells were incubated with 1,000 MOI AAV-Luc-Htt and cc-siGFP and there was a 1.45-fold 
increase in luminescence in the cc-siGFP treated group (T-test, p=0.0242). Data is presented as 
mean ± SD. *p<0.05, **p<0.01, ***p<0.001 
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Figure 3-7: siRNA silences luciferase activity in the brain. A-D.) Mice were injected on the 
left side with 14nmol siRNA and AAV9-Luc-Htt and on the right side with PBS and AAV9-Luc-
Htt. (A) Co-injection with 14nmol siLuc resulted in an overall decrease in luminescence over 
time compared with the injections of PBS (n=8, 2-way mixed methods ANOVA p=0.0064). The 
ratio of left side to right side luminescence shows a 43% silencing of luciferase activity day 3 
after injection compared with ratio one year after injection (One-way ANOVA p=0.0008, 
Dunnett’s multiple comparisons test, mean diff 0.5174 (95% CI 0.05767 to 0.9771, p=0.027). B, 
C.) Groups of mice were co-injected with 14nmol siRNA targeting SNP site 2307 (n=5), and 
2273 (n=6). There were no differences in luminescence between sides or any difference in the 
left to right ratio compared with one year later. D.) Mice were co-injected with AAV-Luc-Htt 
with control siRNA on the left side and PBS on the right side. There was a decrease in the 
luminescence on the siCon side overall (2-way mixed methods ANOVA, p=0.0369, n=4). 
However, there was no difference in the ratio of left to right side luminescence compared with 
one year. Data is presented as mean ± SEM. *p<0.05
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Figure 3-8: AAV-shRNA targeting luciferase reduces luminescence in the brain. A.) Mice 
were co-injected with AAV-shLuc and AAV-Luc-Htt (2:1 ratio of AAV-shLuc to AAV-Luc-Htt) 
on the left side and PBS and AAV-Luc-Htt on the right. Luminescence was decreased on the 
AAV-shLuc side compared with the contralateral PBS injection (Mixed model ANOVA, 
p=0.0002, n=9). The average difference between the two sides is 23%. B.) Ratio of luminescence 
from the left side (AAV-shLuc) to the right side (PBS). Average ratio is less than 1.0 for most 
time points. C.) Representative mouse two days after injection. Data is presented as mean ± 
SEM. 
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Figure 3-9: AAV-miRNA targeting human huntingtin SNP site 2273 does not decrease 
luminescence in the brain. (A) We tested a 1:1 ratio of AAV-Luc-Htt to AAV-shRNA targeting 
human huntingtin SNP site 2273. The left side was injected the AAV-Luc-Htt virus and AAV-
miR2273G matching the target sequence. On the right side we injected AAV-Luc-Htt and AAV-
sh2273A containing a mismatch at the SNP site. There was no significant difference in the flux 
between the two sides (2-way ANOVA, n.s. n=8). (B) We then increased the dose of AAV-
miR2273 to a 9:1 ratio of AAV-Luc-Htt to AAV-miRNA. One group was co-injected on the left 
side with AAV-Luc-Htt and AAV-miR2273G matching the target and the right side injected 
with AAV-Luc-Htt and PBS (n=5). A second group was co-injected with AAV-Luc-Htt and 
AAV-miR2273A, which has a mismatch to the target sequence (n=5). There was a significant 
1.7 fold increase in the AAV-miR2273A injected side (2-way ANOVA p<0.0496). The last 
group was co-injected on the left side with AAV-miRCon that does not match the target at all 
(n=5). There was a 1.33 fold increase in the AAV-miRCon side (2-way ANOVA p=0.076). The 
right side of all mice was injected with the same amount of AAV-Luc-Htt and PBS. (C) We 
calculated a ratio of left side to right side for each mouse, and comparing the averages for all 
groups. There was no difference between the ratios for each group. Data is presented as mean ± 
SEM. *p<0.05, **p<0.01, ***p<0.001
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Figure 3-10: AAV-miRNA targeting huntingtin SNP 2307 results in allele-specific silencing 
in the brain. (A) We tested a 1:1 ratio of AAV-miRNA targeting the huntingtin 2307 SNP. In a 
group of mice, the left side was injected with AAV-Luc-Htt with AAV-miR2307 that matches 
the target. On the right side, AAV-Luc-Htt was injected with PBS in the same volume. There 
was no significant difference (n=5 for both groups). (B) We tested a 5:1 ratio of AAV-Luc-Htt to 
AAV-miRNA targeting the human SNP site 2307 (AAV-miR2307). In one set of animals, the 
left side was injected with AAV-Luc-Htt and AAV-miR2307 matching the target sequence, and 
the right side was injected with AAV-Luc-Htt and PBS. In another set of animals the left side 
was injected with AAV-Luc-Htt containing the alternate SNP site with the same AAV-miR2307 
resulting in a mismatch of the shRNA and target sequence. There is a significant difference in 
the luminescence between the two sides of the match injected animals, the AAV-miR2307 side is 
42% less than the control side (Mixed methods ANOVA, p=0.0051). There is no significant 
difference between the right and left luminescence of the mismatch injected animals. (C) The 
ratio of matched vector injected side to control side is 0.8834±0.1287 and the ratio between the 
mismatch side compared with control side is 1.0665±0.1503. The difference between the means 
is not statistically significant. (match n =11, mismatch n=8, error bars are SEM). (D) 
Representative image of mice co-injected with AAV-Luc-Htt and matching AAV-miRNA, 
mismatching AAV-miRNA, or PBS. 
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Figure 3-11: Re-injection strategy to assess silencing of luciferase in the brain. (A) We 
tested a re-injection strategy to compare silencing with a baseline measurement of luminescence. 
One set of mice was bilaterally injected with AAV-Luc-Htt and after 14 days a baseline 
luminescence was measured. The same mice were then injected on the left side with AAV-
miR2307. There was no injection on the right side. In a second group of mice, the left side was 
re-injected with PBS and the right side was not injected. (B) The left to right ratio for each 
mouse was calculated. There was no difference in the AAV-miR2307 injected group overall. 
There was a significant difference in the PBS injected group with an increase one day after PBS 
injection compared with baseline measurement (One-way ANOVA, p=0.0157, Dunnett’s 
multiple comparisons, mean diff. -1.308 (95% CI -2.312 to -0.3029, p=0.0107). n=4 per group. 
Data is presented as mean ± SEM. *p<0.05 
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Table 3-1: Sequences, structures and modifications of siRNA and RNA hairpins. Each 
silencing construct is listed by its full descriptive name, sequence with modifications and/ or 
hairpin structure, and IC50 value if applicable. IC50 values were determined as the amount of 
siRNA needed to decrease luminescence by 50% using a dual luciferase cell culture assay. (* 
represents phosphorothioate linkage; p represents phosphate group; m represents 2’O-methyl 
linkage) 
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Sequence of siRNA or miRNA IC50 (nmol)
Cholesterol conjugated 
firefly luciferase siRNA
(cc-siLuc)
3’-chol*mU*mU*AAAGCUUCAUGAGUCGCAC-5’
5’-pUUUCGAAGUACUCAGCGUG*mA*mG-3’
8.27  0.115
Cholesterol conjugated 
renilla luciferase siRNA
(cc-siCon)
3’-chol*mU*mU*GAUCGAUAUUACUUUACGG-5’
5’pAUAGCUAUAAUGAAAUGCC *mU*mU-3’
8.47  0.149
Firefly luciferase siRNA
(siLuc)
3’-mU*mU*AAAGCUUCAUGAGUCGCAC-5’
5’-pUUUCGAAGUACUCAGCGUG*mA*mG-3’
0.1336  0.082
Renilla luciferase siRNA
(siCon)
3’-mU*mU*GAUCGAUAUUACUUUACGG-5’
5’-pAUAGCUAUAAUGAAAUGCC*mU*mU-3’
0.326  0.09
Huntingtin SNP site 2307T
(si2307)
3’-mU*mU*CUGUUACCGUGUCUGAAGG-5’
5’-pUACAAUGGCACAGACUUCC*mU*mU-3’
0.923  0.046
Huntingtin SNP site 2273G
(si2273)
3’-mC*mC*CAACGAGACGUCGUCGUCG-5’
5’-pUUUGCUCUGCAGCAGCAGC*mU*mU-3’
0.0336  0.014
AAV2-U6-miR2307T-CMV-
eGFP
(AAV-miR2307)
. . . GGAU  A  GA   C                       GUAAAGC
CC GU  GCG AGGAAGUCUGUGCCAUUGUAUCA       C
GG CA  CGC UCCUUCAGACACGGUAACAUAGU        A
. . . UGGG  G  UC   U                        GUAGAC
scAAV8-CB.PI.egfp-U6-
shLuc
(AAV-shLuc)
CAA
. . . GAUCCCGCUUACGCUGAGUACUUCGAUU    A
. . . UUUUUUGAAUGCGACUCATGAAGCUA      A
G AC
scAAV9-CB/CMV-
miR2273A-GFP
(AAV-miR2273A)
GC    UUGGCC
. . . UGCUGUUUGCUCUGUA  AGTAGCTTGUU A
. . . AAACGAGACAU  UCAUCGAACAG       C
UCAGU  
scAAV9-CB/CMV-
miR2273G-GFP
(AAV-miR2273G)
GC           UUGGCC
. . . UGCUGUUUGCUCUGCA  AGUAGCUUGUU      A
. . . AAACGAGACGU  UCAUCGAACAG C
UCAGU
scAAV9-CB/CMV-
miREmpty-GFP
(AAV-miRCon)
CU           UUGGCC
. . . UGCUGUUUCUCGCCCU  UCGCUCUUGUU      A
. . . AAAGAGCGGGA  AGCGAGAACAG       C
UCAGU
 
 
Table 3-1: Sequences, structures and modifications of siRNA and RNA hairpins.
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Table 3-2: Summary of AAV constructs and results. Each virus used in this study is listed by 
the name used to identify it in the text. The table summarizes the serotype, genotype structure, 
promoter, site of injection, concentration, and effectiveness for each virus with the corresponding 
figure number. For all experiments, AAV-Luc-Htt was co-injected with one of the silencing 
constructs. The concentration of the viruses refers to the ratio of silencing vector to AAV-Luc-
Htt. For all experiments, the concentration of AAV-Luc-Htt is 5e9GC. N/A, not applicable; 
CMV, cytomegalovirus (RNA polymerase II); ssDNA, single-strand DNA; scDNA, self-
complementary DNA; CBA, chicken beta actin promoter with cytomegalovirus enhancer (RNA 
polymerase II); U6 an RNA polymerase III promoter for transcribing short hairpin RNA. 
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Construct Serotype 
Genome 
structure 
Promoter 
Injection 
Site 
Ratio 
Effective at 
silencing 
luciferase in 
vivo? 
AAV-Luc-Htt AAV 9 ssDNA CMV 
Striatum 
and cortex 
N/A N/A 
AAV-shLuc AAV 8 ssDNA U6 Striatum 2:1 Yes (Fig. 3-8) 
AAV-miR2307T AAV 1 ssDNA U6 Striatum 
1:1 No (Fig. 3-10A) 
5:1 
Yes  
(Fig. 3-10 B-D) 
AAV-miR2237A 
AAV-miR2237G 
AAV 9 scDNA CBA Cortex 
1:1 No (Fig. 3-9A) 
9:1 
Inconclusive  
(Fig. 3-9 B-C) 
 
Table 3-2: Summary of AAV constructs and results.
166 
 
 
CHAPTER IV 
 
 
THE USE OF NOVEL LUCIFERASE SUBSTRATES TO DETECT LUCIFERASE 
ACTIVITY IN THE BRAIN 
 
 
 
This chapter describes work I performed using novel luminescent substrates to detect low 
levels of luciferase activity and silencing of luciferase in vivo. This work was conducted under 
the guidance of Neil Aronin. I planned and executed the majority of the experiment presented in 
this chapter. Wanzhao Liu performed the quantitative real-time PCR. The AAV construct was 
provided by Guangping Gao. Dr. Stephen Miller designed and synthesized the luminescent 
substrates. Results from this chapter are included in the published work:  
Melanie S. Evans, Joanna P. Chaurette, Spencer T. Adams Jr, Gadarla R. Reddy, Miranda A. 
Paley, Neil Aronin, Jennifer A. Prescher, and Stephen C. Miller, A synthetic luciferin 
improves bioluminescence imaging in live mice. Nature Methods 11: 393-395, 2014. 
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A. Abstract 
Bioluminescent imaging (BLI) has emerged as a powerful tool for in vivo visualization of 
biological processes. In mice, BLI has been used to study infection spread, tumor growth and 
metastasis, and gene silencing. The benefits of using BLI are that it is sensitive, low cost, high 
throughput, and can be used for longitudinal analysis in individual animals. There are 
limitations: absorbance by hemoglobin and melanin and the depth of tissue affect the detection of 
luminescence. Ways to improve detection of luciferase reporter activity are to increase luciferase 
activity or increase light output from the substrate. Our objective in this study is to identify 
substrates resulting in improved light output from the brain.  
To screen luciferase substrates, we used mice expressing AAV-delivered firefly 
luciferase in the brain. We tested 34 substrate solutions and identified 19 that exhibited increased 
light output compared with 100mM D-luciferin. From this screen we identified the luciferase 
substrate, CycLuc1, as the highest light-emitting substrate, finding CycLuc1 to be 120 times 
more potent than D-luciferin. We next tested CycLuc1 and another potent substrate, iPr-amide, 
in mice expressing luciferase in dopaminergic neurons (DAT-LUC mice). We were able to detect 
luminescence from CycLuc1 and iPr-amide but not from D-Luciferin. We also tested iPr-amide, 
in AAV-luciferase injected mice with or without fatty acid amide hydrolase (FAAH) inhibitor. 
We found that activation of iPr-amide is dependent upon the activity of FAAH in the brain. 
With potent luciferase substrates, in vivo bioluminescence can be detected at lower levels 
with less luminescent substrate. Improved sensitivity of BLI advances the application to the 
study of fewer cells, deeper structures, and models in which there is a lower level of luciferase 
expression.  
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B. Introduction 
 
Reporter molecules are valuable tools for the study of biological processes in living cells 
and organisms. Following the activity of a reporter molecule in vivo requires the expression of a 
luminescent molecule that can be detected by a cooled charge-coupled device (CCD) camera. 
Detection of fluorescence requires an excitation light reaching the molecule, which upon 
activation emits light at a shifted wavelength detected by a CCD camera [294]. Fluorescent 
reporter molecules can be visualized in living tissue as well as fixed tissue, however 
autofluorescence impairs the sensitivity of fluorescent imaging [294]. Luminescent reporter 
molecules are enzymes that react with a chemical substrate to emit light [256]. One benefit of 
luminescence is that there is little background signal from tissue, so low levels of luminescence 
can be detected [294]. Drawbacks to both fluorescent and luminescent are that signal detection is 
limited by the depth of the tissue [294]. For in vivo studies using mice and rats, bioluminescent 
imaging is widely used due to its high sensitivity, efficiency, and relatively low cost [256].  
The luciferase gene from the firefly, Photinus pyralis, is commonly used in 
bioluminescence imaging. Firefly luciferase reacts with its substrate, D-luciferin, in the presence 
of adenosine triphosphate (ATP) and oxygen to create an excited-state oxyluciferin molecule 
[295]. The coding region of firefly luciferase is 1.633 kb and the gene has been cloned into 
lentiviral, adenoviral and adeno-associated viral delivery systems as well as delivered in a 
plasmid form by high pressure tail vein injection [260, 265, 296-298]. Many transgenic mouse 
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lines expressing firefly luciferase controlled by a variety of promoters also exist. Emission 
wavelength for firefly luciferase is 560 nm, in the yellow-green spectrum of visible light [273].  
D-luciferin analogs have been created by modifying the chemical structure, resulting in 
brighter light emission, red-shifted light emission, and extended decay kinetics [299-301]. So-
called caged analogs of luciferin have also been created. Caged luciferin analogs are inactive 
until enzymatic cleavage that occurs under specific biological conditions such as caspase-3/7 
activation, caspase-8 activation or elevated levels of H2O2 [302-304]. Caged luciferin molecules 
allow luciferin to act as an in vivo biosensor for identification and imaging of a specific process. 
Luciferase mutants have also been characterized that result in prolonged and red-shifted light 
emission [305, 306]. Each improvement in the luciferase-substrate reaction provides a greater 
variety of tools for use in bioluminescent imaging. 
The light emission properties from luciferase are dependent on the structure of the 
substrate on which it acts [301]. By modifying the substrate one can engineer reactions with 
longer duration, greater intensity, and red-shifted emission [301]. Luciferase substrates with 
enhanced properties could be used to study luciferase as a reporter gene in deeper tissues and 
fewer cells, expanding the utility of BLI. One objective of this study was to screen a panel of 
luciferase substrates identifying those with the highest light emission in the brain. To test the 
utility of these substrates, they were examined in a low-expressing transgenic luciferase mouse, 
which expresses luciferase in dopaminergic expressing cells in the brain (DAT-LUC mice). 
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C. Results 
 
1. A screen of modified luciferase substrates identifies molecules with improved light 
output compared with D-luciferin. 
 27 luciferase substrates were tested in this study, 14 synthetic cyclic alkaminoluciferins 
and 13 luciferin derivatives (chemical names and abbreviations listed in Table 4-1). We 
performed a screen to compare luminescence among the substrates using mice previously 
injected with AAV-Luciferase (AAV-Luc) in the striatum (Fig. 4-1, Table 4-2). Each mouse was 
injected with a novel substrate and imaged after 10 minutes, 1 hour, and 2 hours. After 24 hours, 
a point when previous signal has completely diminished, the same mice were injected with 
100mM of D-luciferin and imaged after 10 minutes. For each mouse, the light output relative to 
100mM of D-luciferin at the 10 minutes time point was calculated. 18 solutions resulted in 
greater light output compared with D-luciferin. One substrate was imaged twice, 0.5mM iPr-
Amide, which is the same as 0.5mM iPrNH-Amide, both in 1% DMSO. Both substrates 
demonstrate increased luminescence compared with D-luciferin of 12.7-fold and 6.45-fold, 
respectively. The difference between two measurements of the same substrate seems relatively 
substantial, however, we have previously noted a large degree of variation within this in vivo 
imaging system. CycLuc1 was identified to have the greatest light output relative to D-luciferin.  
To further investigate the difference between CycLuc1 with D-luciferin, we used groups 
of AAV-Luc injected FVB mice. We measured the luminescence of 5mM CycLuc1 and 100mM 
D-luciferin in the same mouse. There was a 6-fold increase in light output from CycLuc1 
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compared with D-luciferin (Fig. 4-2 B). Equal concentrations of the substrates could not be 
tested due to CycLuc1 insolubility above 5mM in concentration. This experiment demonstrates 
that the luciferase substrate CycLuc1 emits more light than D-luciferin and could increase the 
sensitivity in BLI applications. The 6-fold difference from D-luciferin is substantially less than 
the 15-fold difference that was initially detected in the screen, possibly reflecting variability of 
this system. 
 
2. Novel luciferase substrates enable the detection of luminescence in transgenic mice 
expressing luciferase in dopaminergic neurons. 
We wanted to test CycLuc1 and another strong light-emitting substrate, iPr-amide, in a 
transgenic model of luciferase expression in the brain. We bred transgenic mice to express 
luciferase in dopaminergic neurons by crossing mice transgenic for Cre-recombinase inserted 
into the dopamine transporter locus behind an internal ribosome entry site (IRES) (DatIREScre/wt) 
with mice transgenic a conditional luciferase gene whose activity is dependent upon excision by 
Cre-recombinase (Rosa26-Fluc) (Fig. 4-3 A) [307, 308]. DatIREScre/wt mice had black fur and 
Rosa26-Fluc mice had white fur, therefore the original offspring all displayed black fur (all mice 
obtained from Jackson Laboratories, Bar Harbor, ME; see methods section for full description). 
Since luminescence does not cross through black fur, we crossed DatIREScre offspring with white 
Rosa26-Fluc to obtain a line of DatIREScre+ Fluc+ progeny with white fur. The resulting offspring 
express luciferase in all dopaminergic cells of the substantia nigra (SN), ventral tegmental area 
(VTA), and retrorubal field, and we will refer to them as DAT-LUC mice [307, 308]. 
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We were unable to detect any luminescence in DAT-LUC mice with the standard dose of 
D-luciferin (100mM). The two top light-emitting substrates, CycLuc1 and iPr-amide, in DAT-
LUC mice produced detectable luminescence (Fig. 4-3 B). To increase luciferase expression, we 
bred DAT-LUC mice to homozygosity for the conditional luciferase gene, Rosa26-Fluc+/+. In a 
preliminary test of two mice, the Rosa26-Fluc+/+ mouse emitted twice as much light as the 
Rosa26-Fluc+/- mouse (Fig. 4-3 C). 
 
3.) FAAH-dependent activation of iPr-amide is required for reaction with luciferase.  
Fatty acid amide hydrolase (FAAH) is an enzyme expressed in many tissues that 
functions to hydrolyze the endocannabinoid, N-arachidonoyl ethanolamide, and other amides 
[309]. The luciferase substrate iPr-amide is inactive until hydrolyzed by an amidase such as 
FAAH. To test the sensitivity of iPr-amide to FAAH inhibition in vivo we injected 10mg/kg of 
the selective FAAH inhibitor, PF-3845, in AAV-Luciferase injected mice as previously 
described [310]. Another set of mice were injected with vehicle and for each group, one mouse 
was not injected with the inhibitor to demonstrate that the iPr-amide was functional. 30 minutes 
after PF-3845 administration, iPr-amide was injected and the mice were imaged. Results show 
that FAAH inhibitor blocked luminescence of iPr-amide (Fig. 4-4 A, B) (unpaired t-test, 
p=0.0028, n=3 per group). This demonstrates that FAAH inhibition affects the activation of iPr-
amide into an active substrate of luciferase.  
 
 
173 
 
D. Discussion 
In this study we identify CycLuc1 in a screen of 34 test solutions as a luciferase substrate 
that resulted in greater light emission than D-luciferin in the brain. We tested the two highest 
light emitters identified in the screen, CycLuc1 and iPr-amide, in DAT-LUC mice. With both 
CycLuc1 and iPr-amide at 5mM we could detect luminescence in DAT-LUC mice but not with 
100mM D-luciferin. These findings demonstrate that luciferase substrates with improved light 
emission properties result in greater detection of luciferase activity, meaning that lower levels of 
luciferase expression can be detected with improved substrates. Improved substrates can be used 
to increase the sensitivity of bioluminescent imaging.  
Lastly, we tested whether iPr-amide is being hydrolyzed by FAAH using a selective 
inhibitor of FAAH. In mice previously injected into the striatum with AAV-Luc, we found that 
the specific FAAH inhibitor PF-3845 blocked activation of iPr-amide into an active luciferase 
substrate [310]. This suggests that FAAH is the hydrolase that converts iPr-amide into its active 
form in the brain. This is significant for several reasons. Using iPr-amide as a luciferase 
substrate, it might be possible to study the silencing of FAAH. This would be more relevant to 
the study of gene silencing in the brain than silencing luciferase because it is not an 
overexpressed transgene. The second use for iPr-amide and luciferase is to study the inhibition of 
FAAH, a hydrolase that is responsible for cleaving the endogenous cannabinoid, N-arachidonoyl 
ethanolamide, as a strategy for the treatment of chronic pain [311]. One additional control that 
would be helpful in strengthening the conclusion is to test the FAAH inhibitor with D-luciferin 
or another luciferase substrate that does not require FAAH cleavage for activation. This would 
demonstrate that the inhibitor is not interfering with a luminescent or transport process unrelated 
to blocking the hydrolase activity of FAAH. 
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In conclusion, we used mice injected with AAV-Luc in the striatum to screen 34 
luciferase substrate solutions and identified CycLuc1 as a substrate with improved light-emitting 
properties compared with D-luciferin, confirming other studies done in vitro and in cell culture 
[301]. Improved light-emitting substrates can be applied to studies involving BLI to improve 
their sensitivity. BLI has been used in a variety of studies measuring and inhibiting growth of 
tumor cells, studying spread and replication of infectious diseases, and following gene silencing 
[257, 260, 263, 264, 312, 313]. BLI is a widespread tool for following biological processes in 
vivo and a promising tool for drug discovery applications [314]. With improved substrate for 
detection of low levels of luciferase, BLI applications can be expanded to study structures in 
deeper tissues or when luciferase is expressed in fewer numbers of cells. 
 
E. Materials and Methods 
1. Mouse lines and genotyping  
14 FVB mice (female, 3-6 months old, FVB/NJ from Jackson Laboratory, Bar Harbor, 
ME) were injected with 5e9GC AAV-Luc-Htt (described in Chapter III). Experiments in AAV-
injected mice were performed one year after injection. Each mouse was used 1 or 2 times to test 
luciferase substrates. 
Mice homozygous for the Rosa26-Fluc transgene (male and female, 3-6 months old, 
129S-Gt(ROSA)26Sortm3(CAG-luc)Tyj/J, stock number 009043 from Jackson Laboratory, Bar Harbor, 
ME) were mated with mice heterozygous for the DatIREScre allele (male and female, 3-6 months 
old, B6.SJL-Slc6a3tm1.1(cre)Bkmn/J, stock number 006660 from Jackson Laboratory, Bar Harbor, 
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ME) [307, 308]. Genotyping for Rosa26-Fluc and DatIREScre mice was performed according to 
protocols found on the Jackson Laboratory website. Primers for presence of Cre-recombinase: 
oIMR6625 5'-TGGCTGTTGGTGTAAAGTGG-3' “Common”, oIMR6626 5'-
GGACAGGGACATGGTTGACT-3' “Wild type Reverse”, oIMR8292 5'-
CCAAAAGACGGCAATATGGT-3' “Mutant Reverse”; mutant band =152 bp, 
heterozygote=152 bp and 264 bp, and wild type band= 264 bp. Primers for GtRosa-Luciferase: 
oIMR8038 5'-TAAGCC TGCCCAGAAGACTC-3', oIMR8545 5'-
AAAGTCGCTCTGAGTTGTTAT-3', oIMR9493 5'-AAATCAGAGAGATCCTCATAAAGG-
3';  mutant band 190 bp, heterozygote bands 235 bp an 190 bp, wild type band 235 bp. 
 
2. Stereotactic injection  
Mice were anesthetized with 250 mg/kg tribromoethanol (2.5 g 2, 2, 2, tribromoethanol 
dissolved in 5mL amylene hydrate into 200mL PBS). Anesthetized mice were placed on a heated 
pad in a stereotactic frame. Superglue (Loctite) was applied to the surface of the fur between the 
ears, avoiding eyes and exposed skin. After 10-20 seconds, the glue is gently pulled off to 
remove fur. The exposed skin is cleaned with betadine and an incision is made posterior to 
anterior. The skin is pulled aside and the needle is placed over the bregma. Measurements for 
drilling the hole and placing the needle are: anterior 1mm, lateral 3mm and ventral 2mm from 
the bregma. Once the needle is lowered, it rests there for 2 minutes before infusion begins. After 
infusion the mouse rests for 2 minutes before the needle is withdrawn. The incision is closed 
with clear, undyed suture (monocryl undyed monofilament) and the animals are allowed to 
recover on a heated pad at 37C. 
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3. Imaging mice 
Mice were anesthetized with 5% isoflurane and placed into the Xenogen (now Caliper) in 
vivo imaging system (IVIS 100). In mice with black fur, the fur was removed with glue as 
previously described in the stereotactic injection methods.10 minutes prior to imaging, mice are 
injected with 100mM D-luciferin into the ip space (from a 30mg/mL stock solution dissolved in 
sterile water). Luminescence measurements were taken by 1 minute exposure. In AAV-injected 
mice, a region of interest (ROI) is drawn over each injection site to quantify luminescence from 
the injected area. In transgenic mice, ROI were generated over the entire head for the albino mice 
or over the exposed skin in the black mice. Data were collected as flux (photons / second) or 
radiance (p/s/cm2/sr).  
 
4. FAAH inhibition 
Eight mice were pre-treated with either 10mg/kg FAAH inhibitor by ip injection (PF-
3845, n=3), vehicle by ip injection (n=3), or not injected with inhibitor (no inj. mice) as a 
negative control. 30 minutes later, all mice received 0.5mM iPr-Amide by ip injection. Mice 
were imaged 10 minutes after iPr-Amide injection. FAAH inhibition was achieved using PF-
3845 dissolved in 18:1:1 v/v/v saline:emulphor:ethanol [310]. 
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Figure 4-2: 5mM CycLuc1 results in 6-fold greater luminescence than 100mM D-luciferin. 
A.) Structures of D-luciferin and CycLuc 1. B.) Mice injected with AAV-Luc-Htt were imaged 
using 100mM D-luciferin. The same mice were imaged the next day with 5mM CycLuc1. There 
was a 6-fold increase in luminescence due to the CycLuc1 substrate (paired t-test p=0.0006, 
n=6). Data are reported as mean luminescence ± SD.
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Figure 4-3: Luminescence can be detected with a novel luminescent luciferase substrate but 
not with D-luciferin. A.) We crossed transgenic mice with the gene for Cre recombinase under 
control of the dopamine transporter promoter (DAT) with mice expressing the gene for firefly 
luciferase under control of the GtRosa promoter. Offspring are referred to as DAT-LUC mice 
and express luciferase in dopaminergic neurons. B.) Luminescence from DAT-LUC mice (black 
mice with fur removed from the head) is not detectable using D-luciferin as a substrate, but is 
detectable using two new luciferase substrates. C.) Two DAT-LUC mice were compared for 
luciferase activity. One mouse was homozygous for luciferase, the other hemizygous for 
luciferase.
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Figure 4-4: FAAH inhibition prevents activation of iPr-Amide resulting in decreased 
luminescence in the brain. Eight mice were pre-treated with either injection of FAAH inhibitor, 
vehicle, or no injection (no inj.) 30 minutes prior to ip administration of 0.5mM iPr-Amide. Mice 
were imaged 10 minutes after iPr-Amide injection. There was significantly less luminescence 
with the FAAH inhibitor (unpaired t-test, p=0.0028, n=3 per group). ** p<0.01.
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Table 4-1: Luciferase substrate names and abbreviations. 27 luciferase substrates were used 
in this study. 14 substrates are synthetic cyclic alkylaminolucferins, and 13 substrates are 
derivatives of luciferin. The chemical names have been abbreviated for use in figures and text, 
and are listed in the right column. 
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Table 4-1: Luciferase substrate names and abbreviations. 
Substrate name Abbreviation 
CycLuc1 CycLuc1 
CycLuc1 amide CycLuc1-Amide 
CycLuc2 CycLuc2 
CycLuc2 amide CycLuc2-Amide 
CycLuc2 potassium salt CycLuc2 K-Salt 
D-Luciferin amide D-Luciferin-Amide 
CycLuc3 CycLuc3 
CycLuc4 CycLuc4 
CycLuc6 CycLuc6 
CycLuc7 CycLuc7 
CycLuc9 CycLuc9 
CycLuc9 potassium salt CycLuc9 K-Salt 
CycLuc10 CycLuc10 
CycLuc11 CycLuc11 
CycLuc12 CycLuc12 
6'-methylamino luciferin or 6'-MeNHLH2 Monomethyl 
6'-dimethylamino luciferin or 6'-Me2NLH2 Dimethyl 
6'-isopropylamino luciferin amide iPr-Amide, iPrNH-Amide 
6'-methylamino luciferin amide MeNH-Amide 
6'-ethylamino luciferin amide EtNH-Amide 
6'-isobutylamino luciferin amide iBuNH-Amide 
6'-propanolamino luciferin Propanol 
6'-propanolamino luciferin amide Propanol-Amide 
6'-dimethylamino luciferin methyl ester Me2N-methyl ester 
6'-ethylamino luciferin methyl amide EtNH-Monomethylamide 
6'-aminoluciferin or 6'-NH2LH2 Amino 
6'-isobutylmethylamino luciferin or 6'-
iBuNMeLH2 
iBuNMe 
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Table 4-2: Luciferase substrates tested in mice injected with AAV-Luciferase in the brain. 
Luciferase substrates were ip-injected in mice expressing AAV-delivered Luciferase in the 
striatum. Mice were imaged 10 minutes, 1 hour, and two hours after injection. On the following 
day, mice were imaged 10 minutes after ip administration of 100mM D-luciferin. All injections 
were 100µL. The concentration of luciferase substrate is noted before the name of the substrate, 
and following the name of the substrate is the concentration of dimethyl sulfoxide (DMSO) if 
present in the solution. The final column is the ratio between the average radiance-background 
radiance of substrate injection and D-luciferin for the same mouse. Each value represents one 
mouse tested.
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Table 4-2: Luciferase substrates tested in mice injected with AAV-Luciferase in the brain. 
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CHAPTER V 
 
 
SUMMARY AND CONCLUSIONS 
 
 
There is no cure for Huntington’s disease, and designing a single therapy is a challenge 
due to the multiple toxic effects mutant huntingtin has on neuronal function [2]. Several 
approaches exist for designing treatments for Huntington’s disease (HD). One approach attempts 
to correct the toxic effects of mutant huntingtin, including strategies to increase global 
transcription, enhance general neuroprotection, and inhibit cleavage of mutant huntingtin into 
toxic fragments. These strategies often address only a single downstream effect of mutant 
huntingtin, and a comprehensive treatment based on this approach would require multiple 
therapies to counteract the toxicities due to mutant huntingtin. A second approach is to decrease 
the amount of mutant huntingtin either through suppression of transcription or translation or by 
augmenting its degradation. Through this approach, a single therapeutic agent could prevent all 
downstream toxicities. This dissertation examines two strategies for reducing mutant huntingtin 
in the cell: by increasing the degradation of huntingtin protein and silencing mutant huntingtin 
mRNA.  
In Chapter II, I used a transgenic mouse model to explore the effect of a decrease in 
puromycin sensitive aminopeptidase (PSA) in the progression of HD. To test the effect of 
decreased PSA on HD-related behavior and pathologies, we bred mice that were heterozygous 
for the PSA allele and homozygous for the knock-in 140Q huntingtin gene. PSA heterozygosity 
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in the HD background resulted in mice with a greater number of inclusion bodies and worsened 
performance on the raised beam test, both of which are markers for the accumulation of mutant 
protein and the progression of HD. The importance of these results within the field of HD 
research is in the evaluation of PSA’s effect within the brain in a mouse model of Huntington’s 
disease, advancing the work done in studies using cultured cells or transfected muscle tissue. 
These findings are consistent with what has been seen in other experimental systems and support 
the hypothesis that normal PSA expression contributes to the defense of neurons against mutant 
huntingtin.  
The mechanism of PSA degradation of huntingtin remains unknown, with reports 
differing on whether PSA functions directly to degrade huntingtin or indirectly by increase 
autophagic clearance of aggregated proteins. Alternatively, as studies demonstrate the benefits of 
PSA-overexpression in other neurodegenerative diseases, it might act by a general 
neuroprotective mechanism. The ubiquitin-proteasome system represents the primary pathway 
for degradation of damaged or misfolded proteins where they are digested by endopeptidases 
into peptides from 3 to 22 residues in length [115, 315]. Peptides exit the proteasome for further 
degradation by exopeptidases in the cytosol [127]. PSA is one such exopeptidase, able to cleave 
all amino acid sequences while also possessing the unique ability to cleave polyQ [122]. The 
mechanism of PSA protection in HD may be in digesting polyglutamine-containing peptides 
released by the proteasome, especially as mutant huntingtin can lead to ejection of long polyQ 
peptides, increasing the importance of PSA in clearing the aggregate-prone polyQ peptides  
[125][121]. 
The autophagy-lysosomal pathway degrades misfolded and aggregated mutant 
huntingtin, and differing opinions exist regarding the effect of PSA on autophagy. In cell culture 
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experiments grossly over-expressing PSA, markers of autophagy were increased [123]. 
However, in transgenic mice that over-express PSA three-fold in the brain, there was no detected 
increase in markers for autophagosome formation [200]. It is difficult to compare these findings 
as they are performed under vastly different conditions, however, it is possible that the observed 
increase in autophagy in cells may be a response to an acute increase in PSA expression or a 
response to massive overexpression of PSA (10-100-fold). As PSA is a proteolytic enzyme, 
increasing expression could result in a toxic insult to the cells, influencing autophagy activation, 
which would incidentally also increase mutant huntingtin clearance. We observed gliosis and 
neuron loss in mice expressing the human form of PSA from a viral vector, possibly indicating 
that the peptidase activity is damaging to neurons at high and unregulated levels. In transgenic 
animals overexpressing PSA, cells have had the time to adapt and possibly compensate for 
increased PSA expression, these animals show no toxicity and no increase in autophagy. We 
looked for a decrease in autophagy in the PSA heterozygous HD mice, however were unable to 
detect LC3-II under the conditions tested. LC3-II is present at a small amount in wild type 
animals and slightly increased in HD animals, which we were not able to detect. The debate 
remains open as to mechanism for PSA in HD and other neurodegenerative diseases. 
If PSA is protective against mutant huntingtin, then an increase in PSA activity would 
ameliorate the disease, representing a therapeutic strategy for the treatment of Huntington’s 
disease. There are several ways to increase PSA activity including gene therapy to increase gene 
expression and small drug modifiers to enhance its endogenous activity. In this study, we created 
an AAV expressing the human PSA gene under a CMV promoter. As mentioned previously, it 
resulted in gliosis and neuronal cell loss, raising many questions about the effect of PSA 
overexpression in neurons. The majority of published studies overexpressing PSA have shown it 
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to be tolerated in different cell-types and organisms, however there was mention of toxicity when 
expressed in Drosophila photoreceptors [123, 200]. Our results draw into question the benefit 
versus risks related to increased PSA activity in the brain, especially if neurons are particularly 
sensitive to increased expression of PSA. One important question to be answered in future 
experiments is whether there is a threshold for neurons above which PSA expression becomes 
toxic.  
Future study is needed in the design of AAV-PSA, to test weaker promoters for a low 
level of constitutive expression, or conditional promoters, such as tetracycline-regulated 
promoter systems, to control the timing of expression. Aside from viral expression, another 
approach to study the effect of increased PSA expression on HD in vivo is to cross the transgenic 
PSA overexpressing mouse with an HD mouse to see if ameliorates the disease [200].  These are 
methods to test in an experimental manner the interaction of PSA and mutant huntingtin. These 
approaches do not translate easily into therapeutic application, as gene therapy for neurologic 
diseases is still being tested in large animal studies for viral spread and toxicity.  
Another approach is to identify small molecule enhancers of PSA. This would require 
performing a small molecular screen to identify modifiers of PSA activity in a cell culture or in 
vitro assay. Candidate compounds would be further characterized in cell culture experiments and 
then ultimately tested HD animal models to look for modification of disease markers such as 
performance on the raised beam test, rotarod test, or inclusion body formation. A small molecule 
drug would be therapeutically applicable and less invasive than a gene therapy approach. One 
drawback to this approach is that a small molecule modifier could be nonspecific, potentially 
altering other enzymes in the cell or other tissues resulting in adverse effects. Off-target effects 
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could result in toxicity or create confounding variables in interpreting results, especially in 
addressing the mechanism of action.  
Further research must be done to understand the role of PSA in the brain and other 
tissues. PSA knockout animals exhibit interesting phenotype as they are smaller than their 
littermates and behave differently than heterozygous and homozygous littermates during 
handling and on behavioral tests. These knockout animals are difficult to study because they do 
not survive at the same rate as their littermates, often dying shortly after birth. It would be 
fascinating to see the effect of a conditional (brain-specific) knockout of PSA to evaluate the 
differences in behavior in adult mice.  
There were also lessons in experimental design gleaned from performing extensive 
behavioral tests. Initially, without knowing how severely the PSA deficiency would affect the 
HD mice, they were tested on the beam at a young age and followed every 2-4 weeks. This 
presented challenges, as with repeated testing, the mice behaved differently, losing their fear of 
the open beam, which is thought to be a motivating factor to cross to the platform. Mice would 
sit in the middle of the raised beam for 15-20 seconds or until prodded gently. From these 
observations, we chose not to use repeated testing in the later experiments as it interferes with 
the ability to assess locomotion using the raised beam test. This potentially interfered with the 
ability to detect differences in the genotypes that were tested repeatedly because when mice walk 
slowly, inching their way down the beam or refuse to walk altogether, then their locomotor 
ability is not being accurately evaluated. We found that the raised beam test is most effective 
when animals are trained once and then tested once before becoming accustomed to the handler 
and the apparatus. 
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In addition to investigating ways to reduce mutant huntingtin protein, I examined RNAi 
as a way to degrade mutant huntingtin mRNA. In chapter III, I described a method for in vivo 
measurement of gene silencing in the brain. Currently, there is no way to screen RNAi constructs 
in the brain. The general procedure for identifying optimal silencing constructs is to test siRNA 
and miRNA in cell culture after which the best candidates are chosen for in vivo testing. One 
limitation is that a certain sequence, promoter, or structure may be highly efficient in an 
immortalized cell line with transfection reagent, but is less effective in neurons of the brain. The 
goal was to create a model by which gene silencing could be followed in the brain of living mice 
and to apply the system to test RNAi against therapeutically relevant mutant huntingtin 
sequences. This model is based on bioluminescent imaging (BLI) using firefly luciferase as a 
reporter molecule. I created two adeno-associated viruses (AAV) expressing firefly luciferase 
with six huntingtin RNAi target sites in the 3'-UTR. Furthermore, each huntingtin target site 
contained a SNP site that can be used to specifically target the mutant huntingtin allele. With a 
validated system, these two vectors can be used to describe the time course of siRNA, to 
compare structures, sequences, and delivery strategies, and to study the effectiveness of allele-
specific silencing in the brain.  
Several challenges arose in the validation of the silencing system. There was significant 
variation in luminescence between groups of AAV-Luc-Htt injected mice (intermouse variation) 
as well as between measurements of the same mouse on different days (intramouse variation). 
We hypothesized that the intramouse variation was due to inconsistent absorption of luciferin 
from the intraperitoneal space. A comparison of intraperitoneal (ip) and intravenous (iv) 
injections found that there was less variation in the intravenous injected group, supporting our 
hypothesis [316]. They also note poor distribution to the brain, compared to other organs, after 
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both ip and iv injections [316]. To minimize this variation, we injected mice bilaterally and 
calculated luminescence as a ratio of left side flux divided by right side flux. We compared the 
variation between just the flux values on one side in that same group. The amount of silencing to 
achieve silencing when calculating results as a ratio was 35% compared to 40% needed when 
just looking at the flux. Although both methods resulted in highly variable measurements, the 
ratio system provided a slightly more sensitive assay to detect silencing. There was significant 
intermouse variation as well. This has been observed in other experiments within our lab, and 
described in published studies [270]. Intermouse variation could be due to differences in 
measurement and placement of the needle during injection, which can affect slightly different 
anatomical structures within the brain, affecting diffusion and transport of the virus. Meticulous 
measurement and surgical technique was employed to minimize the variation of luciferase 
activity between mice. The large variability, even among mice stably expressing luciferase, 
presents a major limitation of this method and the ability to detect silencing in this study. 
To test this BLI silencing system, I targeted silencing of luciferase using three different 
constructs: cc-siRNA, unconjugated siRNA, and AAV-shRNA. Decreased luminescence was 
detected with all three RNAi agents. These proof-of-principle experiments show that RNA 
silencing can be detected in the brain and pave the way for a comparison of huntingtin specific 
silencing constructs. These luciferase-targeting RNAi molecules demonstrated strong silencing 
properties in vitro, with >80-90% silencing at maximum concentrations in vitro. However, 
despite the strength in cell culture, silencing in vivo was not robust. This draws into question the 
sensitivity of the assay, especially when evaluating RNAi compounds with weak activity under 
optimal in vitro conditions.  
196 
 
Although cc-siRNA targeting luciferase decreased luminescence compared with control 
cc-siRNA, an unexpected finding was that both groups of cc-siRNA increased luminescence 
compared with PBS, and co-transfection in cell culture also increased luminescence independent 
of serotype, cc-siRNA sequence, and cell type. Two possible mechanisms exist by which this is 
possible: cc-siRNA could increase the activity of luciferase or improve the transduction of AAV-
Luc-Htt in cells and in the brain. The finding that cholesterol conjugated siRNA interacts with 
AAV raises the possibility that there could be a synergistic effect of co-administering AAV and 
cc-siRNA. One initial method to test this hypothesis is to label AAV capsid with Cy5 fluorescent 
dye and mixing it with control (non-silencing) cc-siRNA or non-cholesterol-conjugated siRNA 
or control solution. The degree of spread and transduction efficiency can be compared between 
the two groups to evaluate the effect of cc-siRNA on viral uptake. Subsequent to the defense of 
this dissertation, the experiments with in vivo co-injection of AAV-Luciferase and cc-siRNA and 
the cell culture experiments were repeated by a different member of the lab who could not 
replicate the findings presented in this dissertation. One possibility is that there was something in 
the purification of the cc-siRNA from the manufacturer that was subsequently not used in the 
purification several years later that may have influenced luminescence or viral transduction or 
expression. 
Since siRNA and AAV-shRNA against luciferase demonstrated silencing using this 
assay, we tested silencing of two huntingtin-specific sequences, containing either SNP site 2273 
or 2307. High dose (14nmol) single injections of siRNA targeting these sites did not show 
silencing in vivo with our assay, and neither did AAV-miR2273 co-injected with AAV-Luc-Htt 
at a high dose.  AAV-miR2307 showed some silencing effects when analyzed by luminescence, 
(but not by the ratio system) compared with the mismatching target. One limitation of this 
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experiment was that these RNAi sequences were not very effective in vitro, reducing their 
potential effectiveness in vivo. The siRNA and AAV-miRNA showed weak activity in cell 
culture studies, only reaching about 50% silencing at maximal siRNA concentration, whereas the 
siRNA against luciferase approached 100% silencing at the same concentration. It is likely that 
the in vivo system is not sensitive enough to detect silencing by weak siRNA as it is barely able 
to detect silencing from siRNA that demonstrate robust silencing cell culture. 
Is this system feasible? No, under these conditions, the in vivo AAV-Luc-Htt system was 
not able to adequately detect silencing of a range of RNAi constructs. The goal was for this 
method to be sensitive enough to compare RNAi compounds and describe their time course of 
silencing. From my experiments, it appears the system can detect silencing only if it exceeds the 
variation within the system. While the AAV-Luc-Htt BLI system may have shown positive 
results with strong silencing RNA constructs, the results do not demonstrate the sensitivity 
necessary for broad application to a range of RNAi targets as intended. There are several 
experimental changes that could improve the success of the assay. To overcome the variation in 
the system, one could increase the potency of the RNAi by increasing dose, frequency of 
administration, and using silencing sequences demonstrating high efficacy in vitro. Published 
studies using naked siRNA to silence in the brain rely on infusion or pump-delivery system 
rather than single injection [279, 281, 282]. Using a pump-delivery system could increase the 
dose and the distribution of siRNA resulting in a higher likelihood of detecting silencing over 
time. AAV-shLuc at a 2:1 ratio with AAV-Luc-Htt was shown to decrease luminescence, and 
this dose was increased in subsequent experiments with other silencing vectors. A dose curve of 
AAV-shLuc would have been useful to identify the range of effective doses. Other methods of 
increasing potency would be to target multiple binding sites in the 3'-UTR, either repeating the 
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same sequence or targeting two or more different sequences, and by creating silencing vectors 
that express multiple hairpin RNAs. To improve siRNA potency, there are numerous 
conjugations or nanoparticles that may improve diffusion or transport across cell membranes in 
order to improve delivery of siRNA [274, 280, 317]. 
It is imperative that future studies with in vivo BLI use standardized viral constructs that 
employ identical serotypes, promoters, and structures, which influence the distribution, 
transduction efficiency, and potency. The differences in the viruses used in this study are 
described in Table 3-2. The luciferase virus was the same in all experiments, however the 
silencing viruses differed in structure (self-complementary or single-stranded), serotype (1, 8, 9), 
and promoter (CMV, CBA, U6). The results from these experiments cannot be directly 
compared, however they can provide trends that are useful in guiding future experiments. For 
example, both successful viral silencing constructs used the U6 promoter, which may provide the 
strongest miRNA expression able to match the expression from the CMV promoter-driven 
luciferase.  
One limitation in this study is that the serotypes of silencing and reporting vectors were 
often different, which can affect their relative distribution within the brain. Co-localization of the 
viruses is vital to the sensitivity of the assay. There are varying reports comparing the spread of 
different serotypes in the brain, as summarized in Chapter III. In this study, we did not 
investigate the co-localization of the reporter and silencing vectors. I recommend that this be 
done in future studies to improve interpretation of results. Several methods exist, including 
labeling the silencing virus with a fluorescent protein such as GFP and using 
immunofluorescence against luciferase or FISH for luciferase mRNA to calculate the co-
transduction of cells. Fluorescent dyes such can be conjugated to the cc-siRNA to evaluate 
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spread shortly after injection. These labeling experiments should be done using control AAV 
silencing vectors because if the hairpin or siRNA degrades the luciferase protein or mRNA, then 
it will appear as if there is no co-localization. One experimental method that would ensure co-
localization of luciferase and hairpin RNA is to use a Cre/ LoxP recombination system. Stop-
floxed luciferase gene-containing mice would be injected with a silencing vector expressing both 
the Cre-recombinase gene and the silencing hairpin RNA. In this case all cells that have the 
silencing RNA will also express luciferase. 
Another limitation of this system is the high level of luciferase expression by the CMV 
promoter. A lower-expressing promoter would provide more favorable conditions for siRNA-
mediated silencing, necessitating lower siRNA concentrations that are more similar to what 
would be needed to silence an endogenous target. Since it is not practical to use endogenous 
promoters with the AAV-delivery system due to the size constraints and complexity of 
regulatory sequences, an alternative approach is to target insertion of the luciferase gene into the 
genome in a position that it is regulated by a specific promoter. Transgenic mice would express 
luciferase by the same promoter and at the same level as an endogenous gene, such as huntingtin. 
One could also target genes specific to the brain, so that luciferase is only expressed in the brain 
or the striatum using promoters for preproenkephalin, or dopamine 1 receptor [318, 319]. 
Developments in genome editing make this a possibility using the recently characterized system 
known as CRISPR for Clustered Regularly Interspaced Short Palindromic Repeats [320, 321]. 
Somewhat similar to RNAi but targeting double-stranded DNA (dsDNA), CRISPR RNA 
(crRNA) directs sequence-specific cleavage of dsDNA by Cas (CRISPR-associated) 
endonucleases [320]. Although it is a system unique to Bacteria and Archaea, the CRISPR-Cas9 
complex has been engineered to function in eukaryotic cells, correcting mutant genes in human 
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and mouse cells, creating targeted knockouts and conditional alleles [322-327]. Two studies have 
produced targeted knock-in alleles using the CRISPR-Cas9 system, by co-injecting Cas9 mRNA, 
single guide RNAs, and DNA oligos that incorporate into the nicked or cut dsDNA by 
homology-directed repair [328, 329]. To target the luciferase gene to a specific promoter, the 
Cas9 mRNA, CRISPR guide RNA, and luciferase DNA oligos must be injected into a single cell 
embryo where the Cas9 would introduce a sequence-specific cut to the genome of one or both 
alleles. Homology-directed repair would insert the luciferase DNA into the genome. Potential 
drawbacks include that the endogenous gene would likely be disrupted resulting in a total or 
partial knockout of that gene. Careful gene targeting or use of an internal ribosomal entry site or 
2A peptide sequence would be necessary to insert the luciferase gene within a correct reading 
frame. Off-target effects are also possible, where luciferase would be inserted into other genomic 
sites, thereby disrupting other genes and possibly expressing more luciferase than intended. 
Creating a mouse that expresses luciferase at a lower level would be more amenable to silencing 
but low luminescence could limit detection using D-luciferin. In Chapter IV we test new 
luciferin substrates in vivo that would enable detection of low levels of luminescence. 
The experimental design using bilateral injections was intended to decrease variation, 
however we found that luminescence from one side of the mouse spread across the midline, 
reducing the ability to detect changes in luminescence. This is likely the result of both virus 
diffusion to the midline and light-scattering through the tissue. This method was tested with D-
luciferin, which emits short wavelength light resulting in high light-scattering. Due to these 
challenges, I do not recommend that the bilateral injection design to study RNA silencing in 
vivo.  
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This method could be improved with substrates, such as those tested in Chapter IV, that 
are red-shifted resulting in less light scattering through tissue. In Chapter IV, we demonstrated 
that two compounds, CycLuc1 and iPr-amide, have greater activity than D-luciferin and 
improved sensitivity in luciferase-expressing mice. This capability to detect low luminescence 
from deep brain structures advances the application of BLI to test more subtle findings in mice or 
even larger animals. Newer generations of BLI instruments with three dimensional imaging 
capabilities are now being used with microCT scanning to create three dimensional 
quantification of luminescence [312, 330]. Renilla luciferase and improved luminescent enzymes 
are being used for detection of viral expression and for normalization of firefly luciferase 
expression [313, 331]. A drawback to the viral vectors expressing shRNA in this study is that 
expression by constitutive promoters cannot be turned off. One advance that could be made is to 
employ promoters regulated by small molecules enabling control of shRNA expression [332, 
333]. This would enable differences in luminescence to be compared with and without shRNA in 
the same animal, similar to the studies with siRNA.  
Taken together these studies employ in vivo approaches for testing potential therapeutic 
agents relevant to Huntington’s disease.  Neuronal loss following overexpression of PSA raises 
concerns over the safety and tolerability of this protein in neurons. The implication of this 
observation is that, although a therapy may be tolerated in cell culture or non-neural tissues, it is 
imperative to study overexpression in tissue that manifests the disease for safety and toxicity. To 
a similar extent, this dissertation explores using BLI to follow silencing of luciferase in the brain, 
proposing a method of tagging luciferase with huntingtin target sequences to test potential 
therapeutics in vivo to identify the most effective design. This system requires further 
optimization in order to achieve the sensitivity necessary to detect subtle changes in 
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luminescence for meaningful comparisons. There remain many hurdles to the application of 
RNAi in the treatment of HD, including delivery and design of structures. Bioluminescent 
imaging has the potential to provide valuable information, especially with advances in imaging 
and luminescent substrate design. 
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